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Abstract  
The protein-protein interaction (PPI) between immunoglobulin E (IgE) and its high affinity receptor 
(FcεRI) is an important part of the allergic response. Inhibition of the IgE:FcεRI interaction is a key 
strategy for the development of allergy treatments. This PPI has been validated as a therapeutic 
target by the humanised monoclonal antibody omalizumab, which binds to IgE and prevents the 
formation of the IgE:FcεRI complex and has proved successful at treating allergic asthma. However, 
small molecule inhibitors of the IgE:FcεRI PPI that are orally available would be a more desirable 
form of treatment.  
 
This thesis describes the design, synthesis and testing of two series of inhibitors of the IgE:FcεRI 
interaction; small molecules based on the natural product aspercyclide A and short, linear 
peptides based on a key binding epitope of FcεRI. It also describes the development of a high-
throughput time resolved fluorescence resonance energy transfer (TR-FRET) assay to test 
inhibitors and subsequent x-ray crystallography and SPR experiments to further investigate the 
mode of action of the inhibitors.  
 
An analogue of aspercyclide A has shown inhibition of the IgE:FcεRI interaction in the micromolar 
range and an improved potency compared to the natural product itself. A number of 8-residue, 
linear peptides have been found to inhibit the IgE:FcεRI PPI in the micromolar range when tested 
in the TR-FRET assay. The most potent peptide has been biotinylated and immobilised for SPR 
experiments with IgE and FcεRI. These SPR experiments suggest that the peptide inhibits the 
IgE:FcεRI interaction by binding to the high affinity receptor rather than to IgE.   
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Chapter 1: Introduction 
1.1 Allergies 
Allergies are becoming increasingly prevalent in developed countries with 39% of children and 30% 
of adults in the UK suffering from the most common allergies including asthma, allergic rhinitis 
(hay fever) and eczema.1,2 Allergic reactions produce unpleasant symptoms such as running nose 
and eyes, itchiness and sneezing which reduce quality of life for sufferers. Severe allergies can 
result in serious acute conditions or potentially fatal anaphylaxis.3 Allergies also make up 6% of 
general practice consultations and 0.8% of hospital admissions in the UK, placing a financial 
burden on the NHS.1  
 
Allergies are mainly caused by the antibody immunoglobulin E (IgE) causing immediate or type I 
hypersensitivity reactions in the body. A key component of the allergic response is the protein-
protein  interaction  (PPI)  between  IgE  and  its  high  affinity  receptor  (FcεRI).4,5 FcεRI  is found on the 
surfaces of mast cells in the mucosal linings of the nose, mouth, lungs, skin and digestive tract and 
on the surfaces of basophils, a granulocyte white blood cell.4,5 In an allergy patient, increased 
amounts of IgE are produced which have binding specificity for a particular allergen to which the 
patient   is   sensitive.   This   IgE   circulates   within   the   bloodstream   and   then   binds   to   FcεRI. If that 
particular allergen is then inhaled, ingested or contacts the skin, the allergen can bind to receptor-
bound IgE, cross-linking the IgE molecules and causing the receptors to aggregate.3 This activates 
the mast cell and, after a series of intracellular PPIs, degranulation of the mast cell occurs where 
various proinflammatory mediators such as histamines and cytokines are released.4   
 
These mediators then interact with their receptors in the local tissue which causes inflammation 
and vasodilation, resulting in symptoms characteristic of the organ affected.4 For instance, 
activation of mast cells in the mucosal lining of the respiratory tract causes asthma and results in 
symptoms including inflamed, swollen airways, shortness of breath and wheezing.5,6 This initial 
reaction can happen within minutes and constitutes the acute or early phase of the allergic 
response.4 The late phase of the allergic response, which occurs a few hours later, involves CD40-
ligand and interleukins which are expressed by mast cells during degranulation. These mediators 
interact with B-cells in the local tissue and cause the B-cells to switch from producing the IgM 
antibody isotype to producing IgE, which maintains mast cell sensitisation and allergic symptoms 
via  what  is  known  as  a  ‘positive  feedback  loop’ (Scheme 1).4,5  
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Scheme 1: Overview of the allergic response 
1 = IgE binds to FcεRI on mast cell surface, 2 = allergen binds to FcεRI-bound IgE, 3 = mast cell activation 
and degranulation, 4 = mediators interact with local tissue causing allergic response, 5 = mediators interact 
with local B cells causing class-switching to IgE isotype, 6 = increased IgE synthesis causing persistent mast 
cell sensitisation via a positive feedback loop. 
 
1.2 Treatments for allergies 
1.2.1 Anti-histamines, bronchodilators and corticosteroids 
The most common treatments for allergies are antihistamines, which benefit from being 
inexpensive, widely available over the counter and moderately effective at relieving symptoms of 
various common allergies particularly hay fever, as well as dust, pet and skin allergies.7 
Antihistamines are small molecule antagonists of the H1 histamine receptor, which block the effect 
of histamine and therefore prevent cells in the local tissue from causing inflammation and 
vasodilation. Examples include the first generation antihistamine diphenhydramine (trade name 
Benadryl)8 and the second generation antihistamine loratadine (trade name Claritin)9, the 
structures of which are shown in Figure 1. 
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Figure 1: Structures of antihistamines diphenhydramine (Benadryl) and loratadine (Claritin) 
 
The main disadvantage of antihistamines is that their lack of selectivity for the H1 histamine 
receptor means they cause unpleasant side-effects, mainly drowsiness but also dizziness and 
nausea. Second generation antihistamines are more selective for the H1 histamine receptor than 
first generation antihistamines therefore side-effects are reduced to some extent, but they can 
still occur in some patients. 
 
Inhaled bronchodilators10 and corticosteroids11 are also used to treat the symptoms of asthma. 
Bronchodilators   are   small  molecule   β2-adrenergic receptor agonists which relax airway smooth 
muscle, dilate the airways and increase airflow to the lungs, making it easier to breathe. An 
example of a short-acting bronchodilator is salbutamol (trade name Ventolin), which provides fast, 
temporary relief from asthma symptoms. Corticosteroids work by reducing inflammation of the 
airways and lungs and can be used as a long-term treatment for asthma. However, not all asthma 
patients have a positive response to these types of treatments. 
 
1.2.2 Omalizumab 
The humanised monoclonal antibody omalizumab (trade name Xolair), manufactured by 
Novartis/Genentech, has been used effectively to treat moderate to severe allergic asthma and 
works by targeting   the   PPI   between   IgE   and   FcεRI.12-14 Omalizumab binds to free IgE, reducing 
levels of free IgE in the bloodstream and preventing the   formation   of   the   IgE:FcεRI   PPI and 
subsequent mast cell degranulation. A benefit of omalizumab binding to free IgE, rather than 
receptor-bound IgE, is that this avoids a potential agonist effect of omalizumab where cross-linking 
of IgE and aggregation of receptors could occur which could lead to possible anaphylaxis.13  
 
Despite clinical success, the use of omalizumab has some downsides. Due to its high molecular 
weight, administration is via a subcutaneous injection required every 2 – 4 weeks, which is not 
Diphenhydramine      Loratadine 
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suitable for patients with a high body mass index, and it is also an expensive form of treatment.12 
However,  omalizumab  demonstrates  that  the  IgE:FcεRI  PPI  is  a  viable  therapeutic  target  and that 
inhibiting the formation of this PPI can prevent the allergic response from occurring. All of the 
allergy treatments mentioned in this section have various drawbacks and there is an unmet need 
for improvements in allergy treatments. A selective, small  molecule   inhibitor  of  the  IgE:FcεRI  PPI  
that would be inexpensive to produce and would be orally available without causing side-effects 
would be a huge advance and would meet this need for improved treatments.  
 
1.3 The IgE:FcεRI  PPI 
IgE is a large, globular protein and one of the five immunoglobulin isotypes found in the human 
body (the others are IgA, IgD, IgG and IgM).4 IgE is the least abundant of the immunoglobulins, 
with a concentration of ~ 150 ng/mL in serum, compared to ~ 10 mg/mL for IgG.4 IgE is a monomer 
consisting of two heavy chains and two lights chains. The variable regions of the heavy and light 
chains constitute the two identical antigen binding sites and these, along with the adjacent light 
chain constant regions and the Cε1 domain pair, form the antigen binding fragment (Fab).4 The 
Cε2, Cε3 and Cε4 domain pairs form the constant fragment (Fc) which contains receptor binding 
sites. The structure of IgE is similar to that of IgG, which is the most abundant immunoglobulin and 
provides the majority of immunity against invading pathogens, however IgE has an extra disulfide-
linked Cε2 domain pair which makes IgE less flexible than IgG (Figure 2).15,16   
 
 
 
Figure 2: Schematic representation of the structures of antibodies IgE and IgG 
Image taken from reference5. Antigen binding fragment (Fab) and constant fragment (Fc) are labelled, 
along with disulfide bridges (solid lines) and sites of N-linked glycosylation (grey circles). IgE has an extra 
disulfide-linked domain pair and is therefore less flexible than IgG. 
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The two Cε2 domains of IgE are linked by two crossed disulfide bridges which form between 
Cys(241) on the first domain and Cys(328) on the second domain and vice versa.16 The interaction 
between the two Cε2 domains is unusual for immunoglobulin domain pairs, in that the domains 
associate due to polar buried surface areas, rather than the usual non-polar. The crystal structure 
of the Fc region of IgE (known as IgE-Fc) showed that this Cε2 domain pair folds back onto the IgE-
Fc region in such a way that one Cε2 domain makes extensive contact with the Cε3 and Cε4 
domain pairs but the other Cε2 domain does not, meaning IgE has an overall asymmetric or bent 
conformation (Figure 3).16 
 
Figure 3: Crystal structure of IgE-Fc showing the asymmetric conformation 
IgE-Fc Cε3 and Cε4  domain  pairs  are  shown in green, one of the IgE-Fc Cε2 domains is shown in pink and 
the other is shown in purple. IgE-Fc has an overall asymmetric conformation where the Cε2 domain pair 
folds back onto the IgE-Fc region. Protein data bank (PDB) code 1LS016, figure constructed using PyMOL.   
 
IgE binds to two receptors; the high affinity receptor FcεRI, which is involved in the allergic 
response as discussed above, and the low affinity receptor FcεRII (also known as CD23), which is 
important in regulating IgE levels.4 The high affinity receptor FcεRI is expressed in large quantities 
on the surfaces of mast cells and basophils and is a heterotetramer, consisting of an α-chain, a β-
chain and two γ-chains.4 The α-chain is a type I integral membrane protein and its extracellular 
domains contain binding sites for IgE. The β-chain and γ-chains are involved in cell signalling and 
cytoplasmic functions. In 2000, the crystal structure of a subfragment of IgE-Fc consisting of the 
Cε3-Cε4 domain pairs (known as IgE-Fc3-4) bound to a soluble fragment of the extracellular 
domains of the α-chain of FcεRI (known as sFcεRIα) was first solved.15 
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This crystal structure revealed that one receptor molecule binds to one dimeric IgE-Fc molecule in 
an asymmetric fashion through two   key   binding   epitopes   or   ‘hotspots’   on   FcεRIα that each 
interact with one of the Cε3 domains of IgE-Fc.15 Binding site 1 comprises the C-C’  loop  of  the  D2  
domain,  where  Tyr(131)  of  the  C’-strand of the loop projects into a hydrophobic pocket made of 
the Cε3 domain and the Cε2-Cε3 linker region of IgE-Fc.15,17 Binding site 2 comprises four solvent-
exposed tryptophan residues at the D1-D2 interface region, where Trp(87) and Trp(110) sandwich 
around Pro(426) of the IgE-Fc Cε3 domain (Figure 4).15,17  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Crystal structure of interaction between IgE-Fc3-4 and sFcεRIα  showing  key binding sites 
IgE-Fc3-4 (a subfragment of IgE-Fc consisting of the Cε3 and Cε4 domain pairs) is shown in green and sFcεRIα 
(a soluble fragment of the extracellular domains of the α-chain of the high affinity receptor FcεRI) is shown 
in orange. Binding site 1 (the C-C’  loop  of  sFcεRIα) is shown in pale blue. At binding site 1, the receptor 
Tyr(131) projects into a hydrophobic pocket of IgE-Fc. Binding site 2 (the D1-D2 linker region of sFcαRIα) is 
shown in purple. At binding site 2, receptor Trp(87) and Trp(110) sandwich around Pro(426) of IgE-Fc. PDB 
code 1F6A15, figure constructed using PyMOL.   
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The binding affinity of IgE and FcεRI is very high (Kd ~ 0.1 nM) which is up to five times higher than 
the affinity of IgG binding to its receptors FcγRI, FcγRII and FcγRIII.4,15,16 This is mainly attributed to 
a low dissociation rate of the IgE:FcεRI interaction (koff = 2 x 10-4 s-1) and also due to the large 
number of aromatic residues of FcεRI that are occluded within the extensive buried interface of ~ 
1850 Å2.15,16 As revealed by surface plasmon resonance (SPR) studies on the binding kinetics of the 
IgE:FcεRI   interaction,   there   are   two   binding phases observed.18,19 The interaction comprises a 
lower affinity phase (Ka ~ 2.9 x 107 M-1) and a higher affinity phase (Ka ~ 2.7 x 109 M-1) with the 
dissociation dominated by the higher affinity phase.19 This biphasic interaction is due to a 
conformational   change   occurring   between   two   states   of   the   IgE:FcεRI   complex,   where   IgE  
rearranges  after  first  engaging  with  FcεRI.20,21  
 
More recently, x-ray crystallography22 and fluorescence resonance energy transfer (FRET) 
experiments23 have been used to show that these conformational transformations occur in both 
FcεRI   and   the   IgE Cε2   and   Cε3   domains for the maximum affinity interaction. After the initial 
formation  of  the  IgE:FcεRI  complex,  the  two  IgE Cε3  domains  move  apart  making  IgE-Fc more bent, 
which  allows  FcεRI  to interact  with  subsites  on  both  of  the  two  Cε3  domains.22,23 In free IgE-Fc only 
one of these Cε3  domain  subsites  is  accessible  to  FcεRI. It  has  been  shown  that  both  Cε3  domains  
need  to  engage  with  FcεRI  for  maximum  affinity24 and  that  a  reduction  in  affinity  of  the  IgE:FcεRI 
interaction causes a reduction in the allergic response25 both in vitro and in vivo. Whilst this 
conformation change is occurring in IgE,  a  cavity  between  one  Cε2  domain  and  one  Cε3  domain  
becomes closed. This may present an   opportunity   for   allosteric   inhibition   of   the   IgE:FcεRI  
interaction; if a small molecule could fit into the cavity and prevent it from closing, the 
conformational   changes  could  not  occur  and  FcεRI  would  only  be  able   to  access  one  of   the  Cε3  
subsites and not both. 
 
The binding between IgE and its low affinity receptor CD23 also gives further insights into 
allosteric inhibition  of   the   IgE:FcεRI   interaction.  CD23 is expressed on the membranes of B-cells 
and is structurally distinct from most other immunoglobulin receptors as it belongs to the C-type 
lectin superfamily.5 The membrane-bound form of CD23 consists of   three   lectin  domain   ‘heads’  
projecting  from  the  membrane  on  a  triple  α-helical coiled-coil stalk. IgE binds to CD23 with a lower 
affinity than it binds to FcεRI  (Kd ~ 0.1 – 1  μM  for  binding of IgE to a single CD23 domain head and 
Kd ~ 1 – 10 nM for binding of IgE to the CD23 trimer due to avidity effects).5 
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It has recently been found, using x-ray crystallography and nuclear magnetic resonance (NMR) 
experiments that the  CD23  binding  sites  and  the  FcεRI  binding  sites  are  at  opposite  ends  of  the  IgE  
Cε3   domain,   but   that   IgE   cannot   bind   both   receptors   at   once.26,27 The crystal structure of the 
IgE:CD23 interaction showed that IgE-Fc3-4 binds to two molecules of the soluble monomeric lectin 
head domain of CD23 (known as derCD23), with  each  derCD23  binding  at  the  IgE  Cε3-Cε4 interface 
(Figure 5).26 
 
 
Figure 5: Crystal structure of interaction between IgE-Fc3-4 and derCD23 
IgE-Fc3-4 is shown in green and two derCD23 fragments (a soluble fragment of the low affinity receptor 
CD23) are shown in dark blue. PDB code 4EZM26, figure constructed using PyMOL.  
 
The conformation changes required to bind one receptor have been proposed not to be 
compatible with binding the other receptor and vice versa, reflecting an allosteric mechanism. IgE 
Cε3  domains  bind  only  FcεRI  when  they  are  in  the  ‘open’  conformation  and  bind only CD23 when 
they  are  in  the  ‘closed’  conformation. As  CD23  binds  to  the  IgE  Cε3-Cε4  interface,  an  inhibitor  that  
binds  to  IgE  at  this  site  could  keep  IgE  in  the  ‘closed’  conformation  and  prevent  the  conformational 
changes required for it to move to the ‘open’   conformation   and   bind   to   FcεRI,   suggesting   that  
allosteric   inhibition   of   the   IgE:FcεRI   interaction   would   be   possible.28,29 Further x-ray 
crystallography studies on the interaction between IgE-Fc3-4 and CD23 by Dhaliwal et al. revealed 
that calcium-dependent structural changes in CD23 increase its affinity for IgE30 and found that 
conformational flexibility occurs in two key IgE-binding loops of CD2331 and in IgE-Fc3-432 to 
accommodate the formation of the IgE:CD23 complex. An understanding of these conformational 
changes may prove to be important for allosteric inhibition of the   IgE:FcεRI   interaction,   or   for 
targeting the IgE:CD23 interaction itself with the aim of modulating the production of IgE. 
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Very recent x-ray crystallography and other experiments by Drinkwater et al. revealed that IgE-Fc 
can actually adopt a fully extended, symmetrical conformation in solution.33 This was achieved by 
‘trapping’  IgE-Fc in the extended conformation, by complexing it to two IgG Fab fragments (known 
as  aεFabs)  that  bound  to  IgE-Fc, one on each side. In this complex, the  IgE  Cε2  domains  show  the  
greatest   structural   change,   ‘unbending’   so   that   they  no   longer  have  an  extensive intramolecular 
interface  with  the  Cε3-Cε4  domains  (Figure 6).33 It  was  found  that  aεFab  allosterically  inhibited  IgE  
from  binding  to  FcεRI;  IgE  was  trapped  in  an  extended  conformation  when  complexed  with  aεFab  
and so binding sites 1  and  2  were  both  disrupted  and  it  could  not  engage  with  FcεRI.  aεFab  also  
sterically  inhibited  IgE  from  binding  to  FcεRI;  aεFab  could  complete  with  FcεRI  for  binding  to  free,  
bent IgE-Fc,  since  modelling  of  a  single  aεFab  onto  the  IgE:FcεRI  complex  shows a clash between 
the   aεFab   and   FcεRI.33 This work gives a more complete overview of the structure and 
conformational changes of IgE and may provide a further avenue   for   inhibition   of   the   IgE:FcεRI 
complex; if FcεRI-bound IgE  could  be  encouraged  to  ‘unbend’  it may be able to dissociate from the 
receptor.  
 
Figure 6: Crystal structure of IgE-Fc bound to aεFab and trapped in extended conformation 
IgE-Fc (the Cε2 – Cε4 domains) is shown in green and the two aεFabs (IgE-binding IgG Fab fragments) are 
shown in red. PDB code 4J4P33, figure constructed using PyMOL.  
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1.4 Targeting PPIs with peptides and small molecules 
The number of PPIs is vast and they play a crucial role in almost all biological processes and are 
implicated in a variety of diseases. PPIs are therefore an increasingly important focus for 
therapeutic intervention and there have been a number of comprehensive reviews published on 
inhibiting PPIs.34-39 It would be attractive for a PPI  to  be  targeted  by  a  small,  orally  available  ‘drug-
like’   molecule,   however   due   to   the   complex   nature   of   interacting   protein   surfaces,   the  
development of such small molecule inhibitors is very challenging.36 Firstly, protein surfaces that 
come into contact during a PPI are usually large (~ 1500 – 3000 Å2) and flat, without the grooves 
and pockets found on protein surfaces that interact with small molecules such as enzymes and G 
protein-coupled receptors.36 Furthermore, the key binding regions on interacting proteins are 
often non-contiguous which means they can be difficult to mimic with small molecules or with 
peptides derived from contiguous sequences.36 Finally, ligands that bind to proteins do not 
translate well to the design of PPI inhibitors, therefore high throughput screening (HTS) of 
compound  libraries  does  not  always  find  effective  small  molecule  ‘drug-like’  inhibitors of PPIs.35  
 
However, several strategies for targeting PPIs have been employed to develop effective PPI 
inhibitors regardless of these challenges. Systematic mutation of individual contact residues of a 
PPI to alanine, a technique known as alanine scanning, can identify relative contributions of 
individual residues  to  the  overall  binding  affinity.  These  key  epitopes  or  ‘hotspots’  usually  consist  
of aromatic residues tryptophan and tyrosine40, due to their hydrophobic nature and lack of 
rotatable bonds meaning there is only a small entropic penalty on binding, and mimicking these 
hotspots with synthetic molecules can modulate a PPI.35 Information about key features of protein 
interfaces has also lead to the discovery of various biological molecules that can recognise these 
features and modulate a PPI, including artificial antibodies, small proteins, functional 
oligonucleotides and unnatural biopolymers.35 Small molecules have also been found to modulate 
PPIs, including Cu(II)complexes and tetraphenylporphyrin derivatives35 and certain molecular 
structures such as the biphenyl moiety41 have been found to bind to a range of proteins and could 
be  used  as  a  ‘scaffold’  for  drug  design. 
 
Peptides have also had widespread use for studying and inhibiting PPI binding interfaces and can 
be particularly effective at mimicking protein hotspots. Traditionally, peptides have not been 
considered desirable as drugs or drug leads due to them not conforming to the  criteria  of  Lipinski’s  
rule of five (MW < 500, hydrogen bond donors < 5, hydrogen bond acceptors < 10, CLogP < 5)42 
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and therefore displaying poor oral availability and also as they are typically hydrolysed by protease 
enzymes. However, there are many modifications to peptides that can improve their 
pharmacokinetics, for instance structurally constrained, cyclic peptides may adopt particular 
conformations that make them less susceptible to proteolytic degradation than linear peptides.43-
45 Furthermore, inhibitors of PPIs tend to have a higher MW (up to 800 – 900) than inhibitors of a 
typical enzyme-substrate interaction and many PPI inhibitors do  not  conform  to  Lipinski’s  rule  of  
five.36,37 Unnatural amino acids can be included in a peptide to potentially improve its affinity, 
selectivity and metabolic stability.46,47 Other  modified   peptides,   such   as   ‘retro-inverso’ peptides 
and  β-peptides could also give improved activity and stability.37 Finally, molecules that mimic a 
peptide’s   secondary   structure,   such   as   α-helix,   β-sheet   or   β-turn peptidomimetics can be a 
method  of  developing  more  ‘drug-like’  molecules  from  existing  peptide  inhibitors.37  
 
Natural products provide a range of molecular scaffolds and are good starting points from which 
to prepare extensive compound libraries for high throughput screening against a PPI.37 New 
chemical methods can also allow substituents on the core scaffold to be modified to give 
compounds with high molecular diversity.37 In addition, the chemical structure of a natural 
product is usually predisposed to bind with a high affinity and specificity to a biological target. As 
such, natural products have been the starting point for the majority of approved therapeutics and 
are the main source of compounds that target PPIs.37  
 
1.5 Peptide inhibitors of the IgE:FcεRI PPI 
Despite   the   IgE:FcεRI  PPI  being  a  challenging  target   for   inhibition,  there  have  been  a  number  of  
inhibitors developed, including small molecules, peptides and small proteins, and these have been 
recently reviewed by Smith et al.48 Peptides are the most widely studied type of inhibitors of the 
IgE:FcεRI interaction. Very early work in this area, carried out by Hamburger, used short, linear 
peptides to study the   binding   interface   between   IgE   and   FcεRI and discovered a pentapeptide 
based on IgE that competed with IgE for binding to mast cells in human skin.49,50 Other early work, 
by Stanworth et al., also discovered linear peptides 12 – 15 residues long that could compete with 
IgE for binding to mast cells and studied peptides as synthetic vaccines for the treatment of 
allergies.51-53  Since this work, peptides have continued to be studied and most of the inhibitors of 
the  IgE:FcεRI  interaction  reported  in  the  literature  are  disulfide-constrained, cyclic peptides. These 
peptides  mimic  key  binding  epitopes  of  either  IgE  or  FcεRI  or  have  been  identified  by  other  means 
such as phage display.   
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1.5.1 Peptides based on IgE 
AB loop peptide and 2,2’-tolan peptide 
Helm et al. studied peptides derived from IgE and found that the exposed Ω-loop and the AB β-
strand of the IgE Cε3  domain  was  a  key  binding  hotspot  for  the  interaction  of   IgE  with  FcεRI.54 A 
disulfide-constrained, cyclic peptide mimicking this region known as the ‘AB-loop peptide’, 
containing loop residues Leu(340) – Cys(358), inhibited IgE-triggered 5-hydroxytryptamine release 
from a rat basophilic leukemia (RBL) cell line transfected with FcεRI (IC50 ~ 12 μM).54 The 
aforementioned crystal structure of the IgE:FcεRI complex was then solved, which showed that 
these regions of the IgE Cε3 domain do not make direct contact with FcεRI during the IgE:FcεRI  
interaction15,17, which could suggest a potential allosteric mechanism of inhibition for the AB-loop 
peptide.  
 
Spivey, Helm et al. later  replaced  the  disulfide  bridge  with  the  more  rigid  2,2’-diphenylacetylene 
(2,2’-tolan) bridge in an attempt to improve affinity, however this peptide had a similar activity to 
the original peptide.55 Spivey et al. then synthesised a 9-residue, tolan-bridged peptide comprising 
only loop residues Pro(345) – Ser(353)  known  as  the  ‘2,2’-tolan  peptide’.56 However, when tested 
with an enzyme-linked immunosorbent assay (ELISA), this peptide was less active than the original 
peptide (IC50 ~ 660 μM).56 Despite  this  loss  of  activity,  the  reduction  in  flexibility  of  the  2,2’-tolan 
peptide, compared to the AB loop peptide, may increase the chances of obtaining a co-crystal 
structure of this peptide bound to FcεRI which might allow its mode of action to be determined. 
The structures  of  the  AB  loop  peptide  and  the  2,2’-tolan peptide can be seen in Figure 7. 
 
 
 
Figure 7: AB loop peptide and 2,2’-tolan peptide inhibitors based on IgE Cε3 domain 
Peptides were synthesised by Spivey et al. The AB loop peptide contains residues Leu(340) – Cys(538) of the 
IgE Cε3 domain and inhibits the IgE:FcεRI interaction (IC50 ~ 12 μM).54 The 2,2’-tolan peptide contains 
residues Pro(345) – Ser(353) of the IgE Cε3 domain and inhibits the IgE:FcεRI interaction (IC50 ~ 660 μM).56 
(NB: -NH2 denotes free N-terminus, -OH denotes free C-terminus). 
 
  
AB loop     2,2’-tolan 
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1.5.2 Peptides based on FcεRI 
As discussed previously, binding site 1 of FcεRI, comprising the C-C’-loop, is a key region for 
interaction with IgE and as such a number of peptides mimicking this region have been developed 
with the aim that they bind to IgE and inhibit the IgE:FcεRI interaction. It is advantageous for an 
inhibitor to bind to IgE, rather than to FcεRI, as binding to FcεRI could cause a possible agonist 
effect and mast cell degranulation. 
 
Cyclo(L-262) peptide and cyclo(rD-262) peptide 
McDonnell et al. designed a disulfide-constrained cyclic peptide mimicking the C-C’-loop of FcεRI 
known  as  the  ‘cyclo(L-262)  peptide’, which contained residues Ile(119) – Tyr(129) of FcεRI and was 
found by 2D NMR to adopt a stable β-hairpin structure in solution.44,57,58 This peptide was found to 
bind to IgE (Kd = 2.6 μM) when tested with an SPR assay and was also found to inhibit sensitisation 
of RBL cells with IgE when tested with a β-hexosaminidase release assay (IC50 = 30 μM).44,57 A 
peptide with a reversed sequence and inverted chirality known  as  the  ‘cyclo(rD-262)  peptide’  was  
also synthesised in an attempt to obtain enhanced proteolytic stability whilst keeping the 3D 
structure the same.44,57 It was found by circular dichroism (CD) spectroscopy that the cyclo(rD-262) 
peptide did indeed adopt a mirror image structure in solution, however the activity was slightly 
reduced when tested with the β-hexosaminidase release assay (IC50 = 100 μM).44,57 The structures 
of both peptides can be seen in Figure 8. 
 
 
 
 
Figure 8: Cyclo(L-262) peptide and cyclo(rD-262) peptide inhibitors based on C-C’  loop  of  FcεRI 
Peptides were synthesised by McDonnell et al. Cyclo(L-262) peptide contains residues Ile(119) – Tyr(129) of 
FcεRI and inhibits the IgE:FcεRI (IC50 = 30 μM) and cyclo(rD-262) peptide has a reverse sequence and 
inverted chirality to cyclo(L-262) peptide and inhibits the IgE:FcεRI (IC50 = 100 μM).44,57 (NB: -NH2 denotes 
free N-terminus, -OH denotes free C-terminus). 
 
  
Cyclo(L-262)       Cyclo(rD-262) 
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Ro25-7162 peptide and Ro25-9960 peptide 
Danho et al. carried out similar work and synthesised a variety of linear and disulfide-constrained 
cyclic peptides mimicking the C-C’   loop C-strand and the adjacent F-strand of FcεRI.59 The most 
potent of these was a 21-residue, disulfide-constrained, cyclic peptide known as   ‘Ro25-7162 
peptide’  which   inhibited   IgE  binding   (IC50 = 40 μM) using an undisclosed binding assay, however 
molecular dynamics and NMR studies showed that this peptide had a flexible conformation in 
solution.59 To try to stabilise the β-strand conformation, a series of dimeric peptides were then 
synthesised with the disulfide bridge between the middle of the two strands. The most potent of 
these was an 8-residue, disulfide-constrained homodimer based on the C-strand of FcεRI known as 
‘Ro25-9960  peptide’  which  inhibited IgE binding more strongly than the original cyclic peptide (IC50 
= 2 μM).59 The structures of both peptides can be seen in Figure 9.  
 
 
 
Figure 9: Ro25-7162 peptide and Ro25-9960 peptide inhibitors based on C-strand of FcεRI 
Peptides were synthesised by Danho et al. and inhibit the IgE:FcεRI interaction (Ro25-7162 IC50 = 40 μM and 
Ro25-9960 IC50 = 2 μM).59 (NB: -NH2 denotes free N-terminus, -CONH2 denotes amidated C-terminus). 
 
IgE-Trap peptide and PepE peptide 
More recently, Sandomenico et al. used a comparable approach and synthesised a polypeptide 
that  comprised  the  C’-E loop (residues 129 – 134), the B-C loop (residues 110 – 113) and the F-G 
loop (residues 151 – 162) of FcεRI, to reproduce both binding site 1 and binding site 2.60 Asn(133) 
was mutated to Lys(133) to allow attachment between the peptide sequences and Ser(162) was 
mutated to Cys(162) to allow a disulfide bridge to form between it and Cys(151). This peptide, 
known  as  ‘IgE-Trap  peptide’,   inhibited  the  IgE:FcεRI interaction when tested with an ELISA (IC50 = 
70 μM) and flow cytometry using RBL cells.60  
 
Subsequent   SPR   studies   found   that   the   C’-E loop and the B-C loop displayed cooperativity for 
binding to IgE and that the F-G loop had little contribution for binding to IgE. A further peptide was 
therefore  synthesised  consisting  of  only  the  C’-E loop and the B-C  loop,  known  as  ‘PepE  peptide’.61 
In   PepE   peptide,   the   C’-E loop and the B-C loop were attached via an additional β-Ala residue, 
rather   than   directly   attached   as   in   the   ‘IgE   Trap   peptide’,   to   better   reflect the actual distance 
Ro25-7162       Ro25-9960 
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between these loops in the protein. PepE peptide bound strongly to IgE when tested with an SPR 
binding assay (Kd = 500 nM) which was approximately a 30-fold increase in affinity compared to 
IgE Trap peptide.61 PepE peptide was also found to inhibit the IgE:FcεRI interaction when tested 
with an SPR competition assay (IC50 = 32 μM) which was approximately four times lower than for 
IgE Trap peptide, and PepE peptide was also found to inhibit the release of β-hexosaminidase from 
RBL cells.61 It is noteworthy that PepE peptide has a lower molecular weight than the original IgE 
Trap peptide, yet binding affinity has improved. The structures of both peptides can be seen in 
Figure 10. 
 
 
Figure 10: IgE-Trap  peptide  and  PepE  peptide  inhibitors  based  on  C’-E loop and B-C loop of FcεRI 
Peptides were synthesised by Sandomenico et al. and inhibit the IgE:FcεRI interaction (IgE Trap IC50 = 70 
μM60, PepE peptide IC50 = 32 μM61). (NB: Ac denotes acetylated N-terminus, -NH2 denotes free N-terminus, -
CONH2 denotes amidated C-terminus, bAla denotes a β-alanine residue). 
 
PepE peptide was recently tested in vivo using a line of mice sensitive to IgE-mediated systemic 
anaphylaxis.62 Mice that received a single dose of PepE before sensitisation were fully protected 
from anaphylaxis, whereas control mice reacted strongly with core body temperature drops and 
increased levels of mouse mast cell protease in the serum.62 However, PepE that was administered 
after sensitisation had no effect on IgE-mediated anaphylaxis. This suggests that PepE is able to 
bind to IgE and prevent the formation of the IgE:FcεRI complex, but it cannot disrupt the IgE:FcεRI  
complex once it has formed.   
IgE Trap 
 
 
PepE 
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1.5.3 Peptides unrelated to IgE or FcεRI 
β-hairpin peptide and ζ-peptide 
There are a number of alternative methods to using protein hotspots that have been used to 
develop peptide inhibitors of the IgE:FcεRI interaction, such as phage display. Nakamura et al. at 
Genentech carried out binding selections using FcεRI and polyvalent peptide-phage libraries to 
identify novel peptides that bound to FcεRI and inhibited IgE binding.63 Optimisation with 
monovalent phage display yielded peptides with micromolar binding affinity for FcεRI that were 
also able to inhibit histamine release. Analogous peptides containing a disulfide bond were then 
synthesised and the most potent was a 15-residue, disulfide-constrained, cyclic peptide known as 
‘β-hairpin  peptide’  due  to  its  3D  structure  in  solution,  as  determined  by  2D  NMR  spectroscopy.63 
The β-hairpin peptide was found to inhibit allergen-induced activation of RBL cells when tested 
with a cell-based potency assay  (IC50 = 1 μM).63  
 
Further optimisation using an expanded series of peptide-phage libraries gave a series of disulfide-
constrained, bicyclic peptides that had a zeta 3D structure in solution and the most potent was a 
21-residue  peptide  known  as  ‘ζ-peptide’.64 The ζ-peptide had an improved activity (IC50 = 32 nM) 
and is the most potent peptide inhibitor of the IgE:FcεRI reported to date.64 The structures of both 
peptides can be seen in Figure 11. 
 
 
 
Figure 11: β-hairpin peptide and ζ-peptide inhibitors identified using phage display  
Peptides were developed by Nakamura et al. and inhibit the IgE:FcεRI interaction (β-hairpin peptide IC50 = 1 
μM63, ζ-peptide IC50 = 32 nM64). (NB: -NH2 denotes free N-terminus, -OH denotes free C-terminus, -CONH2 
denotes amidated C-terminus). 
 
Receptor mutagenesis experiments and 2D NMR spectroscopy revealed that both the β-hairpin 
peptide and the ζ-peptide bound competitively to binding site 2 of FcεRI, despite their different 
sequences, and that the key residue on both peptides was a proline.65 Binding site 2 of FcεRI (see 
Figure 4) comprises residues Trp(87) and Trp(110) of FcεRI which sandwich around Pro(426) of IgE, 
so it would seem likely that these peptides mimic the Pro(426) of IgE and therefore compete with 
IgE for binding to FcεRI. X-ray crystallography experiments confirmed this and the co-crystal 
β-hairpin             ζ-peptide 
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structure of ζ-peptide bound to FcεRI shows that a proline residue does sit in between the 
tryptophans of FcεRI (Figure 12).65 These peptides undoubtedly show high activity against the 
IgE:FcεRI interaction and this appears to be the only example of a co-crystal structure of a peptide 
inhibitor bound to either of the proteins which is significant. The only downside could be if the 
proline-tryptophan interaction was found at other PPI interfaces then these peptides may suffer 
from a lack of selectivity for the IgE:FcεRI interaction. 
 
Figure 12: Co-crystal structure of ζ-peptide bound to binding site 2 of FcεRI 
ζ-peptide (dark blue) synthesised by Nakamura and co-workers. Pro(16) of ζ-peptide is sandwiched 
between Trp(87) and Trp(110) (both purple) of FcεRI (orange). PDB code 1RPQ65, figure constructed using 
PyMOL. 
 
D-PAM peptide 
The development of peptides for the purification of antibodies using affinity chromatography has 
also enabled researchers to discover peptides that bind to IgE. Fassina et al. screened synthetic, 
tetrameric, tripeptides for inhibition of the interaction between various immunoglobulins and 
protein A using an ELISA.66-68 A peptide known as protein A mimetic (PAM) peptide was selected 
from this screen, immobilised onto a solid support and used in affinity columns for purifying IgA, 
IgE, IgG, IgM and IgY.69-72  
 
Verdoliva et al. then synthesised the inverso form of this peptide known as ‘D-PAM peptide’  for a 
more effective purification of IgG.73 D-PAM peptide comprises four subunits of the tripeptide 
(R)Tyr-(R)(S)Thr-(R)Arg on a scaffold of a Gly and three (S)Lys residues.74 D-PAM peptide was also 
studied for the treatment of the inflammatory disease systemic lupus erythematosus.74,75 Rossi et 
al. more recently studied D-PAM peptide as a potential allergy treatment and it was found to bind 
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selectively to IgE when tested using ELISA and SPR experiments, inhibit β-hexosaminidase release 
from RBL cells (IC50 = 5 μM) and suppress rat passive cutaneous anaphylaxis.76 However, D-PAM 
was not found to disrupt the interaction between IgE and FcεRI which suggests it may only bind to 
IgE that is already bound to FcεRI. It could work by adding a broad positive charge to the FcεRI-
bound IgE, causing repulsion between IgE molecules and preventing them from cross-linking and 
activating the cell. The structure of  D-PAM peptide can be seen in Figure 13. 
 
 
Figure 13: D-PAM peptide inhibitor developed from affinity purification of antibodies 
D-PAM peptide was synthesised by Verdoliva et al. and inhibits the IgE:FcεRI interaction (IC50 = 5 μM)76. 
 
Val(6)Ala(12) MCD peptide 
Natural products extracted from the venom of bees, wasps and ants have the potential to be used 
as pharmaceuticals.77 Buku et al. studied a series of biologically active peptides extracted from the 
venom of the European honey bee and found a disulfide-constrained, bicyclic peptide, known as 
mast cell degranulating (MCD) peptide.78-85 At low concentrations MCD peptide was found to have 
histamine-releasing activity and at high concentrations it was found to have anti-inflammatory 
activity and was therefore interesting for its application to inflammation and allergies.78-81 Further 
investigation found that MCD peptide was able to bind to RBL mast cell surfaces by receptor-
mediated endocytosis and prevent the binding of IgE.82  
 
MCD peptide was then prepared synthetically and this peptide also competed with IgE for binding 
FcεRI when tested with a fluorescence polarisation assay (IC50 = 114 μM).82 Alanine scanning on 
MCD peptide found that substituting Pro(12) for Ala(12) gave a more potent peptide, known as 
Ala(12)MCD peptide82-84, which  bound  strongly   to  FcεRI  when  tested  using RBL cells transfected 
with fluorescent IgE (IC50 = 40 nM).85 Ala(12)MCD peptide also displayed low histamine-releasing 
activity when tested using peritoneal mast cells (ED50 =   212   μM).85 Further analogous peptides 
were synthesised and substituting Lys(6) for Val(6) gave a peptide, known as Val(6)Ala(12)MCD 
peptide, that still bound strongly   to  FcεRI   (IC50 = 600 nM) and almost completely inhibited mast 
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cell secretion when tested using a β-hexosaminidase release assay (ED50 =   6.6   μM).85 Binding 
affinity in the nanomolar range is noteworthy and a positive feature of this peptide inhibitor, 
however at 22 residues long this peptide has quite a high molecular weight therefore may have 
limited therapeutic potential without the use of a delivery vehicle. In addition, the fact that 
Val(6)Ala(12)MCD   peptide   binds   to   FcεRI,   rather   than   IgE,   could   be   undesirable   for the reasons 
mentioned previously.  The structure of this peptide can be seen in Figure 14.  
 
 
 
Figure 14: Val(6)Ala(12)MCD peptide inhibitor optimised from bee venom peptide 
Val(6)Ala(12)MCD peptide was synthesised by Buku et al. and inhibits the IgE:FcεRI interaction (IC50 = 600 
nM).85 (NB: -NH2 denotes free N-terminus, -CONH2 denotes amidated C-terminus). 
 
1.5.4 Overview of peptide inhibitors of the IgE:FcεRI PPI 
As described in this section, there are a variety of disulfide-constrained, cyclic peptide inhibitors of 
the IgE:FcεRI interaction that have been reported in the literature. These peptides are either 
based on functional epitopes of IgE or FcεRI or have been identified by other means such as phage 
display and show inhibition in the micromolar to nanomolar range. A summary of these peptide 
inhibitors can be seen in Table 1 and they are listed in order of potency. The peptides have 
molecular weights in the range of ~ 1300 – 2500 and Table 1 shows that in general the larger 
peptides are better able to inhibit the IgE:FcεRI interaction than the smaller peptides. For example, 
the most active peptide inhibitor, ζ-peptide, has MW 2534 and IC50 = 32 nM whereas the least 
active  peptide  inhibitor,  2,2’-tolan peptide, has MW 1324  and IC50 = 660 μM.  
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Name/ 
Synthesised by MW 
Method of 
development 
Binding 
partner 
IC50/ 
assay type 
ζ-peptide 
Nakamura et al.64 2534 Phage display FcεRI 
32 nM 
activation of RBL cells 
[Val6,Ala12] MCD peptide 
Buku et al.85 2532 
Isolated from 
been venom FcεRI 
600 nM 
β-hexosaminidase release  
Ro 25-9660 peptide 
Danho et al.59 2161 Mimics  FcεRI Unknown 
2  μM 
undisclosed binding assay 
D-PAM peptide 
Rossi et al.76 2141 
Affinity 
purification  IgE 
5  μM 
β-hexosaminidase release 
Cyclo(L-262) peptide 
McDonnell et al.57 1567 Mimics  FcεRI IgE 
30  μM   
β-hexosaminidase release 
PepE peptide 
Sandomenico et al.61 1994 Mimics  FcεRI IgE 
32  μM 
SPR 
2,2’-tolan peptide 
Spivey et al.56 1324 Mimics IgE Unknown 
660  μM 
ELISA 
 
Table 1: Peptide inhibitors of the IgE:FcεRI PPI in order of potency 
 
1.6 Natural product inhibitors of the IgE:FcεRI PPI 
1.6.1 Aspercyclide A and analogues 
Singh et al. used an IgE:FcεRI binding ELISA to screen natural product extracts of microbial origin 
and identified a fungal extract that displayed activity.86 Following fractionation of the extract using 
a bioassay, three novel compounds were isolated; aspercyclides A, B and C and the only active 
compound of these was aspercyclide A which inhibited IgE binding (IC50 = 200 μM) (Figure 15).86 
Despite the only moderate affinity of aspercyclide A, it has a low molecular weight of 410 so its 
ability to inhibit a high affinity PPI is significant and it is an interesting starting point for the design 
and synthesis of analogues. 
 
 
 
Figure 15: Structures of Aspercyclides A, B and C 
Aspercyclide A        Aspercyclide B             Aspercyclide C 
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Furstner et al. then reported the total synthesis of (+)-aspercyclide A, which employed a 
diastereoselective Nozaki-Hiyama-Kishi reaction as the key cyclisation step to form the core of the 
molecule.87 This synthesis was completed in 14 steps, however (+)-aspercyclide A was unstable 
and purification resulted in decomposition, therefore this synthetic route may be of limited use for 
analogue synthesis. Also, since the NHK reaction installs both stereocentres at the same time, it is 
likely that the diastereomeric ratio would vary between analogues. Yoshino et al. later reported 
another total synthesis of (+)-aspercyclide A, which employed an intramolecular oxidative diaryl 
ether formation of a diphenol and phenolic oxidation to give the aryl C-O bond.88 This synthesis 
was also completed in 14 steps with control of chemo-, stereo- and region-selectivity, however no 
biological data was reported for (+)-aspercyclide A. They also later reported a similar synthesis of 
the related but inactive compound (+)-aspercyclide C.89 
 
Spivey et al. reported the total synthesis of (±)-aspercyclide A and its C19 methyl ether, employing 
a Heck-Mizoroki reaction as they key macrocyclisation step.90 The synthesis of (±)-aspercyclide A 
was completed in 8 steps and its C19 methyl either completed in 7 steps, with one less step 
needed for this compound as it used a commercially available acetal as the starting material. Both 
compounds were tested with an ELISA and displayed similar activities to those first reported by 
Singh; (±)-aspercyclide A (IC50 = 95 μM) and (±)-aspercyclide A C19 methyl ether (IC50 = 110 μM).90 
Spivey et al. then reported a new synthesis of (±)-aspercyclide A C19 methyl ether, which used a 
Pd(0)-catalysed, fluorous-tagged, germyl-Stille reaction as they key macrocyclisation step.91 The 
enantiomers were separated by chiral stationary phase high-performance liquid chromatography 
(CSP-HPLC) and the (+)-enantiomer was 10 times more active than the (-)-enantiomer when tested 
using an ELISA (IC50 = 40 μM for (+)-enantiomer and IC50 = 483 μM for the (-)-enantiomer).91  
 
Spivey et al. went on to develop the enantioselective synthesis of (+)-aspercyclide A using Krische 
iridium-catalysed diastereo- and enantioselective alkoxyallylation to form the key anti-diol 
intermediate, and this (+)-aspercyclide A inhibited the IgE:FcεRI interaction as before when tested 
with an ELISA (IC50 = 5 - 200 μM).92 It was considered, however, that the benzaldehyde of 
aspercyclide A could potentially react irreversibly with amines of protein lysine residues to form 
Schiff bases and lead to toxicity.93 In order to check that the activity of (+)-aspercyclide A was not 
due to such non-specific binding, an analogue containing a benzoxathiazine moiety in place of the 
aldehyde was synthesised and this compound also inhibited the IgE:FcεRI interaction with a similar 
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potency (IC50 = 160 – 460 μM).92 This work forms part of this PhD thesis and so will be discussed 
further in Chapter 3. 
 
Aspercyclide A is a good starting point for the synthesis of further analogues with the aim of 
improving affinity, but it would be important to determine the mode of action of these 
compounds to facilitate the development of more potent analogues, as it is not currently known 
whether they bind to IgE or FcεRI. 
 
1.7 Other inhibitors of the IgE:FcεRI PPI 
1.7.1 Synthetic fluorescein dyes 
The Heska Corporation reported another class of small molecule inhibitors of the IgE:FcεRI 
interaction, the synthetic fluorescein dyes K2-rose bengal, Na2-rose bengal and ethyl eosin (Figure 
16).94,95 These dyes exhibited a range of activities when tested using functional whole-cell assays 
and rat passive cutaneous anaphylaxis models (IC50 = 0.48  - 5.0 mM).94,95  The binding mode of 
these compounds is not reported, but it is thought to be non-specific binding therefore the 
compounds are likely to have limited potential for development for therapeutic use.  
 
 
Figure 16: Structures of synthetic fluorescein dyes Rose Bengal and Ethyl Eosin  
 
1.7.2 Oligonucleotides 
Wiegand et al. reported various oligonucleotide inhibitors of the IgE:FcεRI  interaction,  discovered 
using a systematic enrichment of ligands by exponential enrichment method (SELEX).96 Three 
libraries of oligonucleotides were found to bound to IgE with high affinity; 25-nucelotide RNA 
ligands (Kd ~ 35 nM), 35-nucleotide RNA ligands (Kd ~ 30 nM) and 37-nucleotide single-stranded 
DNA ligands (Kd ~ 10 nM).96 An RBL cell-based ELISA was used to test the ability of the 
oligonucleotides to inhibit the IgE:FcεRI interaction and it was found they bound to two distinct 
but overlapping sites on the IgE Cε3 domain. Oligonucleotides are reasonably large molecules 
(MW ~ 7 – 20 kDa) so may have limited therapeutic use by oral administration. 
K2-Rose Bengal       Na2-Rose Bengal        Ethyl Eosin 
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1.7.3 Designed ankyrin repeat proteins 
Eggel et al. reported the use of ribosome display and ELISA screening to identify a series of 
designed ankyrin repeat proteins (DARPins) that inhibited the IgE:FcεRI interaction.97 Two 
monovalent DARPins that recognised different epitopes of FcεRI were identified from SPR 
experiments and these were fused together to create the bispecific DARPin known as C-A3-30/B-
A4-85. This DARPin bound to FcεRI with very high affinity (Kd = 0.067 nM), inhibited the IgE:FcεRI 
interaction and prevented IgE-mediated degranulation from RBL cells transfected with FcεRI.97 A 
similar method was used to identify the bivalent DARPin known as E2_79/E2_79 which bound with 
a high affinity to the IgE Cε3 domain (Kd = 0.88 nM) and inhibited the release of proinflammatory 
mediators from RBL cells expressing FcεRI (IC50 = 0.54 nM).98 DARPins that bind to IgE may be a 
possible alternative allergy treatment to omalizumab after extensive in vivo studies. Eggel et al. 
then went on to describe a fusion protein known as DE53-Fc, which consisted of IgE-Fc fused to a 
DARPin that specifically bound to IgE, which could attach FcεRI-bound IgE to the low-affinity IgG 
receptor FcγRII and inhibit allergen-induced activation of basophils.99   
 
Kim et al. later reported the co-crystal structure of DARPin E2_79 bound to IgE-Fc3-4, where 
residue 335 of IgE was mutated to Cys(335) to keep IgE-Fc3-4 in the closed conformation where it 
cannot bind to FcεRI.100 This co-crystal structure showed that DARPin E2_79 bound to the IgE Cε3 
domain but did not interact with those residues involved in binding to FcεRI, which lead to the 
suggestion that DARPin E2_79 bound to the IgE:FcεRI complex and partially overlapped with IgE 
residues  binding  to  FcεRI  at  binding  site  2.  Kinetic  modelling  and SPR studies indicated that E2_79 
bound  to  FcεRI-bound IgE with a 2:1 stoichiometry and was thought to cause dissociation of the 
IgE:FcεRI  complex  by  competing  for  binding  to  FcεRI  at  site  2,  partially  exposing  these    interfaces  
and causing full dissociation  in  what  was  referred  to  as  a  ‘facilitated  dissociation’  mechanism.100 
 
Eggel et al. then assessed the therapeutic potential of the DARPin E2_79 in comparison to 
omalizumab.101 They  showed  that  DARPin  E2_79  could  remove  IgE  from  FcεRI  in  a  dose-dependent 
manner, when tested with competitive ELISA and SPR experiments. Omalizumab was also found to 
act in the same way as DARPin E2_79 but to a lesser extent. It was also found that DARPin E2_79 
could remove IgE from primary human basophils expressing  FcεRI  which prevented IgE-dependent 
cell activation and subsequent release of proinflammatory mediators. Further studies on the 
pharmacokinetics of DARPins would be required, but they seem promising to be studied as a 
potential alternative to omalizumab for allergy treatment. 
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1.8 Testing inhibitors of the IgE:FcεRI PPI 
To effectively test inhibitors of the IgE:FcεRI PPI, or indeed any PPI, a sensitive, reproducible and 
robust assay is required in order to distinguish between compounds that display a range of 
activities.102 In addition, if an assay is also simple, automatable, high-throughput and cost-effective 
it can be amenable to HTS, whereby large numbers of compounds in a library are quickly tested 
against  a  target  in  order  to  identify  active  compounds  or  ‘hits’  for  further  studies.103 Some useful 
parameters for measuring the suitability or quality of an assay are signal to background ratio (S/B) 
and signal to noise ratio (S/N):102  
 
 
 
 
However, the S/B and S/N are not always reliable parameters for assay quality as they do not fully 
take into account signal and background variability and the dynamic range of the signal. The data 
variability band for a given signal is defined by the mean of the signal ± 3 standard deviations, 
which gives a 99.73% confidence limit.102 A   ‘hit’  would  be  a   signal   that  was   significantly   shifted  
away from the mean of the general sample population. The difference between the data 
variability band for the sample and for the control, known as the separation band, is a 
useful  ’window’  for  defining  hit  compounds  and  is  also  referred  to  as  the  usable  dynamic  range  of  
an assay (Figure 17). 
 
Figure 17: Schematic of data variability bands and separation band for a HTS assay 
The data variability band for a signal is the mean (μ) ± 3 standard deviations (σ). The difference between 
the data variability band for the sample (s) and for the control (c) is known as the separation band and is a 
useful  ‘window’  for  defining  hit  compounds. 
  
  
S/B = mean signal – mean background  
standard deviation of background 
mean signal 
mean background  S/N = (Eq. 1) (Eq. 2) 
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As there are various units in which this separation band can be expressed, it is useful to have a 
simple, dimensionless parameter to describe it and this is known as the Z-factor. The Z-factor is 
defined as the ratio of the separation band to the assay signal dynamic range and is preferable to 
S/B and S/N as it takes into account data variability and the dynamic range and it can be used to 
compare assays of different format since it has no dimensions:102  
 
 
 
The Z-factor is always less than or equal to 1 and the higher the Z-factor the better the assay, since 
a good assay has a large signal dynamic range and a low data variability. An assay can be 
categorised according to its Z-factor (Table 2). 
Z-factor Assay Quality 
1 Ideal 
0.5 – 1 Excellent 
0 – 0.5 Good 
0 Poor 
< 0 Screening impossible 
 
Table 2: Categorisation of assay quality by Z-factor 
 
1.8.1 In vitro binding assays 
Enzyme-linked immunosorbent assay (ELISA) 
Since being first described in 1971 by Engvall and Perlmann104 and also by Van Weemen and 
Schuurs105, ELISAs have had widespread use as a biochemical assay, as a diagnostic tool in 
medicine, in toxicology and even in the food industry.106 ELISAs can be used to measure PPI 
binding and therefore the competition between a PPI and a small molecule inhibitor.107 This is 
achieved by immobilising the first protein to a multi-well plate surface, blocking any unbound sites 
on the plate surface, then allowing the second protein to bind to the first protein. After washing 
off any unbound protein, the second protein is then detected by adding an enzyme-labelled 
antibody which binds to the second protein. The enzyme substrate is then added, which reacts 
with the enzyme to produce a measurable readout which is proportional to the amount of second 
protein bound (Scheme 2). Washing between each of these steps removes any substance not 
specifically bound. 
(3 x standard deviation of sample) + (3 x standard deviation of control)  
│  mean of sample – mean of control │ Z-factor  =  1  - (Eq. 3) 
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Scheme 2: Overview of a general ELISA for measuring a PPI 
 
ELISAs have the benefit of being highly adaptable. The first protein can be immobilised by passive 
adsorption to the plate (as in Scheme 2), by antibody capture or by using a biotinylated protein 
and streptavidin capture.107 The second protein can be detected by directly labelling the second 
protein with an enzyme, by adding an enzyme-labelled antibody that binds to the second protein 
(as in Scheme 2) or by using a biotinylated second protein and using enzyme-labelled streptavidin. 
Finally, the enzyme can react with its substrate to give absorbance, fluorescence or luminescence 
readouts. Another benefit is that ELISAs are usually very sensitive assays as the signal is amplified 
as a result of using an enzyme. However, the drawbacks of ELISAs are that they require multiple 
steps, which can reduce throughput and can also result in false positive results due to the number 
of secondary reagents used.  
 
Despite these drawbacks, ELISAs are widely used and they have been applied to test the inhibition 
of   the   2,2’-tolan peptide56, the IgE Trap peptide60,61, the DPAM peptide76, aspercyclide A 
compounds86,90,91, oligonucleotides96 and DARPins97 against the IgE:FcεRI interaction.   
 
Förster/Fluorescence resonance energy transfer (FRET) assay 
An alternative assay to the ELISA for measuring the competition between a PPI and a small 
molecule inhibitor, that is potentially higher throughput, is the FRET assay.108,109 FRET was 
originally described by Förster110 in 1948 and has since found numerous applications in biological 
sciences. FRET is the process of non-radiative energy transfer between a donor fluorophore and an 
acceptor fluorophore, which both have specific spectral properties. This energy transfer occurs 
immobilised 
protein 1 
protein 2 binds 
to protein 1 
enzyme-labelled 
antibody binds to 
protein 2 
enzyme reacts 
with substrate 
to give a 
measurable 
signal 
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when the emission spectrum of the donor fluorophore overlaps with the excitation spectrum of 
the acceptor fluorophore (Figure 18).  
 
Figure 18: Overlap of the emission and excitation spectra of a donor and acceptor fluorophore 
The emission spectrum of the donor fluorophore and the excitation spectrum of the acceptor fluorophore 
overlap, meaning FRET can occur between the two fluorophores. 
 
When the donor fluorophore is excited, energy is transferred to the acceptor fluorophore via long-
range dipole-dipole interactions, and emission from the acceptor is observed (Scheme 3). The ratio 
of the acceptor emission to the donor emission, following excitation, comprises the assay readout 
and is proportional to the amount of protein complex formed. This energy transfer only occurs 
when the two fluorophores are in close proximity to each other, usually within 10 nm or less, 
which makes it a very useful technique for measuring the interaction of two proteins as this is the 
distance over which many proteins interact. 
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Scheme 3: Overview of a general FRET assay for measuring a PPI 
 
FRET efficiency (EFRET) is measured by the following equation107: 
 
 
where r is the distance between the fluorophores and R0 is the Förster distance at which FRET 
efficiency is 50% for the specific donor/acceptor fluorophore pair. The energy transfer is inversely 
proportional to the sixth power of distance between the fluorophores, meaning FRET is extremely 
sensitive to even small changes in distance. R0 depends on the spectral overlap of the donor 
emission spectrum and the acceptor excitation spectrum. A large spectral overlap means FRET can 
be observed over longer distances, however 10 nm is the limit for most donor/acceptor pairs. 
 
A variety of fluorophores can be used for a FRET assay, from small molecules107 such as fluorescein, 
tetramethylrhodamine, 5-((2-aminoethyl)amino)naphthalene-1-sulfonic acid (EDANS), 4-([4-
(dimethylamino)phenyl]azo)benzoic acid (DABCYL), cyanines and Alexa Fluor compounds to 
biologically encoded proteins such as green fluorescent protein (GFP)111. The main benefit to the 
FRET assay is that it is carried out in solution, so no immobilisation or washing steps are needed 
donor 
fluorophore 
acceptor  
fluorophore 
protein 1 protein 2 
excite 
donor 
donor 
emits 
excite 
donor 
acceptor 
emits 
FRET 
>10 nm 
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Proteins not 
bound  
= no FRET 
Proteins 
bound  
= FRET 
1 
1 + (r/R0)6  
EFRET = (Eq. 4) 
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and no secondary reagents are required to detect the amount of proteins bound. This makes the 
FRET assay faster and more amenable to HTS than the ELISA. 
  
An intramolecular FRET assay has been applied to study the IgE:FcεRI interaction by Hunt et al., 
who labelled IgE-Fc with biologically encoded proteins to measure the conformational changes on 
binding to FcεRI.23 Monomeric red fluorescent protein (mRFP) was fused to the IgE-Fc Cε2 domain 
and enhanced green fluorescent protein (eGFP) was fused to the IgE-Fc Cε4 domain, positioning 
the fluorophores ~ 9 nm apart so FRET could occur. On binding of this labelled IgE to FcεRI, IgE 
became more bent, so the fluorophores moved closer together and the FRET signal increased.  
 
Despite the benefits and widespread use of FRET assays, there are some drawbacks. 
Autofluorescence from the buffer and from the compounds being tested may affect the signal and 
light scattering from precipitated compounds and coloured compounds can absorb excitation and 
emission radiation. Another problem is that a wide acceptor excitation spectrum may cause the 
acceptor to be excited directly by incident light. Finally, FRET assays do require the proteins to be 
labelled with fluorophores, which may affect the protein function. A variation of the FRET assay 
known as a time-resolved FRET (TR-FRET) or a homogeneous time-resolved FRET (HTRF) has been 
developed which overcomes some of these challenges. 
 
Time resolved – fluorescent resonance energy transfer (TR-FRET) assay 
TR-FRET uses donor fluorophores with long emission half-lives of up to 1500 μs, most notably 
chelates of the lanthanides terbium3+ (Tb3+) and europium3+ (Eu3+).112-120 The long lifetimes of 
these lanthanides means that a time delay of 50 – 150 μs can be introduced between excitation of 
the donor and measurement of the acceptor emission.114 This time delay means that any 
autofluorescence from the buffer or inhibitors being tested and any acceptor excitation from 
incident light will have decayed (these occur on the ns timescale) before the measurement of the 
acceptor emission (Figure 19). Another benefit of the TR-FRET assay is that the lanthanides have a 
slightly larger proximity limit for FRET to occur, of up to 20 nm, which means that larger 
biomolecular complexes could be measured.114 The use of these lanthanides means this technique 
can also be referred to as lanthanide resonance energy transfer (LRET). 
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Figure 19: Improvement in FRET signal due to time delay  
A time delay of 50 – 150 μs after donor excitation and before measurement means that autofluorescence 
from buffer or inhibitors has decayed. 
 
Polyaminocarboxylates113 are commonly used as chelates for Tb3+ and Eu3+, with the 8-dentate 
diethylenetriaminepentaacetic acid (DTPA) chelate115,116,119 being the most popular, but other 
chelates such as triethylenetetraaminehexanoic acid (TTHA)121 are also used as well. The chelate is 
covalently linked to a chromophore such as 7-amino-4-methyl-2(1H)-quinoline (carbostyril 124 or 
cs124)113,115,116,119, or a derivative of this122,  which  acts  as  an  ‘antenna’  or  sensitiser  to  absorb  the  
excitation light. The chelate is also linked to an amine-reactive functional group115 (eg. an 
isothiocyanate) or a thiol-reactive functional group116,119 (eg. a maleimide) for attachment to a 
protein. 
 
TR-FRET assays have been used to study the interactions between IgE and its receptors FcεRI and 
CD23. Kim et al. applied the technique of TR-FRET for monitoring and finding inhibitors of the 
IgE:FcεRI interaction, using a Tb donor fluorophore attached to an anti-His-tag antibody (known as 
Tb-Ab), an Alexa Fluor 488 acceptor fluorophore attached to  IgE-Fc (known as A488-IgE-Fc) and 
His-tagged FcεRIα (known as His-FcεRIα).123 In the assay Tb-Ab bound to His-FcεRIα, then A488-
IgE-Fc bound to His-FcεRIα to form a complex and FRET occurred between Tb-Ab and A488-IgE-Fc. 
They tested the DARPin E2_79100 as an inhibitor of the IgE:FcεRI interaction, as described in 
section 1.7.3, and found that in caused a concentration-dependent reduction in the FRET signal, 
demonstrating this TR-FRET assay was a robust method for testing inhibitors of the IgE:FcεRI 
interaction. 
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Dhaliwal et al.26 and Borthakur et al.27 used TR-FRET for monitoring the binding of IgE to its 
receptors FcεRI and CD23. IgE-Fc was labelled with the acceptor fluorophore Alexa Fluor 647 
(known as A647-IgE-Fc) and each receptor was labelled with a Tb chelate donor fluorophore 
(known as Tb-derCD23 and Tb-sFcεRIα). TR-FRET experiments showed that unlabelled sFcεRIα 
could displace Tb-derCD23 from IgE and that unlabelled derCD23 could displace Tb-sFcεRIα  from  
IgE, which confirmed that IgE cannot bind both receptors at once.26  
 
Drinkwater et al. recently used intramolecular TR-FRET to study the conformations of IgE-Fc and 
how it flexes between acutely bent and extended conformations.33 The IgE-Fc Cε2 domain was 
labelled with a Tb chelate donor fluorophore and the IgE-Fc Cε4  domain was labelled with biotin 
and then conjugated to streptavidin labelled with the acceptor fluorophore Alexa Fluor 488. FRET 
occurred between the donor and acceptor fluorophores due to the acutely bent conformation of 
IgE which brought them into close proximity. As IgE became extended, on trapping in the 
extended  conformation  by  aεFab as described in section 1.3, there was a decrease in FRET due to 
the fluorophores moving apart. 
 
Fluorescence anisotropy/polarisation assay 
Fluorescence anisotropy or polarisation is another fluorescence technique that is used to study the 
binding of proteins and a small molecule inhibitor or ligand.107,124,125 If a small molecule inhibitor 
labelled with a fluorophore is excited with polarised light, it emits light that has a degree of 
polarisation inversely proportional to the rate that the molecule is rotating. Since small molecules 
tend to rotate faster than large molecules, they will emit depolarised light. If the fluorescently-
labelled small molecule then binds to a protein, it rotates much more slowly and therefore if it is 
excited with polarised light, it will emit light that remains polarised. The change in polarisation of 
emitted light can therefore be used to measure the extent of the binding of the small molecule to 
the protein.  
 
1.8.2 Cell-based activity assays 
Whilst the ELISA, TR-FRET and other binding assays described in section 1.8.1 can determine the 
ability of a compound to bind to one of the proteins and inhibit the PPI between IgE and FcεRI, it is 
important to also test if an inhibitor can actually prevent the subsequent downstream cellular 
activity as a result of the IgE:FcεRI PPI. Various cell-based assays have been used to test if 
inhibitors can prevent mast cell degranulation (the release of proinflammatory mediators from a 
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mast cell). RBL cells are most commonly used for studying allergies, as they are physiologically 
similar to mast cells but are a more stable cell line in tissue culture.126  The ability of an inhibitor to 
inhibit passive sensitisation of RBL cells with IgE and prevent the release of the mast cell enzyme 
β-hexosaminidase is a technique that has been used with the cyclo(L-262) peptide44,57, the PepE 
peptide61, the D-PAM peptide76 and the Val(6)Ala(12)MCD peptide85. Another mediator of mast 
cell degranulation is 5-hydroxytryptamine (serotonin) and the AB loop peptide was tested for its 
ability to inhibit IgE-triggered 5-hydroxytryptamine secretion from RBL cells transfected with 
FcεRI.54 RBL cell based assays have also been used to test the β-hairpin peptide63 and the DARPin 
C-A3-30/B-A4-8597 inhibitors of the IgE:FcεRI interaction. 
 
1.8.3 Biophysical assays and structural techniques 
Surface Plasmon Resonance (SPR)  
SPR is a useful biophysical technique that can be used to study PPIs.107 SPR is a phenomenon that 
occurs when light is reflected off a conducting film positioned between two substances with a 
different refractive index. In a typical SPR experiment, the conducting film is a thin gold layer onto 
which the first protein is immobilised.  Microfluidics are then used to inject a solution containing 
the second protein over the immobilised protein. Formation of the protein-protein complex 
causes a change in refractive index of the sample, which changes the angle/intensity of the 
reflected light and is a measurable signal. The first SPR instrument was developed by Biacore (now 
part  of  GE  Healthcare)  and  so  sometimes  this  technique  can  be  referred  to  as  ‘Biacore’,  however  
SPR is now widely used and many other companies also market SPR instruments. 
 
As well as measuring PPIs, SPR can also be used to measure the competitive inhibition of a PPI by 
an inhibitor and also the binding of an inhibitor directly to an immobilised protein. The change in 
signal is proportional to the change in mass on the conducting film (since proteins have near 
identical refractive index values). It is therefore usually easier to measure binding of a second 
protein to an immobilised protein (which would give a large increase in mass on the surface), 
rather than to measure binding of a small molecule to an immobilised protein (which would give a 
small increase in mass on the surface). However, many instruments are now sensitive enough to 
detect even these small changes in mass. SPR is a very versatile technique and can measure 
binding stoichiometry, reversibility and affinity through kinetic or steady-state experiments and 
binding can be monitored in real time.127,128  
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SPR has been widely used to study the interactions of inhibitors of the IgE:FcεRI PPI. The binding 
affinity of cyclo(L-262) peptide to IgE was measured with SPR44,57, IgE-Trap peptide was found to 
bind selectively to IgE over other immunoglobulins when tested with SPR60, the binding affinity of 
PepE peptide to IgE was measured with SPR, competition experiments were also carried out to 
measure the inhibition of the IgE:FcεRI interaction with PepE peptide61 and D-PAM peptide was 
found to bind specifically and selectively to IgE using SPR experiments76. SPR has also been used to 
measure how DARPins can modulate the IgE:FcεRI interaction and it was found by SPR that DARPin 
E2_79 bound with a 2:1 stoichiometry to IgE that was already bound to FcεRI and caused the 
dissociation of the IgE:FcεRI complex.100 
 
X-ray crystallography 
X-ray   crystallography   is   sometimes   referred   to   as   the   ‘gold   standard’   technique   for  determining  
how a small molecule interacts with its protein target. Obtaining a high resolution x-ray co-crystal 
structure of a protein with a small molecule bound, can give valuable information on exactly what 
contacts are made between the small molecule and the protein at the binding site and can 
facilitate the development of molecules that bind with a higher affinity. A co-crystal structure can 
be obtained either by soak crystallisation (soaking the compound into crystals of the protein) or by 
co-crystallisation (growing protein crystals in the presence of the compound). However, it can 
sometimes be challenging to obtain a co-crystal structure; if the protein does not crystallise well, if 
the compound binding to the protein causes changes in the protein structure that prevent 
crystallisation, or if the compound has poor affinity or solubility. 
 
X-ray crystallography has been widely used to study the interaction between IgE and FcεRI (as 
described in section 1.3). It has also been used to obtain a co-crystal structure of the ζ-peptide 
bound to FcεRI65 (Figure 12), which appears to be the only published co-crystal structure of an 
inhibitor of the IgE:FcεRI interaction bound to one of the proteins. 
 
Nuclear magnetic resonance (NMR) spectroscopy 
NMR spectroscopy is an alternative technique to x-ray crystallography for determining a protein 
structure and for carrying out experiments with proteins and small molecules.129 Firstly, NMR 
experiments can measure the signal changes for a small molecule as it binds to a protein. An 
example of this type of experiment is saturation transfer difference (STD) NMR, where energy is 
transferred from the solvent or protein to the small molecule.130 The signal changes for the small 
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molecule indicate which parts of the molecule are involved in binding to the protein. STD NMR is a 
particularly useful technique as it can be used to measure transient and weak binding inhibitors.  
 
Alternatively, NMR experiments can measure the signal changes for a protein as it interacts with a 
small molecule. 2D NMR experiments with isotopically-labelled proteins are commonly used, and 
one example is 15N-1H heteronuclear single-quantum correlation (HSQC) spectroscopy.34,107 15N-1H 
HSQC gives a signal for every hydrogen bound to a 15N atom, therefore each residue in a protein 
will give one signal and any residues with nitrogen-containing side chains will give additional 
signals. If a small molecule is bound to the protein, any conformational changes in the protein can 
be identified due to changes in signals, which would suggest the part of the protein involved in 
binding. There is a vast array of other 2D NMR techniques that can also be used to study proteins. 
These techniques include homonuclear through-bond correlation methods such as correlation 
spectroscopy (COSY) and total correlation spectroscopy (TOCSY) and through-space correlation 
methods such as nuclear Overhauser effect spectroscopy (NOESY) and rotating frame nuclear 
Overhauser effect spectroscopy (ROESY).34,107,129 
  
Various 2D NMR techniques have been used to study peptide inhibitors of the IgE:FcεRI 
interaction. TOCSY and NOESY were used to show that cyclo(L-262) and cyclo(rD-262) peptide 
inhibitors adopted a stable β-hairpin structure in solution.58 TOCSY, NOESY, COSY and ROESY were 
used to determine that the β-hairpin peptide and the ζ-peptide inhibitors adopted stable β-hairpin 
structures in solution.63,64 
 
Isothermal titration calorimetry (ITC) 
ITC is a useful technique for measuring the thermodynamics of binding of a small molecule to a 
protein, by measuring the heat absorbed or generated by the interaction.107 This allows the 
binding affinity, enthalpy, entropy and stoichiometry to be determined. ITC is useful as it directly 
measures the energy of binding meaning no labels are required and it is carried out in solution. 
However, for weak inhibitors the heat of binding can only be small and in general relatively large 
quantities of the protein partners are required to obtain useful results. 
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Differential scanning calorimetry (DSC) and differential scanning fluorimetry (DSF/thermal shift 
assay) 
These techniques are based on the fact that when a small molecule binds to a protein, the 
resulting complex is more stable than the protein by itself, therefore the melting temperature (Tm) 
of the protein increases.107 By measuring the increase in Tm as a compound binds to a protein, the 
binding affinity can be determined. DSC measures the heat absorbed by the protein as the 
temperature is increased. DSF measures the binding of a hydrophobic fluorophore to the protein 
as the temperature is increased. The fluorophore binds non-specifically to the hydrophobic parts 
of the protein that get exposed as the protein melts, and this binding causes an increase in 
fluorescence. 
 
1.9 Aims and objectives of PhD 
The long-term goal of this area of research is to identify a potent and selective small molecule 
inhibitor of the PPI between IgE and FcεRI which has good oral bioavailability, favourable 
pharmacological properties and could potentially be developed to have therapeutic use in the 
treatment of allergies. With this is mind, the overall aim of the PhD was to investigate inhibitors of 
the IgE:FcεRI interaction by designing and synthesising small molecule and peptide inhibitors and 
developing and using binding assays, biophysical experiments and structural techniques to test 
these inhibitors. The study of peptide inhibitors of the IgE:FcεRI interaction builds upon work 
carried out in the MRes research project and this will be discussed in Chapter 4. Specific objectives 
for the PhD were to: 
 
1) Develop and optimise a TR-FRET assay to test inhibitors of the IgE:FcεRI interaction 
2) Develop SPR experiments with immobilised IgE and FcεRI 
3) Express and purify individual domains of IgE for further experiments 
4) Test aspercyclide A and analogues as inhibitors of the IgE:FcεRI PPI in the previously 
developed ELISA and the new TR-FRET assay  
5) Test dibenzofurans as inhibitors of the IgE:FcεRI PPI in the ELISA and TR-FRET assays 
6) Synthesise additional peptide inhibitors to add to peptide library developed during MRes 
research project 
7) Test all peptides in the TR-FRET assay 
8)  Carry out x-ray crystallography experiments with IgE-Fc and the most potent peptides and 
small molecules  
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Chapter 2: Assay development and biophysical/structural techniques 
2.1 ELISA 
An ELISA was used to test inhibitors of the IgE:FcεRI interaction, employing the methodology 
developed previously as part of the MRes research project131. This ELISA methodology is described 
in this section and more details can be found in section 6.3. 
 
The two proteins used for the ELISA were IgE-Fc and FcεRIα-IgG4-Fc (the extracellular domains of 
the α-chain of FcεRI fused to the Cγ2 – Cγ3 domains of IgG4), which is referred to as αγ.  These  
proteins were kindly provided by the MRC/Asthma UK Centre in Allergic Mechanisms of Asthma, 
Protein Production Facility  at  the  Randall  Division  of  Cell  and  Molecular  Biophysics,  King’s  College  
London (KCL). As discussed in section 1.3, IgE-Fc consists of the Cε2, Cε3 and Cε4 domain pairs 
which contain key sites for binding of IgE-Fc to the high affinity receptor FcεRI. The αγ fusion 
protein is a substitute for sFcεRIα   as   it   is   easier   to  express   in   large  quantities   and   considerably  
cheaper  than  sFcεRIα. 
 
The first step of the ELISA was immobilisation of αγ  to a flat-bottom F96 MaxiSorp 96-well plate by 
passive adsorption of a solution of αγ (0.02  μM) for 16 hours at 4 °C. This was followed by washing 
with phosphate buffered saline (PBS) with 0.1% Tween 20 surfactant (PBS-T), the Tween 20 acts as 
a detergent to prevent non-specific protein binding, to remove any αγ that was not adsorbed to 
the plate. Bovine serum albumin (BSA) was then added to the plate for 1 hour at 37 °C to block any 
exposed plate surface and prevent any other substances binding non-specifically to the plate, 
followed by washing with PBS-T. A solution of IgE-Fc (0.033 nM), that had been pre-incubated for 1 
hour at room temperature (rt) with the inhibitor, was then added to the plate and incubated at 
37 °C for 1 hour, followed by washing with PBS-T. Inhibitors were prepared in 12 different 
concentrations, with a maximum concentration of 1 mM and 2-fold dilutions to obtain each new 
concentration, and a minimum concentration of 0.5 μM. A potent inhibitor should be able to 
prevent the IgE-Fc from binding to the immobilised αγ on the plate and the next stage of the assay 
involves the detection of the amount of IgE-Fc:αγ complex formed. 
 
Biotinylated anti-IgE-Fc was then added for 1 hour at 37 °C, which would bind to any IgE-Fc that 
was bound to the immobilised αγ, followed by washing with PBS-T. Streptavidin conjugated to the 
enzyme horseradish peroxidase (HRP) was then added for 1 hour at 37 °C, which would bind to 
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any biotinylated anti-IgE-Fc, followed by washing with PBS only. Finally, a solution of the 
chromogenic enzyme substrate ortho-phenylenediamine (OPD) was added for 4 minutes at rt in 
the dark, following which the enzymatic reaction was quenched with 3 M HCl. The colourless OPD 
was oxidised by HRP to give the orange/brown product 2,3-diaminophenazine and the absorbance 
at 492 nm was then measured using a Multiskan EX Microplate Photometer. The amount of 
absorbance was proportional to the amount of IgE-Fc  bound  to  αγ;  the  lower  the  absorbance,  the  
less IgE-Fc:αγ  complex   formed  and  therefore   the  more  potent   the   inhibitor.  An  overview  of   the  
ELISA can be seen in Scheme 4 and the enzymatic reaction can be seen in Scheme 5. 
 
 
 
Scheme 4: Overview of ELISA inhibition assay 
1 = immobilisation of αγ onto the 96-well plate, 2 = addition of IgE-Fc which bound to immobilised αγ, 3 = 
addition of biotinylated anti-IgE-Fc antibody which bound to IgE-Fc, 4 = addition of streptavidin conjugated 
to the enzyme HRP which bound to biotinylated anti-IgE-Fc, 5 = addition of the enzyme substrate OPD, 6 = 
oxidation of OPD by the enzyme HRP to generate the coloured product 2,3-diaminophenazine. Between 
each addition step extensive washing was carried out to remove any substance not specifically bound.  
 
 
 
 
Scheme 5: Oxidation of OPD by the enzyme HRP  
Oxidation of the chromogenic substance OPD by HRP with H2O2 formed the soluble, orange-brown product 
2,3-diaminophenazine in the final stage of the ELISA inhibition assay. The oxidation reaction was quenched 
with 3M HCl after 4 min then the plate was read spectrophotometrically at 492 nm. The amount of signal 
was proportional to the amount of IgE-Fc bound to immobilised αγ. 
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2.2 Development of the TR-FRET assay 
Even though the ELISA described in section 2.1 has been used for testing inhibitors of the IgE:FcεRI, 
it does have some drawbacks, mainly that the multiple processing steps and extensive washing 
required between each step can reduce assay throughput. One main aim of this PhD was therefore 
to develop and optimise a simple and robust TR-FRET assay for testing inhibitors of the IgE:FcεRI, 
which would potentially be higher throughput than the ELISA.  
 
The two proteins used for the TR-FRET assay were IgE-Fc  and  αγ  as  described  in  section  2.1.  It was 
planned to label one protein with a long lifetime donor fluorophore and one protein with an 
acceptor fluorophore. On binding of IgE-Fc   to   αγ, the fluorophores would be in close enough 
proximity that FRET would occur between them. If a compound that inhibited the formation of the 
IgE-Fc:αγ  complex was also present, then the amount of FRET would decrease. The inhibitor would 
be added in increasing concentrations, allowing a dose-response curve to be plotted and therefore 
IC50 values be calculated to allow a comparison between the inhibitors. The IC50 value is defined as 
the concentration of inhibitor required to reduce the response by 50%. 
 
2.2.1 Choice of fluorophores 
As discussed in section 1.8.1, TR-FRET requires a long lifetime donor fluorophore (usually a 
lanthanide chelate) and an acceptor fluorophore, where the donor emission spectrum overlaps 
with the acceptor excitation spectrum. A Tb chelate was chosen as the donor fluorophore and 
Alexa Fluor 647 was chosen as the acceptor fluorophore (Figure 20).  
 
 
 
 
Figure 20: Structures of Tb chelate donor fluorophore and Alexa Fluor 647 acceptor fluorophore  
Alexa Fluor 647 (acceptor) Tb chelate (donor) 
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Tb chelate donor fluorophore 
A Tb chelate fluorophore, with an isothiocyanate reactive group for attachment to the protein, 
was purchased from Invitrogen/Life Technologies. Although the exact structure of the chelate is 
not disclosed by the manufacturers, it was thought to be a DTPA chelate with a cs124 antenna 
attached and a linker such as ethylenediamine between the chelate and the isothiocyanate group, 
as in the papers by Selvin et al.112,115,116,118 Terbium chelates are excited at a wavelength of 340 nm 
and their emission spectrum displays four sharp, distinct peaks at 490 nm, 546 nm, 585 nm and 
620 nm (Figure 21).112,116,118  
 
 
Figure 21: Emission spectrum for Tb chelate donor fluorophore  
The chelate consists of DTPA with a cs124 antenna. Figure adapted from reference.116 
 
Alexa Fluor 647 acceptor fluorophore 
An Alexa Fluor 647 fluorophore with an N-hydroxysuccinimide (NHS) ester reactive group comes 
from an extensive library of Alexa Fluor fluorophores originally produced by Molecular Probes 
(now Invitrogen/Life Technologies) whose excitation and emission spectra cover the visible and 
the near infrared spectrum.132 The number refers approximately to the maximum excitation 
wavelength of the dye in nm. Alexa Fluor fluorophores are synthesised by sulfonation of existing 
fluorophores including rhodamine, fluorescein and cyanine dyes, which makes them negatively 
charged and hydrophilic.132 They generally tend to be brighter, more photostable and less 
sensitive to pH than the original dyes.133 Alexa Fluor 647 has a maximum excitation wavelength of 
650 nm and a maximum emission wavelength of 668 nm (Figure 22).134 This particular fluorophore 
was chosen as an acceptor as the Tb chelate emission peak at 620 nm overlaps with the excitation 
peak at 650 nm for Alexa Fluor 647. 
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Figure 22: Excitation and emission spectra for Alexa Fluor 647 acceptor fluorophore 
Maximum excitation wavelength is 650 nm (dashed line) and maximum emission wavelength is 688 nm 
(solid line). Image adapted from www.lifetechnologies.com Fluorescence SpectraViewer (accessed Nov 
2014). 
 
2.2.2 Format of the TR-FRET assay 
It was decided to label IgE-Fc with Alexa Fluor 647 and to label αγ  with  Tb  chelate.  If no inhibitors 
were present (Scheme 4 A), the labelled IgE-Fc  and  αγ  would  bind  to  each  other  and  this  would  
bring the fluorophores into close proximity. If the Tb chelate donor fluorophore was excited using 
a wavelength of 340 nm, then the energy it emits at 620 nm would non-radiatively transfer to and 
excite the Alexa Fluor 647 acceptor fluorophore, due to the Tb chelate emission peak at 620 nm 
overlapping with the Alexa Fluor 647 broad excitation peak centred at 650 nm. The Alexa Fluor 
647 would then emit at 665 nm. The Tb chelate donor emission would be measured at 620nm and 
the Alexa Fluor 647 acceptor emission would be measured at 665nm. The ratio between these 
values, known as the TR-FRET ratio, would give the signal for this assay.  
 
If an inhibitor was added (Scheme 4 B), the extent to which it inhibited the interaction between 
labelled IgE-Fc  and  αγ  would  be  reflected  in  the  reduction  in  the  TR-FRET ratio; the more potent 
the inhibitor the more the TR-FRET ratio would be reduced. A time delay of 100 μs would be 
allowed, before taking the emission measurements, so that any autofluorescence from the buffer 
or inhibitors or any acceptor excitation from incident light would have decayed, giving a more 
accurate measurement. This assay has the benefit of being homogenous (i.e. all components are in 
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solution) with no washing steps required or secondary reagents needed, therefore it should be 
relatively simple to carry out and higher throughput than the ELISA.  
 
 
 
Scheme 6: Overview of TR-FRET inhibition assay 
A = inhibitor not present therefore IgE-Fc and αγ are bound and FRET occurs. Excitation at 340 nm of Tb 
chelate donor fluorophore on αγ causes non-radiative transfer of energy to Alexa Fluor 647 acceptor 
fluorophore on IgE-Fc due to its close proximity, this causes excitation of the Alexa Fluor 647, which then 
emits at 665 nm. B = inhibitor present therefore inhibition of the IgE-Fc:αγ interaction occurs causing loss of 
FRET. Excitation of Tb chelate donor fluorophore on αγ occurs, but energy transfer to Alexa Fluor 647 
cannot take place as it is too far away, therefore only emission at 620 nm from the Tb chelate is observed. 
 
2.2.3 Fluorescent labelling of proteins 
With the design of the TR-FRET assay decided, the first stage was to label the IgE-Fc and αγ 
proteins with the fluorophores. In both cases, labelling was achieved via the covalent reaction of 
the amine groups of the protein lysine residues with the amine-reactive group on the fluorophore, 
which meant that labelling was non-specific. The advantage of this method, over a site-specific 
reaction on the protein, is that there is no need for protein modification and it is a relatively 
simple reaction to carry out.  
 
The disadvantage could be that multiple labelling reactions may each give a slightly different 
dye:protein ratio, depending on the extent of the lysine labelling, and it may be difficult to control 
this. It may be that one particular dye:protein ratio would give the highest TR-FRET signal. Another 
potential issue could be if key binding regions of the proteins were labelled by a fluorophore, this 
may affect the ability of the two proteins to interact with each other as they would do without the 
label present. However, the fluorophores are much smaller molecules than the proteins, so this 
IgE-Fc-Alexa Fluor 647 (acceptor) 
αγ-Tb chelate (donor) 
excite 340 nm 
emit 665 nm 
FRET 
excite 340 nm 
emit 620 nm 
inhibitor 
A B 
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was not envisaged to be a problem, and the lysine labelling was carried out in the first instance as 
it was the simplest technique.  
 
Labelling of αγ with Tb chelate isothiocyanate 
For the labelling of αγ with Tb chelate isothiocyanate, a solution of Tb chelate isothiocyanate (final 
concentration 378 μM) in dimethylsulfoxide (DMSO) was added to a solution of αγ (final 
concentration 37.8 μM) in carbonate buffer and allowed to react in the dark for 3 hours with 
vigorous shaking, according to the manufacturer’s instructions (Scheme 7). The resulting 
fluorescently-labelled protein (known as αγ-Tb) was then dialysed into PBS at 4 °C for 48 hours in 
the dark to remove any unreacted fluorophore. Further experimental details can be found in 
section 6.2.4. 
 
 
Scheme 7: Mechanism for labelling of a lysine residue of αγ with Tb chelate isothiocyanate 
 
To determine the degree of labelling and to check that the dialysis had removed all the unreacted 
dye, αγ-Tb was subjected to size exclusion chromatography (SEC). This technique uses a porous 
solid phase to separate molecules according to their size. A solution is passed through a column 
which contains porous beads; smaller molecules travel through the pores in the beads and elute 
63 
 
more slowly, whereas larger molecules cannot fit through the pores and so elute more quickly. 
Absorbance, measured at a particular wavelength, detects when a substance elutes.   
 
A solution of αγ-Tb in PBS was subjected to analytical SEC using a Superdex 200 5 x 150 mm gel 
filtration column and a dual wavelength of 280 nm (protein absorption) and 343 nm (Tb chelate 
absorption). Absorbance at 280 nm and at 343 nm both peaked at approximately 3 minutes, which 
indicated that the   αγ   was   successfully   labelled with Tb chelate (Figure 23). Free Tb chelate 
isothiocyanate   is   a  much   smaller  molecule   than  αγ-Tb so would elute later at approximately 10 
minutes. The absence of a 343 nm absorbance peak at 10 minutes indicated that any unreacted Tb 
chelate isothiocyanate was successfully removed during the dialysis. The  final  concentration  of  αγ-
Tb  was  determined  using  a  spectrophotometer  and  found  to  be  5.1  μM and a dye:protein ratio of 
6.3:1 was achieved (see section 6.2.4 for the calculation used to determine this ratio). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: Size exclusion chromatogram of αγ-Tb 
Red trace = absorbance at 280 nm (for αγ), green trace = absorbance at 343 nm (for Tb chelate). Peaks for 
280 nm and 343 nm at approximately 3 min were concurrent which indicated the successful labelling of αγ 
with Tb chelate. No peak between 10 and 15 minutes for 343 nm indicated that any unreacted Tb chelate 
isothiocyanate had been removed from the labelled protein during dialysis. 
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Labelling of IgE-Fc with Alexa Fluor 647 NHS ester 
The IgE-Fc was labelled with Alexa Fluor 647 NHS ester (carried out by Dr Marie Pang, KCL). A 2.5-
fold molar excess of fluorophore was used and the resultant fluorescently-labelled protein (known 
as IgE-Fc-A647) had a dye:protein ratio of 1.9:1 (Scheme 8).  
 
Scheme 8: Mechanism for labelling of a lysine residue of IgE-Fc with Alexa Fluor 647 NHS ester 
 
2.2.4 Purification of IgE-Fc-A647 
At a later time during the course of the research described in this thesis, it was thought that IgE-
Fc-A647 had decomposed, therefore IgE-Fc-A647 was subjected to analytical SEC using a Superdex 
200 10 x 300 mm gel filtration column and measuring protein absorbance at 280 nm. The 
chromatogram showed the presence of a main peak at 17 minutes (for IgE-Fc-A647) and a less 
intense peak at 20 minutes which was assumed to be for a smaller, degraded fragment of IgE-Fc-
A647 (Figure 24). Another small peak at 32 minutes was likely to be for unreacted Alexa Fluor 647 
isothiocyanate. 
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Figure 24: Size exclusion chromatogram of IgE-Fc-A647 
Absorbance was measured at 280 nm. Peak at 17 min indicated IgE-Fc-A647, peak at 20 min indicated 
degraded IgE-Fc-A647 and peak at 32 min indicated unreacted Alexa Fluor 647. 
 
IgE-Fc-A647 was therefore purified using preparative SEC to remove any degraded protein and 
unreacted dye using a Superdex 75 10 x 300 mm gel filtration column and measuring protein 
absorbance at 280 nm. The chromatogram showed the peak at 12 minutes was for the pure IgE-
Fc-A647 and that degraded protein and unreacted dye were successfully removed (Figure 25). A 
sample of unlabelled IgE-Fc was also subjected to preparative SEC to check that the fractions 
containing pure IgE-Fc-A647 were correct and both chromatograms are overlaid in Figure 25. This 
showed that the peak at 12 minutes was for the pure IgE-Fc-A647 and that fractions 3 and 4 were 
pure.  
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Figure 25: Preparative size exclusion chromatogram of IgE-Fc-A647 and IgE-Fc 
Red trace = absorbance at 280 nm for IgE-Fc-A647. Peak at 12 min was for IgE-Fc-A647, peak at 13.5 min 
was for degraded IgE-Fc-A647 and peaks at 19.2 min, 22 min and 23 min were for free Alexa Fluor 647. 
Green trace = absorbance at 343 nm for unlabelled IgE-Fc. Peak at 12 min was concurrent with the peak for 
IgE-Fc-A647. Fractions 3 and 4 contained pure IgE-Fc-A647. 
 
2.2.5 Optimisation of the assay conditions 
Initial binding assays 
To determine if the binding of IgE-Fc and αγ could be measured using TR-FRET, initial binding 
assays were first carried out between IgE-Fc-A647 and αγ-Tb. Assays were carried out in opaque, 
flat bottom 384-well plates at room temperature. TR-FRET dilution buffer was used for all assays, 
however the exact buffer composition was undisclosed by the manufacturers (Invitrogen). Various 
other buffers, including PBS, tris(hydroxymethyl)aminomethane (tris) and 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), were tested by co-workers at KCL, however the TR-FRET 
buffer was found to give by far the highest TR-FRET signal (unpublished results, Dr Marie Pang, 
KCL), which is why it was used for the assays.  
 
As the Kd of the IgE:FcεRI interaction is ~ 0.1 nM4,15,16 it was anticipated that IgE-Fc-A647 and αγ-
Tb concentrations in the low nanomolar range would be suitable. The concentration of αγ-Tb was 
initially fixed at 0.5 nM, 1 nM, 2 nM and 5 nM and in each case IgE-FcA647 was added in increasing 
amounts until a 10-fold molar excess was achieved. The plate was then read using an Artemis 
HTRF-compatible microplate reader. The plate was excited at 340 nm and, following a time delay 
of 100 μs, absorbance was measured at 620 nm and 665 nm. The TR-FRET ratio was calculated by 
the following equation:  
 
IgE-Fc-A647 
IgE-Fc 
emission at 665 nm 
emission at 620 nm TR-FRET ratio = 
(Eq. 5) x 10,000 
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For each assay the TR-FRET ratio was plotted against the concentration of IgE-Fc-A647 using a 4-
parameter logistic to give dose-response or binding curves (Figure 26).  
 
 
 
 
 
 
 
 
 
 
 
Figure 26: TR-FRET binding curves for IgE-Fc-A647 and αγ-Tb  
The concentration of αγ-Tb was fixed at 0.5 nM, 1 nM, 2 nM and 5 nM and in each case IgE-Fc-A647 was 
added in increasing concentrations up to a 10-fold molar excess. 
 
It can be seen that for each binding assay, a high TR-FRET signal of ~ 19,000 was achieved. It was 
therefore decided to use αγ-Tb at the lowest concentration of 0.5 nM, as this would use the least 
material whilst still giving a high signal.  A concentration of 1.25 nM was chosen for IgE-Fc-A647 as 
this is at the highest point of the binding curve for αγ-Tb at 0.5 nM.  
 
Initial inhibition assays 
It was then investigated if these concentrations of IgE-Fc-A647 and αγ-Tb were suitable for an 
inhibition assay, using unlabelled proteins as inhibitors. The concentration of αγ-Tb was fixed at 
0.5 nM, the concentration of IgE-Fc-A647 was fixed at 1.25 nM and unlabelled IgE-Fc was added in 
increasing amounts until a 10-fold molar excess was achieved. This assay was also repeated with 
unlabelled αγ as an inhibitor. The order of addition was investigated in each case; the unlabelled 
protein inhibitor was incubated for 1 hour either with IgE-Fc-A647 or with αγ-Tb, before the other 
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labelled protein was added. The plate was then read straightaway after the addition of the final 
protein. The inhibition curves for unlabelled IgE-Fc as an inhibitor can be seen in Figure 27 and the 
inhibition curves for unlabelled αγ as an inhibitor can be seen in Figure 28. 
 
 
 
Figure 27: TR-FRET inhibition curves for unlabelled IgE-Fc 
The concentration of αγ-Tb was fixed at 0.5 nM, the concentration of IgE-Fc-A647 was fixed at 1.25 nM and 
increasing concentrations of unlabelled IgE-Fc were used up to a 10-fold molar excess. The key denotes the 
order in which the proteins were added. Unlabelled IgE-Fc was incubated with the first labelled protein for 
1 hour, before addition of the second labelled protein. 
 
 
 
 
Figure 28: TR-FRET inhibition curves for unlabelled αγ  
The concentration of αγ-Tb was fixed at 0.5 nM, the concentration of IgE-Fc-A647 was fixed at 1.25 nM and 
increasing concentrations of unlabelled αγ were used up to a 10-fold molar excess. The key denotes the 
order in which the proteins were added. Unlabelled αγ was incubated with the first labelled protein for 1 
hour, before addition of the second labelled protein. 
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Figures 27 and 28 show that good inhibition curves are obtained when using unlabelled proteins 
as inhibitors of the interaction between IgE-Fc-A647 and αγ-Tb. In all cases, when the unlabelled 
protein inhibitor concentration reached a 10-fold molar excess, the TR-FRET signal was reduced to 
a background level. This indicated that the concentrations of labelled proteins were suitable to use 
in subsequent inhibition assays with small molecules or peptides. It can also be seen that the IC50 
values are similar, within error, regardless of the order of addition of the proteins suggesting that 
the proteins are in equilibrium. 
 
The incubation time once all proteins had been added was also investigated. After initial reading 
of the plate, all proteins were incubated for a further hour then the plate was read again. However, 
this gave an almost identical result, likely due to the high affinity of the IgE:FcεRI interaction, 
therefore it was not deemed necessary for any incubation after all proteins were added in 
subsequent inhibition assays. 
 
2.2.6 Comparison of ELISA vs TR-FRET assay 
The main advantages and disadvantages of the ELISA and the TR-FRET inhibition assays are 
summarised in Table 3. The S/B and the Z-factor were calculated with equations 1 and 3 
respectively and using the data from the inhibition assay of Bip(3)-peptide (this peptide will be 
discussed in more detail in Chapter 4). 
 
ELISA 
S/B: 14.7, Z-factor: 0.97 
TR-FRET 
S/B: 12.6, Z-factor: 0.79 
Advantages Disadvantages Advantages Disadvantages 
No need to label 
proteins 
Multiple processing 
steps , takes ~ 1 day 
per assay 
Few processing 
steps, takes ~ 0.5 
day per assay 
Labelling of proteins 
required 
Larger volumes in 96-
well plate - easier 
handling 
Extensive washing 
required 
Homogenous, no 
washing required 
Smaller volumes in 384-
well plate - more 
difficult handling 
 Larger volumes - uses more material 
Smaller volumes - 
uses less material  
 
Higher protein 
concentration - uses 
more material 
Lower protein 
concentration - uses 
little material 
 
 
Table 3: Comparison of advantages and disadvantages of ELISA vs TR-FRET assay 
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It can be seen from Table 3 that the main advantages of the TR-FRET assay over the ELISA are that 
this assay is carried out in solution, with no need to add secondary reagents or carry out extensive 
washing steps and the assay uses lower volumes and concentrations therefore conserving material. 
These factors make the TR-FRET assay more attractive for testing libraries of inhibitors. The Z-
factors in both cases are high (0.97 for the ELISA and 0.70 for the TR-FRET assay) and a good S/B is 
achieved (14.7 for the ELISA and 12.6 for the TR-FRET assay). Whilst these parameters are slightly 
higher for the ELISA, they are still very good for the TR-FRET assay and the advantages of the TR-
FRET assay are such that this was chosen as the assay of choice for future inhibitor testing. 
 
2.3 Expression and purification of IgE Cε2 and Cε3 domains 
In addition to IgE-Fc, it would be useful to have individual domains of IgE to use in experiments 
and investigate their interaction with inhibitors, therefore it was decided to express the Cε2 and 
Cε3 domains of IgE. The Cε3 domains constitute the key region of IgE that interacts with FcεRI (see 
section 1.3) and it was therefore thought that if a compound inhibited the interaction between IgE 
and FcεRI by binding to IgE, it would likely bind to the Cε3 domain. The Cε2 domain of IgE does not 
interact with FcεRI, therefore it would be unlikely that a compound would inhibit the IgE:FcεRI 
interaction by binding to Cε2, although this could be possible if an allosteric mechanism of 
inhibition was adopted. It was thought that the Cε2 and Cε3 proteins could be used in subsequent 
SPR experiments, for compounds that had exhibited inhibition in the ELISA or TR-FRET assays. 
These proteins could also be used for STD NMR experiments and, if they were 15N-labelled, used 
for 15N-HSQC NMR experiments.  
  
2.3.1 Expression and purification of IgE Cε3 domain 
Cε3 was expressed in BL21 Escherichia coli (E. coli) cells grown in minimal media and induced with 
isopropyl β-D-1-thiogalactopyranoside (IPTG) when optical density (OD) had reached at least 0.6, 
according to the procedures of McDonnell et al.135-137 Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) analysis of induced and uninduced cells was used to confirm that 
expression had taken place. Cε3 formed inclusion bodies which were solubilised in a buffer 
containing 6 M guanidinium chloride denaturant to ensure the protein was unfolded. To ensure 
the intradomain disulfide bond form correctly between Cys(358) and Cys(418), refolding was 
carried out using a Ni2+ affinity column. The amount of refolding buffer was gradually increased, 
which meant that the guanidinium-containing solubilisation buffer was gradually decreased, 
allowing the disulfide bond to form (Figure 29). After elution from the Ni2+ column, refolded Cε3 
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was then run through a gel filtration column to remove any unfolded protein. The elution trace 
(Figure 30) shows a single peak for Cε3 confirming that the refolding and purification steps were 
successful. Further details of the Cε3 expression and purification procedures can be found in 
section 6.4. 
 
 
Figure 29: Elution trace from Ni2+ affinity column for first purification of IgE-Fc Cε3 domain 
Blue line = absorbance at 280 nm, red line = % of refolding buffer (increased from 0 – 100% with 
simultaneous decrease of guanidinium chloride from 100 – 0%). 
 
 
 
 
Figure 30: Elution trace from gel filtration column for second purification of IgE-Fc Cε3 domain 
Blue line = absorbance at 280 nm. Single peak indicated successful purification of Cε3. 
 
SDS-PAGE analysis was then used to determine the purity of Cε3 and this was carried out with 5 μg, 
10 μg and 20 μg of Cε3. The SDS-PAGE gel (Figure 31) showed that refolded, pure Cε3 was mainly 
monomeric, with a MW of ~ 14.3 kDa, but that small amounts of dimeric and trimeric Cε3 were 
also present. This meant that Cε3 may need further purification before being used in any 
experiments with inhibitors. The gel also showed that 5 μg was a large enough amount of Cε3 for 
visualisation by SDS-PAGE. 
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Figure 31: SDS-PAGE gel showing IgE-Fc Cε3 domain 
M = molecular weight marker and 20, 10 and 5 refer to the amount in μg of Cε3. 
 
1H NMR spectroscopy was used to characterise Cε3 and the 1H NMR spectrum (Figure 32) was 
typical of a molten globule such as Cε3, which typically lack rigid tertiary structure.136,137 The peak 
at δ ~ 1 parts per million (ppm) is indicative of methyls in a molten globule, as for a well folded 
protein these would normally appear more upfield at around 0.5 ppm. The broad peak at δ ~ 8.3 
ppm indicates that there is little dispersion of the amide backbone chemical shifts. Finally, the 
weak but broad signal at δ ~ 10 ppm is for the tryptophan residues of Cε3. 
 
 
 
Figure 32: 1H NMR spectrum of IgE Cε3 domain 
Spectrum showed peaks for methyls (δ ~ 1 ppm), amides (δ ~ 8.3 ppm) and tryptophans (δ ~ 10 ppm).136,137 
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Mass spectrometry (MS) was also used to characterise pure Cε3, however the presence of strong 
polyethylene glycol (PEG) signals in the mass spectrum, with characteristic peaks 44 Da apart, 
obscured the mass spectrum of the protein. The Cε3 could have been contaminated with PEG 
from the dialysis tubing (when Cε3 was dialysed into H2O for the MS experiments), although the 
tubing was thoroughly washed before dialysis. The dialysis was carried out again, with more 
extensive washing of the tubing and a longer dialysis time, then the MS was repeated. However, 
despite these precautions, the presence of PEG signals still swamped the spectrum. Further details 
of all analysis and characterisation procedures can be found in section 6.4. 
 
2.3.2 Expression of IgE Cε2 domain 
Cε2 was also successfully expressed using the same procedures as for Cε3 (see section 6.4 for full 
details) and Cε2 cell pellets are ready for purification. 
 
2.4 Development of SPR experiments with immobilised IgE-Fc and αγ 
As discussed in section 1.8.3, SPR is a very useful biophysical technique that has been widely used 
to study the interactions of inhibitors with IgE and FcεRI. It was decided to develop and use SPR 
experiments with immobilised IgE-Fc and immobilised αγ  and carry out inhibition assays with any 
compounds that displayed inhibition in the ELISA or TR-FRET assays. If  αγ  was  immobilised  to  the  
SPR sensor chip and a solution of IgE-Fc injected over the chip, the binding of IgE-Fc  to  αγ  should  
be detected by an increase in signal. If a pre-incubated solution of IgE-Fc and an inhibitor was 
injected over the chip, the extent to which the inhibitor prevented binding of IgE-Fc to 
immobilised αγ  would  be  shown  by  a  smaller  increase  in  signal  (or  no  increase  if  none  of  the  IgE-Fc 
bound   to   αγ).   This   inhibition assay could also be carried out the other way round, with IgE-Fc 
immobilised   to   the   chip   and   a   solution   of   αγ   and   an   inhibitor   injected   over   the   chip. If any 
inhibition was seen in either of these experiments, it was planned to monitor the direct binding of 
the inhibitor to each of the immobilised proteins, which would hopefully shed some light on which 
protein the inhibitor was binding to.  
 
A CM5 sensor chip was chosen for the SPR experiments as it comprises a carboxymethylated 
dextran matrix (CM) on top of the gold chip surface which allows a covalent attachment of the 
protein to the chip. The carboxyl groups of the dextran matrix are activated, then allowed to react 
with the primary amine of the lysine residues of the protein to form an amide bond. This method 
is suitable for immobilising  αγ,  however  for  IgE-Fc if the attachment to the chip was via the lysine 
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residues this would orientate the IgE-Fc into an inactive conformation due to the position of the 
lysines  at  the  Cε3  domain  of  IgE-Fc. It was therefore decided to immobilise streptavidin onto the 
chip   (in   the  same  way  as   the  αγ   immobilisation),   then  to   inject  biotinylated   IgE-Fc over the chip 
(biotin-IgE-Fc provided by Dr Marie Pang, KCL). The biotin was positioned in a site-specific manner 
to the IgE-Fc to ensure an active conformation of the protein once immobilised. An overview of 
the inhibition assays and direct binding assays with both immobilised proteins can be seen in 
Scheme 9.  
 
 
Scheme 9: Overview of SPR experiments with immobilised proteins  
1 = immobilisation of biotin-IgE-Fc onto a streptavidin coated SPR chip, 2 = inhibition assay with injection of 
a mixture of αγ  and  inhibitor, 3 = direct binding assay with injection of inhibitor only, 4 = immobilisation of 
αγ onto SPR chip, 5 = inhibition assay with injection of a mixture of IgE-Fc and inhibitor, 6 = direct binding 
assay with injection of inhibitor only. 
 
2.4.1 Immobilisation of αγ   
All SPR experiments were carried out at room temperature using a Biacore T200 instrument. More 
details on the experimental procedures can be found in section 6.5. Prior to the αγ immobilisation, 
the carboxymethylated dextran matrix on the chip surface was first activated with 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) and NHS to form reactive esters. αγ (100 nM) was then 
added, the lysine residues of which reacted with the active esters on the chip surface to form a 
gold surface of sensor chip 
streptavidin 
biotin-IgE-Fc 
αγ 
inhibitor 
IgE-Fc 
 
1 
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stable amide linkage (Scheme 10). An increase of ~ 1000 resonance units was achieved, indicating 
the αγ  was   successfully   immobilised.   Ethanolamine was then added to cap any unreacted NHS 
esters on the chip surface to prevent further reaction and ensure that IgE-Fc or any inhibitors that 
were subsequently injected would only bind specifically to αγ and not react directly with the chip. 
All immobilisation steps were carried out in HEPES buffered saline (HBS). 
 
 
 
Scheme 10: Activation of carboxyl groups of SPR sensor chip surface with EDC and NHS 
EDC coupled to carboxyl group of carboxymethylated dextran matrix on surface of SPR sensor chip to form 
an unstable o-acylisourea intermediate. NHS then coupled to the carboxyl group forming the more stable 
NHS ester. The NHS-ester then reacted with the primary amine of the lysine residues of the protein to form 
an amide bond and a stable conjugate. 
 
2.4.2 Binding of IgE-Fc  to  immobilised  αγ   
IgE-Fc (10 nM) was injected over the chip containing immobilised αγ, to check the αγ was active 
and able to bind IgE-Fc. An increase of ~ 300 resonance units was observed which indicated that 
the proteins were successfully bound. Due to the slow off-rate between IgE-Fc and αγ15,16, the 
dissociation of IgE-Fc and a corresponding return to baseline would take approximately 2 days, 
therefore the IgE-Fc was removed with an injection of glycine pH 2.5. 
 
The SPR running buffer was then changed from HBS to PBS with 2% DMSO and 0.005% Tween 20. 
This was because PBS was used in the ELISA so it was more consistent and it was thought that 
when adding inhibitors there would need to be a small percentage of DMSO to aid compound 
solubility. The IgE-Fc  binding  to  immobilised  αγ  was  repeated  in  the  new  SPR  running  buffer  and  
an increase of ~ 30 resonance units was observed, which was approximately 30 pg/mm2. This was 
lower than the increase when HBS was used, which could have been due to the addition of DMSO 
in the buffer. However, the IgE-Fc binding and removal was reproducible when repeated twice 
more, with an increase of ~ 30 resonance units being observed each  time,  therefore  this  αγ-chip 
was deemed suitable for subsequent inhibition assays with IgE-Fc and inhibitors.  
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2.4.3 Immobilisation of biotin-IgE-Fc 
Prior to the IgE-Fc immobilisation, the carboxymethylated dextran matrix on the chip surface was 
activated with EDC and NHS to form reactive esters. Streptavidin (160 nM) was then added, the 
lysine residues of which reacted with the active esters on the chip surface to form a stable amide 
linkage. An increase of ~ 1000 resonance units was achieved, indicating the streptavidin was 
successfully immobilised to the chip. Ethanolamine was then added to cap any unreacted NHS 
esters on the chip surface. Biotin-IgE-Fc (125 nM) was then added, which bound to the 
streptavidin coated chip and gave an increase of ~ 900 resonance units, indicating successful 
immobilisation. All immobilisation steps were carried out in HBS.  
 
2.4.4 Binding of αγ to immobilised biotin-IgE-Fc 
αγ (10 nM) was injected over the chip containing immobilised biotin-IgE-Fc, to check the IgE-Fc 
was active and able to bind αγ, and this binding experiment was carried out in PBS with 2% DMSO. 
An increase of ~ 30 resonance units was observed, which was approximately 30 pg/mm2 and 
indicated that the αγ was successfully bound to IgE-Fc. This was the same increase in resonance 
units as seen with IgE-Fc   binding   to   immobilised   αγ   (section   2.4.2)  which   implied   that   the two 
proteins could bind equally well to each other, regardless of which one was immobilised to the 
chip. The  αγ  was  then  removed  using  glycine pH 2.5. This was repeated once more with the same 
result,  which  confirmed  the  reproducibility  of  the  αγ  binding  and  removal and indicated that the 
IgE-Fc-chip was ready to be used in subsequent inhibition assays. 
 
2.4.5 Inhibition of IgE-Fc binding to immobilised  αγ  by  free  αγ   
To see if IgE-Fc could be prevented from binding to immobilised αγ  by  free  αγ,  a  solution  of  IgE-Fc 
(10  nM)  and  αγ  (10  nM)  was  injected  over  the  immobilised  αγ.  No  change  in  signal  was  observed,  
which indicated that the IgE-Fc was successfully  inhibited  by  free  αγ,  as  would  be  expected. 
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Chapter 3: Small molecule inhibitors of  the  IgE:FcεRI  PPI 
3.1 Aspercyclide A and analogues 
3.1.1 Design and synthesis of aspercyclide A and analogues 
As discussed in section 1.6.1, the natural product aspercyclide A isolated by Singh et al. was 
reported to display inhibition of the IgE:FcεRI interaction when tested with an ELISA (IC50 = 200 
μM).86 This was an interesting starting point for the design of small molecule inhibitors of this PPI 
and there have since been a number of total syntheses of (+)-aspercyclide A reported.87,88,90,91 
Most recently, the total synthesis of (+)-aspercyclide A and an analogue as well as their ELISA 
inhibition assay results was reported by Spivey et al.92 The ELISA testing of these compounds, and 
of other unpublished analogues, forms part of this PhD research and is described in this section. 
 
Initial work in the Spivey group at Imperial College London (IC) on aspercyclide A was to synthesise 
the racemic (±)-aspercyclide A C19 methyl ether of the natural product. This compound had the 
advantage over the natural product that its synthesis started from a commercially available acetal 
so one less synthetic step was required and it displayed an improved activity when tested in an 
ELISA to that reported by Singh et al. for the natural product itself (IC50 for (±)-aspercyclide A C19 
methyl  ether  =  110  μM).90 Racemic (±)-aspercyclide A C19 methyl ether (±)-1 was synthesised by 
Dr Jimmy Sejberg, IC.91 This synthesis used a Pd(0)-catalysed  germyl-Stille reaction as the key 
macrocyclisation step. Optical resolution of the racemic compound by CSP-HPLC was also used to 
separate the (+)-enantiomer  (+)-1 in 98.4% enantiomeric excess (ee).91  
 
The enantioselective synthesis of the natural product (+)-aspercyclide A was later carried out also 
by Dr Jimmy Sejberg, which employed a Krische iridium-catalysed, diastereo- and enantioselective 
alkoxyallylation to form the key anti-diol intermediate (two batches of this compound were 
synthesised: (+)-2a and (+)-2b.92 In order to check that the activity of aspercyclide A was not due 
to the benzaldehyde forming a Schiff base with the protein lysine residues, three analogues were 
also synthesised by Dr Jimmy Sejberg, where the benzaldehyde moiety was replaced with a 
different functional group. The first was an aldoxime (+)-3, which was synthesised by the reaction 
of (+)-aspercyclide A with hydroxylammonium chloride. The second was a benzisoxazole (+)-4 
which was synthesised by reacting the aldoxime (+)-3 with 2,3-dichloro-5,6-dicyano-1,4-
benzoquinone (DDQ) and PPh3. The final analogue was a benzoxathiazine-2,2-dioxide (+)-5 which 
was made by reacting (+)-aspercyclide A with sulfamoyl chloride (see Table 4). 
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3.1.2 Testing aspercyclide A and analogues with the TR-FRET assay 
(±)-Aspercyclide A C19 methyl ether (±)-1, (+)-aspercyclide A C19 methyl ether (+)-1 and (+)-
aspercyclide A (+)-2a were tested with the TR-FRET assay. The concentration of IgE-Fc-A647 was 
fixed at 1.25 nM, the concentration of αγ-Tb was fixed at 0.5 nM and the inhibitor was prepared in 
12 different concentrations, starting at 1 mM with 2-fold dilutions to a final concentration of 0.49 
μM.  For each compound, two TR-FRET assays were carried out to investigate the order of addition 
of the proteins. Either the compound was pre-incubated with IgE-Fc-A647 for 1 hour, before 
adding  αγ-Tb then reading the plate, or alternatively the compound was pre-incubated  with  αγ-Tb 
for 1 hour, before adding IgE-Fc-A647 and reading the plate. Further experimental details can be 
found in section 6.2.6 and the TR-FRET assay results are shown in Table 4. 
  
Compound 
reference Structure 
IC50 (μM) 
Pre-incubated 
with IgE-Fc-A647 
Pre-incubated 
with  αγ-Tb 
 
 
 
 
(±)-1 
 
 
(JS-039)  
>1000 >1000 
 
 
 
 
(+)-1 
 
 
(JS-039-E1)  
>1000 >1000 
 
 
 
 
(+)-2a 
 
 
(JS-291)  
>1000 >1000 
 
Table 4: TR-FRET inhibition assay IC50 values for aspercyclide A and analogues 
NB: The references in parenthesis indicate the Spivey research group compound reference number. 
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Unfortunately none of the compounds tested in the TR-FRET assays showed any inhibition of the 
interaction between IgE-Fc-A647 and αγ-Tb as they all had IC50 values of > 1 mM. This could have 
been because the fluorophores on the proteins were preventing the compounds from binding as 
they would do in the ELISA where unlabelled proteins are used. Or it could have been that the 
compounds were inhibiting the PPI, but they were also interfering with the TR-FRET assay in some 
way, for instance by autofluorescing, although this should have been accounted for with the 100 
μs time delay. Another possibility could be that their previous ELISA results were false positives, 
due to the number of processing steps and multiple reagents involved in the ELISA. It was 
therefore decided to test these aspercyclide A compounds with the ELISA described in section 2.1 
to see if they displayed any activity. 
 
3.1.3 Testing aspercyclide A and analogues with the ELISA 
(±)-Aspercyclide A C19 methyl ether (±)-1, (+)-aspercyclide A (+)-2a and (+)-2b and the three 
analogues of (+)-aspercyclide with the benzaldehyde replaced with another functional group (+)-3, 
(+)-4 and (+)-5 were tested with the ELISA (see section 6.3.3 for the experimental details) and the 
results are shown in Table 5. 
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Compound 
reference Structure IC50 (μM) 
 Compound 
reference Structure IC50 (μM) 
 
 
 
(±)-1 
 
 
 
(JS-039)  
 
 
 
 
>1000 
  
 
 
(+)-3 
 
 
 
(JS-287)  
 
 
 
>1000 
 
 
 
(+)-2a 
 
 
 
(JS-291)  
 
 
 
424 ± 27 
540 ± 220 
  
 
 
(+)-4 
 
 
 
(JS-289)  
 
 
 
>1000 
 
 
 
(+)-2b 
 
 
 
(JS-256-P)  
 
 
 
>1000 
  
 
 
(+)-5 
 
 
 
(JS-312) 
 
 
 
 
162 ± 5 
463 ± 19 
 
Table 5: ELISA inhibition assay IC50 values for aspercyclide A and analogues 
NB: The references in parenthesis indicate the Spivey research group compound reference number. 
Multiple IC50 values indicate the assay has been repeated on a different occasion. 
 
It can be seen from Table 5 that (±)-aspercyclide A C19 methyl ether (±)-1 did not show inhibition 
of the IgE:FcεRI interaction when tested in the ELISA. However, (+)-aspercyclide A (+)-2a did show 
moderate inhibition, for the two times this assay was carried out (IC50 = 424 μM - 538 μM). This 
was likely to have been because it was enatiomerically pure (and it was found earlier that the (+)-
enantiomer of the C19 methyl ether compound was 10-fold more active than the (-)-
enantiomer).91 However, the other sample of the same compound (+)-2b did not display any 
activity, which could have been because it had a slightly different solubility or possibly because it 
contained residual contaminants from the synthesis. Neither the aldoxime analogue (+)-3 nor the 
benzisoxazole analogue (+)-4 of (+)-aspercyclide A displayed any activity. However, pleasingly, the 
benzoxathiazine-2,2-dioxide analogue of (+)-aspercyclide A (+)-5 inhibited the IgE:FcεRI interaction 
with a slightly higher potency (IC50 = 162 μM - 463 μM). These values are comparable to the ELISA 
IC50 value of 200 μM first reported by Singh et al.86 and to the ELISA IC50 values reported by Spivey 
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et al.90,91 for (±)-aspercyclide A C19 methyl ether. These results also indicated that the activity of 
(+)-5 was not attributed to the benzaldehyde moiety forming a Schiff base with protein lysine 
residues, which is consistent also with a specific binding mode and the difference in activity 
between the two enantiomers. These results for the (+)-aspercyclide A (+)-2a and its 
benzoxathiazine derivative (+)-5 were published recently.92   
 
A challenging aspect of the ELISA testing of these compounds was that the compounds tended to 
display poor solubility when diluted from the 50 mM stock solution in DMSO to the 1 mM assay 
solution in PBS with 2% DMSO. This would mean that if not all the compound had gone into 
solution, the ELISA may not have given accurate results if the insoluble material was removed 
during the extensive washing steps and therefore the concentration of the compound in solution 
was not as high as it should have been. Alternatively, any insoluble compound could have bound 
non-specifically to the various components of the assay and the compound could have appeared 
to be more active than it actually was.  
 
To overcome these solubility issues, the ELISA was repeated multiple times with variations in the 
assay conditions using compound (±)-1. The assay solution of (±)-1 was made up in carbonate 
buffer pH 9.6, rather than PBS pH 7.3, in the hope that the more basic pH would deprotonate the 
compound and increase aqueous solubility. However, the ELISA did not work with the carbonate 
buffer, probably due to the sensitivity of the proteins to changes in pH. The original ELISA was 
then repeated using PBS 5% DMSO, rather than PBS 2% DMSO, in the hope the increased DMSO 
content would aid solubility, however this technique did not result in any improvement on the 
solubility of the compound. Finally, the original assay was carried out as normal, but the 
compound was first heated in a water bath up to ~ 50 °C, with intermittent vigorous shaking, 
which was successful in ensuring all of the compound was dissolved and it was also found that the 
high temperature did not cause any decomposition of the compound. This technique for dissolving 
was used to varying degrees for all compounds tested in the ELISA, to ensure complete dissolution 
into the aqueous buffer for use in the assay. 
  
82 
 
3.1.4 Soak crystallisation of (+)-aspercyclide A C19 methyl ether (+)-1 with IgE-Fc 
Obtaining an x-ray co-crystal structure of aspercyclide A or an analogue bound to either IgE-Fc or 
FcεRI would give valuable information on what contacts are made between the inhibitor and the 
protein and would facilitate the development of molecules that bind with a higher affinity. As it is 
not known which protein of the IgE:FcεRI interaction is targeted by aspercyclide A, it was decided 
to first carry out crystallisation experiments with IgE-Fc and an aspercyclide A compound, as IgE-Fc 
was readily available and the crystallisation conditions had been previously established.16,22,33 
 
(±)-Aspercyclide A C19 methyl ether (+)-1 was chosen, as this was previously found to inhibit the 
IgE:FcεRI interaction with ELISA (IC50 = 40 μM) reported by Spivey et al.91 and there was a large 
enough quantity of this compound available for the experiments (unfortunately there was not 
enough of the more active compound (+)-5 available). Soak crystallisations were carried out, 
where the compound was added into crystals of IgE-Fc, as a compound of this size should fit 
through the protein crystal channels. Soak crystallisations were carried out using (+)-1 (2.5 mM) 
and 4 – 6 apo crystals of IgE-Fc (crystals provided by Dr Nyssa Drinkwater, KCL). After incubation at 
18 °C for 5 – 10 days, individual crystals were frozen in liquid nitrogen and x-ray diffraction data 
was collected at the Diamond Light Source synchrotron (data collection carried out by Dr Nyssa 
Drinkwater, KCL). Further experimental details can be found in section 6.6. Figure 33 shows a 
photo of the crystal used for the data collection and the x-ray diffraction pattern obtained and 
Table 6 shows the data collection statistics. 
 
 
 
Figure 33: Crystal photo and x-ray diffraction - soak crystallisation of (+)-1 with IgE-Fc 
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Resolution (Å) 2.29 
Rmerge 0.092 
I/sigma 13.8 
Completeness (%) 98.0 
Multiplicity 3.9 
Average unit cell a = 129.31, b = 74.60, c = 79.78  
Space group P 21 21 2 
 
Table 6: Data collection statistics for soak crystallisation of (+)-1 with IgE-Fc 
 
It can be seen from Table 6 that the crystal diffracted to a high resolution of 2.29 Å with ideal data 
collection statistics for the subsequent solving of the crystal structure. The crystal structure was 
solved by molecular displacement using a high resolution structure of IgE:Fc (PDB code 2WQR22) 
and the CCP4 software Phenix Refine and Coot. Weak electron density was found, that did not 
match to the IgE-Fc structure, therefore (+)-1 was modelled into the structure using its simplified 
molecular-input line-entry system (SMILES) code. A second round of refinement was carried out, 
however unfortunately the electron density refinement did not improve enough to confirm if the 
compound was bound to IgE-Fc.  
 
This result could indicate that (+)-1 does not bind to IgE-Fc,  but  binds   instead  to  FcεRI,  which   is  
why a co-crystal structure of (+)-1 bound to IgE-Fc was not obtained. Alternatively, (+)-1 could bind 
to IgE-Fc, but not with a high enough affinity for a co-crystal structure to be obtained. Further x-
crystallography experiments could be carried out, for instance co-crystallisations with IgE-Fc 
instead of soak crystallisations, or using IgE-Fc3-4  instead of IgE-Fc, as this protein is more flexible 
and may give different packing forms. The receptor   protein   sFcεRIα   could   be   used   instead   for  
crystallisation experiments, as this may be the protein with which (+)1 interacts,  although  sFcεRIα  
is more expensive and less easily crystallised than IgE-Fc, so potency may need to be improved 
before it would be worth using this protein. 
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3.2.6 Novartis data for aspercyclide A and analogues 
The (±)-aspercyclide A C19 methyl ether (±)-1, (+)-aspercyclide A (+)-2b and the benzoxathiazine 
analogue of (+)-aspercyclide A (+)-5 were also tested in an ELISA by a collaborator at Novartis, 
Horsham (Dr Jeffrey Stonehouse) in order to confirm the earlier ELISA results. (±)-1 showed no 
inhibition of the IgE:FcεRI interaction which confirmed the earlier result, (+)-2b displayed 
inhibition of the IgE:FcεRI interaction but an IC50/EC50 value could not be calculated from the data 
and (+)-5 inhibited the interaction (EC50 = 124 – 156 μM). These are pleasing results and confirm 
the ELISA activity reported earlier for these compounds (Table 4).  
 
The same compounds were also tested by Novartis in a FRET assay, however none of the 
compounds displayed inhibition in this assay. This also confirms the earlier result where it was 
found that (±)-1a and (+)-2a did not display activity in the TR-FRET assay (Table 3). 
 
(±)-1, (+)-2b and (+)-5 were also tested for binding to immobilised IgE-Fc and full length IgE in SPR 
experiments carried out by Novartis. The benzoxathiazine derivative of (+)-aspercyclide A (+)-5 
was found to display weak binding to both IgE-Fc and full length IgE when tested at 200 μM, 
however  this  binding  was  not  enough  for   the  compound  to  be  considered  as  a   ‘hit’  by  Novartis.  
Further details can be found in section 6.10. 
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3.2 Dibenzofurans 
3.2.1 Design and synthesis of dibenzofurans 
Further work in the Spivey group at IC was to synthesise more analogues of aspercyclide A to try to 
build up information about the structure activity relationship (SAR) of these compounds. Heck-
Mizoroki reactions of bromide intermediates (±)-6 and (±)-7 were carried out (by Dr Helena 
Dennison, IC) which made use of ligand 8. As well as forming the desired aspercyclide A C19 
methyl ether analogues (±)-9 and (±)-10, the dibenzofuran by-products (±)-11 and (±)-12 were also 
formed (Scheme 11).138 
 
Scheme 11: Dennison’s  Heck-Mizoroki reaction of bromide intermediates138 
A and B denote the two benzene rings of the dibenzofuran compounds and side-arm denotes the large 
substituent on ring B. 
 
It was decided to isolate dibenzofurans (±)-11 and (±)-12 and test them as potential inhibitors of 
the IgE:FcεRI interaction, as it would be interesting to see if compounds containing this different 
scaffold could also inhibit the interaction.  
 
3.2.2 Testing dibenzofurans with the TR-FRET assay 
The dibenzofuran compounds (±)-11 and (±)-12 were tested in the TR-FRET assay using the same 
procedure as before and the results can be seen in Table 7. 
  
8 
R = H          (±)-6 
R = OMe    (±)-7 
A 
 
B 
 
R = H          (±)-9 
R = OMe    (±)-10 
R = H          (±)-11 
R = OMe    (±)-12 
side 
arm 
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 Compound 
reference Structure 
IC50 (μM) 
Pre-incubated 
with IgE-Fc-A647 
Pre-incubated 
with  αγ-Tb 
 
 
(±)-11 
 
 
(HJD-107)  
 
 
>1000 
 
 
>1000 
 
 
(±)-12 
 
 
(HJD-115)  
 
 
>1000 
 
 
>1000 
 
Table 7: TR-FRET inhibition assay IC50 values for dibenzofurans (±)-11 and (±)-12 
NB: The references in parenthesis indicate the Spivey research group compound reference number. 
 
Unfortunately, neither of the dibenzofurans (±)-11 and (±)-12 inhibited the IgE:FcεRI interaction 
when tested with the TR-FRET assay. As mentioned in section 3.1.2, this lack of inhibition could 
have been because the fluorophores on the proteins were preventing the compounds from 
binding as they would do to the native protein. Or it could have been that the compounds were 
inhibiting the interaction between IgE and FcεRI,  but  were   interfering  with  the  TR-FRET assay by 
possibly autofluorescing. It was decided to test these dibenzofurans with the ELISA to confirm the 
results. 
 
3.2.3 Testing dibenzofurans with the ELISA 
The dibenzofuran (±)-11 had previously been tested in an ELISA by collaborators at KCL and it was 
found to show good activity against the IgE:FcεRI interaction (IC50 = 2 μM, unpublished data, Dr 
Fabienne Saab and Dr Mary Holdom, KCL). Dibenzofurans (±)-11 and (±)-12 were tested with the 
ELISA described in section 2.1 and the results can be seen in Table 8. 
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Compound 
reference Structure IC50 (μM) 
 
 
(±)-11 
 
 
(HJD-107)  
 
 
3 ± 0.1 
5 ± 0.3 
 
 
(±)-12 
 
 
(HJD-115)  
 
 
205 ± 51 
 
Table 8: ELISA inhibition assay IC50 values for dibenzofurans (±)-11 and (±)-12 
NB: The references in parenthesis indicate the Spivey research group compound reference number. 
Multiple IC50 values indicate the assay has been repeated on a different occasion. 
 
It can be seen that dibenzofuran (±)-11 showed good inhibition of the IgE:FcεRI PPI (IC50 = 3 μM - 5 
μM). This is consistent with the ELISA IC50 value reported by collaborators at KCL, however it is 
unusual that this compound exhibited no inhibition at all in the TR-FRET assay (Table 7) and this 
could indicate that both sets of ELISA results were false positives. As there are multiple processing 
steps involved in the ELISA, this may have resulted if (±)-11 was inhibiting the binding of 
biotinylated anti-IgE-Fc to IgE-Fc for instance, or inhibiting the enzymatic reaction of OPD by the 
enzyme HRP. However, the thorough washing between each stage of the assay should have 
ensured that there was no inhibitor left when these secondary reagents were added. The false 
positive hypothesis could be investigated by carrying out a modified ELISA, with either IgE-Fc or αγ 
not present, to see if the ELISA signal was still inhibited by (±)-11. The other dibenzofuran (±)-12 
showed inhibition of the IgE:FcεRI interaction to a lesser extent (IC50 = 205 μM), which indicated 
that the methoxy substituent is not tolerated in this position on ring A. 
 
Since (±)-11 displayed such promising activity against the IgE:FcεRI interaction, a series of 
analogues were synthesised by Dr Helena Dennison, IC138 in order to build up SAR data for these 
compounds. In these dibenzofuran analogues, either the methoxy group, the pentyl group or both 
groups were not present on the side arm of ring B, and for each case, the methyl substituent on 
ring B was either present or not present (compounds 13, 14, 15, (±)-16, 17, 18 and 19). It would be 
interesting to find out if the dibenzofuran scaffold was required for activity or not, so a bromide 
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analogue (±)-20, where only ring B was present, was synthesised (Dr Jimmy Sejberg, IC). 
Conversely, it would also be interesting to determine if the side arm of ring B was required for the 
activity or not, so analogue 21, with a carboxylic acid group in place of the side arm on ring B, was 
also synthesised (Dr Jimmy Sejberg, IC). Finally, the commercially available compound 
dibenzofuran-4-carboxylic acid 22 was also obtained. All of these compounds were then tested 
with the ELISA and the compound structures and ELISA IC50 results can be seen in Table 9. 
 
Compound 
reference Structure IC50 (μM) 
 Compound 
reference Structure 
IC50 
(μM) 
 
 
13 
 
 
(HJD-205)  
 
 
576 ± 122 
 
 
 
 
18 
 
 
(HJD-214) 
 
 
 
 
>1000 
 
 
14 
 
 
(HJD-210)  
 
 
 
 
>1000 
  
 
19 
 
 
(HJD-212)  
 
 
>1000 
 
 
15 
 
 
(HJD-211)  
 
 
>1000 
  
 
(±)-20 
 
(JS-
004/26) 
 
 
 
>1000 
 
 
(±)-16 
 
 
(HJD-186)  
 
 
>1000 
  
 
21 
 
 
(JS-322)  
 
 
462 ± 89 
 
 
17 
 
 
(HJD-213)  
 
 
>1000 
  
 
22 
 
 
 
>1000 
 
Table 9: ELISA inhibition assay IC50 values for dibenzofuran analogues of (±)-11 
NB: The references in parenthesis indicate the Spivey research group compound reference number.  
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It can be seen that compounds 13 and 21 displayed a moderate inhibition of the IgE:FcεRI 
interaction (IC50 = 576 μM and 462 μM respectively), but none of the other inhibitors showed any 
activity. This indicates that the methyl substituent is required on ring B and that the dibenzofuran 
core is also important, but that the exact nature of the side arm is less important. It was 
unexpected that of all these analogues, only two showed a moderate activity, which was 100-fold 
weaker than that of (±)-11. It therefore seemed likely that the (±)-11 ELISA IC50 value was indeed a 
false positive and that this compound was inhibiting a different component of the ELISA and not 
actually the IgE:FcεRI interaction.  
 
In order to confirm the activity, or lack thereof, of (±)-11 this compound was re-synthesised (by Dr 
Jimmy Sejberg, IC) which is referred to as (±)-23 and this was also tested in the ELISA. The ligand 8 
from the Heck-Mizoroki reaction in Scheme 11 (synthesised by Dr Daniel Offerman, IC) was also 
tested in the ELISA, in case a very small amount of this ligand could have been contaminating the 
sample of (±)-11 and causing the activity. These ELISA results can be seen in Table 10.  
 
Compound 
reference Structure IC50 (μM) 
 
 
(±)-23 
 
 
(JS-331)  
 
 
>1000 
>1000 
 
 
8 
 
 
(DAO-268) 
 
 
 
>1000 
 
Table 10: ELISA inhibition assay IC50 values for dibenzofuran (±)-23 and ligand 8 
NB: The references in parenthesis indicate the Spivey research group compound reference number. 
Multiple IC50 values indicate the assay has been repeated on a different occasion. 
 
The re-synthesised dibenzofuran (±)-23 was tested twice but did not show any inhibition of the 
IgE:FcεRI interaction. This seems to confirm that the original sample of this compound, (±)-11, was 
a false positive, or was possibly contaminated with a small amount of another much more active 
compound, however all compounds were analysed by liquid chromatography-mass spectrometry 
90 
 
(LC-MS) to confirm their purity before testing in all assays. Ligand 8 did not inhibit the IgE:FcεRI 
interaction, indicating that it was unlikely to be this ligand that was contaminating the sample and 
contributing to the activity. At the same time as the synthesis and testing of these new analogues 
of (±)-11, other biophysical and structural experiments were also being carried out on (±)-11, 
which are discussed below. 
 
3.2.4 Soak crystallisation of dibenzofuran (±)-11 with IgE-Fc 
Soak crystallisation experiments were carried out using (±)-11 (2.5 mM) and 4 – 6 apo crystals of 
IgE-Fc (crystals provided by Dr Nyssa Drinkwater, KCL). After incubation at 18 °C for 5 – 10 days, 
individual crystals were frozen in liquid nitrogen and x-ray diffraction data was collected at the 
Diamond Light Source synchrotron (data collection carried out by Dr Nyssa Drinkwater). Figure 34 
shows a photo of the crystal used for the data collection as well as the x-ray diffraction pattern 
obtained and Table 11 shows the data collection statistics. 
 
 
 
 
Figure 34: Crystal photo and x-ray diffraction for soak crystallisation of (±)-11 with IgE-Fc 
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Resolution (Å) 2.15 
Rmerge 0.064 
I/sigma 18.2 
Completeness (%) 99.7 
Multiplicity 3.9 
Average unit cell a = 129.08, b = 74.67, c = 79.29 
Space Group P 21 21 2 
 
Table 11: Data collection for soak crystallisation of (±)-11 with IgE-Fc 
 
It can be seen from Table 11 that the data collection statistics for this experiment are good and 
the crystal diffracted to a high resolution of 2.15 Å. Crystal structures were solved as described in 
section 3.1.4, by molecular displacement using a high resolution structure of IgE:Fc (PDB code 
2WQR22). As for the aspercyclide compound, weak electron density was found, that did not match 
to the IgE-Fc structure, therefore (±)-11 was modelled into the structure using its SMILES code. A 
second round of refinement was carried out, however the electron density refinement did not 
improve enough to confirm if the compound was bound to IgE-Fc. This result could indicate that 
(±)-11 does not bind to IgE-Fc, but binds instead to FcεRI, or that it does bind to IgE-Fc, but not 
with a high enough affinity for a co-crystal to be obtained. The additional crystallisation 
experiments described in section 3.1.4 could be carried out for (±)-11, but in light of the ELISA 
results of analogues of (±)-11 and the re-synthesised compound (±)-23, it seems likely that this 
compound does not actually inhibit the IgE:FcεRI interaction. 
 
3.2.5 SPR experiments with dibenzofuran (±)-11 
SPR experiments were carried out, using the SPR chip with immobilised αγ as described in section 
2.4. An initial experiment was carried out, to see if (±)-11 could inhibit the binding of IgE-Fc to 
immobilised  αγ.  A  solution  of  IgE-Fc (10 nM) with (±)-11 (10  μM), that had been pre-incubated for 
1 hour, was   injected  over  the  αγ-chip. An increase of ~ 30 resonance units was observed, which 
was the same increase as when no inhibitor was present, which indicated that no inhibition was 
taking place. An inhibition assay was then set up to confirm this, where various different 
concentrations of (±)-11 were used. Solutions of (±)-11 at 10 different concentrations (160  μM  to  
0.3  μM)  and  IgE-Fc (10 nM in each solution) were pre-incubated for 1 hour, before being injected 
92 
 
over  the  αγ-chip. A glycine injection between each different solution was used to remove any IgE-
Fc bound to the chip. The sensorgrams for this inhibition assay can be seen in Figure 35. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35: SPR sensorgrams for inhibition assay of IgE-Fc and immobilised αγ  with  (±)-11 
 
These sensorgrams show that for the highest concentration of (±)-11 of  160  μM,  there is a higher 
signal. However, it would be expected that at the highest concentration of (±)-11, there would be 
less IgE-Fc  binding  to  immobilised  αγ  which  would  result  in  a  lower signal. This result could imply 
that the compound was binding non-specifically to the chip itself, however there was only a small 
difference  of  ~  5  resonance  units  between  no  inhibitor  present  and  160  μM  inhibitor present, so it 
would seem that the compound was not inhibiting IgE-Fc  binding   to   immobilised  αγ.  This   is  also  
consistent with the fact that (±)-11 did not show binding to IgE-Fc in the crystallography 
experiments. 
 
3.2.6 Novartis data for dibenzofurans 
The dibenzofurans 13, (±)-16, 21 and (±)-23 were tested for their ability to inhibit the IgE:FcεRI 
interaction in an ELISA and a FRET inhibition assay and for their ability to bind to immobilised IgE-
Fc and full length IgE in SPR  experiments by a collaborator at Novartis, Horsham (Dr Jeffrey 
Stonehouse). No inhibition or binding was observed for any of these compounds by Novartis. This 
mainly confirms the results found earlier. There was a moderate inhibition seen in my ELISA for 13 
and 21 (Table 8) but it may have been because my ELISA is more sensitive than the Novartis ELISA.  
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(±)-11  0 μM 
(±)-11  0.13 μM 
(±)-11  0.63 μM 
(±)-11  1.25 μM 
(±)-11  2.5 μM 
(±)-11  5 μM 
(±)-11  10 μM 
(±)-11  20 μM 
(±)-11  40 μM 
(±)-11  80 μM 
(±)-11  160 μM 
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Chapter 4: Peptide inhibitors  of  the  IgE:FcεRI  PPI 
As discussed in section 1.5, peptides have been widely investigated as inhibitors of the interaction 
between IgE and FcεRI. A number of disulfide-constrained, cyclic peptides have been reported, 
that inhibit this interaction with IC50 values in the micromolar to nanomolar range. The design, 
synthesis and testing of peptide inhibitors of the IgE:FcεRI interaction forms the main part of this 
PhD research and is discussed in this section. 
 
4.1 Design and synthesis of peptide inhibitors 
4.1.1 Peptide design 
An 8-residue, linear peptide was synthesised which consisted of residues Tyr(116) to Asp(123) of 
the C-strand of the C-C’  loop  of  FcεRI, a hotspot  region of FcεRI which binds to the IgE Cε3 domain 
and the IgE Cε2-Cε3 linker region (Figure 36). 
 
 
 
 
 
 
 
 
 
 
Figure 36: Structure of linear, 8-mer peptide based on C-strand of C-C’  loop  of  FcεRI 
IgE-Fc3-4 is shown in green, sFcεRIα  is shown in orange and binding site 1 is shown in pale blue. 
Tyr(116) 
Asp(123) 
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It was originally envisaged that this peptide (based on the key binding epitope of FcεRI) may mimic 
this region and therefore compete with FcεRI for binding to IgE-Fc. However, it was found (by Dr 
Bingli Mo, IC) that the reverse sequence of this peptide (which was synthesised by Dr Bingli Mo in 
error) inhibited the IgE:FcεRI interaction when tested with an ELISA (IC50 ~ 100 μM) but that the 
actual C-strand peptide sequence from FcεRI (Figure 36) did not show any inhibition.139 This could 
imply that the original C-strand peptide was not actually mimicking the FcεRI hotspot region and 
therefore its mode of action of inhibition could actually involve binding to either protein, or 
indeed binding to the complex. Subsequent alanine scanning of the reverse-sequence peptide 
found that Tyr(3) was a key residue for binding affinity (Dr Bingli Mo, IC).139 During the MRes 
research project, the reverse-sequence peptide was synthesised, along with analogues where 
Tyr(3) was substituted for other aromatic residues Phe, Trp and His.131 These peptides were tested 
in an ELISA and it was found that the reverse-sequence peptide inhibited the IgE:FcεRI interaction 
(IC50 = 219 μM) and the peptide with Phe in position 3 had improved inhibition (IC50 = 99 μM).131 
 
During this PhD research, these peptides were re-synthesised and another analogue with the 
unnatural amino acid biphenylalanine (Bip) substituted at position 3 was also synthesised to 
further investigate the SAR and to see if a larger group was tolerated at this position. It was 
planned to then use the TR-FRET assay to test the peptides, and compare the results to the ELISA 
results obtained previously. It was also planned to carry out structural and biophysical 
experiments, including x-ray crystallography and SPR assays, on the most active peptides, to 
ascertain their mode of action of inhibition. An overview of the peptides used during this PhD and 
any previous ELISA IC50 values can be seen in Table 12 and their structures can be seen in Figure 37. 
Peptide name Peptide sequence Previous ELISA IC50 (μM) 
C-strand-peptide H2N-Tyr-Lys-Val-Ile-Tyr-Tyr-Lys-Asp-CONH2 >1000a 
Parent-peptide  
(reverse sequence of C-strand) H2N-Asp-Lys-Tyr-Tyr-Ile-Val-Lys-Tyr-CONH2 219 ± 8
b 
Phe(3)-peptide H2N-Asp-Lys-Phe-Tyr-Ile-Val-Lys-Tyr-CONH2 99 ± 17b 
Trp(3)-peptide H2N-Asp-Lys-Trp-Tyr-Ile-Val-Lys-Tyr-CONH2 204 ± 13b 
His(3)-peptide H2N-Asp-Lys-His-Tyr-Ile-Val-Lys-Tyr-CONH2 >1000b 
Bip(3)-peptide H2N-Asp-Lys-Bip-Tyr-Ile-Val-Lys-Tyr-CONH2 not yet tested 
Table 12: Peptides investigated 
aELISA carried out by Dr Bingli Mo, IC.139 bELISA carried out during MRes research project.131 Residues in 
position 3 are shown in bold. (NB: H2N- denotes free N-terminus, –CONH2 denotes amidated C-terminus).  
95 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37: Structures of peptides 
Parent-peptide 
 
 
 
 
 
 
 
 
Phe(3)-peptide 
 
 
 
 
 
 
 
 
Trp(3)-peptide 
 
 
 
 
 
 
 
 
 
His(3)-peptide 
 
 
 
 
 
 
 
 
 
Bip(3)-peptide 
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4.1.2 Solid phase peptide synthesis 
Peptides were synthesised by automated solid phase peptide synthesis (SPPS), a method which 
has been widely used in peptide research for many years. SPPS, originally developed by Merrifield 
in the 1960s, uses a polystyrene resin, to which each amino acid is coupled in turn to build up the 
peptide from the C-terminus to the N-terminus.140 The major benefit of this technique is that the 
insolubility of the resin allows reagents and by-products to be easily removed by simply washing 
the resin and a wide variety of resins are available for various peptide applications. The repetitive 
nature of SPPS lends itself to automation and instruments can simultaneously carry out the 
synthesis of a number of different peptide sequences of up to 30 residues in length. The most 
common method of SPPS makes use of fluorenylmethoxycarbonyl (Fmoc) as a temporary amine 
protecting group for each amino acid, which is removed before each coupling reaction with a mild 
base.141,142 The incoming amino acid is activated and then coupled to the deprotected amine of 
the previous residue.143,144  
 
Peptides were synthesised by automated Fmoc SPPS using an Intavis AG ResPep SL instrument. A 
TentaGel S Rink Amide Resin was used, which is a copolymer consisting of a low crosslinked 
polystyrene matrix onto which PEG is attached via an ethyl ether linker. The linker increases resin 
stability and the PEG group has hydrophilic and hydrophobic properties, therefore the TentaGel 
resins have been found to give good peptide yields. This Rink amide resin was chosen so that the 
C-terminus was left with an amide functionality following cleavage from the resin. Peptides were 
synthesised with a C-terminal amide, as this was previously found (by Dr Bingli Mo) to give 
peptides an improved potency over the C-terminal free carboxylic acid group. 
 
The first step in the synthesis was removal of the Fmoc protecting group from the resin using 20% 
piperidine in dimethylformamide (DMF), then the C-terminal Fmoc-protected amino acid was 
activated and coupled to the resin using 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU) and 4-methylmorpholine (NMM) in 1-methyl-2-pyrrolidinone (NMP). 
The resin was then washed with DMF to remove any side-products or unreacted material and a 
solution of 5% acetic anhydride in DMF was added to cap any unreacted N-terminal amine on the 
growing peptide, followed by another washing step. This process was repeated until the peptide 
was the desired length, then the resin-bound peptide was removed from the synthesiser, washed 
with DMF, dichloromethane, methanol and diethyl ether and dried under vacuum. The peptide 
was then cleaved from the resin, with simultaneous removal of the N-terminal Fmoc group and 
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the side chain protecting groups, with 95% trifluoroacetic acid (TFA), 2.5% H2O and 2.5% 
triisopropylsilane (TIS). The free peptide was then precipitated from the TFA solution with ice-cold 
tert-butylmethylether (TBME). Further details of the experimental procedure can be found in 
section 6.9 and an overview of the synthesis (for Phe(3)-peptide) is shown in Scheme 12. 
 
 
Scheme 12: Overview of Fmoc SPPS of Phe(3)-peptide using TentaGel S Rink amide resin 
The Fmoc protecting group was removed from the resin using 20% piperidine in DMF. The Fmoc-protected 
amino acid (with side-chain protecting group shown in parenthesis) was then coupled using HBTU and 
NMM. The Fmoc deprotection and amino acid coupling cycle was repeated until the peptide was the 
desired length. The peptide was then cleaved from the resin using 95% TFA, 2.5% TIS and 2.5% H2O which 
also removed any side chain protecting groups to leave the free peptide with a C-terminal amide. 
 
The mechanism for the Fmoc deprotection at the N-terminus of a peptide involves piperidine 
abstracting the dibenzylic proton from the Fmoc group, following which the resulting aromatic 
anion undergoes E1CB elimination to generate dibenzofulvene and a carbamic acid terminated 
peptide. Piperidine then adds to the dibenzofulvene to form a side-product, which can be 
removed by washing, and loss of carbon dioxide from the carbamic acid terminated peptide leaves 
the free amine, ready for the subsequent coupling reaction (Scheme 13).  
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Scheme 13: Mechanism for deprotection of an Fmoc group from the N-terminus of a peptide 
The dibenzylic proton of the Fmoc group is abstracted by piperidine to leave an aromatic anion, which 
eliminates dibenzofulvene to leave a carbamic acid terminated peptide. CO2 is eliminated from the peptide 
to leave the free N-terminus and the excess piperidine adds to the dibenzofulvene to give a by-product.  
 
Coupling of the subsequent amino acid requires activation of the amino acid carboxylate to 
generate an active ester which would be a better leaving group. Commonly used 
activating/coupling agents are uronium or phosphonium salts of non-nucleophilic anions, including 
HBTU, 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide 
hexafluorophosphate (HATU), 1-[bis(dimethylamino)methylene]-5-chlorobenzotriazolium 3-oxide 
hexafluorophosphate (HCTU), N,N,Nʹ′,Nʹ′-tetramethyl-O-(benzotriazol-1-yl)uronium 
tetrafluoroborate (TBTU) and (benzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate (PyBOP).  
 
HBTU was used for this peptide synthesis, as it produces hydroxybenzotriazolyl esters that are 
highly reactive towards nucleophiles. The HBTU activation/coupling mechanism begins with 
deprotonation of the amino acid carboxyl group by the organic base NMM. The deprotonated 
carboxyl group then attacks HBTU to form an O-acyl isourea activated intermediate and the 
benzotriazolyl anion, this anion then attacks the intermediate to form a hydroxybenzotriazolyl 
active ester and tetramethyl urea as a by-product. The N-terminal amine group of the peptide 
then couples to this active ester to form the new amide bond and the benzotriazolyl anion is 
regenerated (Scheme 14). 
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Scheme 14: Mechanism for coupling of an Fmoc-amino acid to the N-terminus of a peptide 
The carboxyl group of the amino acid is deprotonated by NMM and then attacks HBTU to form an O-acyl 
isourea intermediate and a benzotriazolyl anion. The anion attacks the intermediate to form a 
hydroxybenzotriazolyl active ester and leave tetramethyl urea as by-product. The free N-terminus of the 
peptide then couples to the ester to form an amide bond the regenerate the benzotriazolyl anion. 
 
The success of the peptide synthesis was determined by analytical LC-MS and peptides were then 
purified by preparative LC-MS, both of which were carried out using mobile phases of methanol 
and H2O, with 0.1% formic acid, and a linear gradient of 5 – 98% methanol. The syntheses of all 
peptides during the PhD were successful and characterisation data can be found in section 6.9.6. 
An example of an LC-MS ultraviolet (UV) trace and negative electrospray (ES-) mass spectrum for 
the pure Bip(3)-peptide can be seen in Figure 38. This presence of a single, sharp peak in both the 
UV trace and the mass spectrum indicates the high level of purity achieved for this peptide and is 
typical of all peptides synthesised during the PhD (other spectra can be seen in appendix section 
8.5). 
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Figure 38: LC-MS UV trace (A) and ES- mass spectrum (B) for pure Bip(3)-peptide 
Single, sharp peaks at Rt = 10.07 min in the UV trace and at m/z = 1148.68 in the mass spectrum indicate 
the purity of the peptide.  
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4.1.3 Biotin-labelled peptides 
It was later decided to synthesise biotin-labelled peptides for use in SPR experiments. It was 
envisaged that a peptide could be labelled with biotin for immobilisation onto an SPR chip and 
either IgE-Fc or αγ could then be injected over the chip and might bind to the immobilised peptide 
(these experiments are discussed in section 4.7). Phe(3)-peptide was chosen to be labelled with 
biotin as it was the most active peptide in the library. It was decided to attach the biotin to the N-
terminus of the peptide, both directly to the N-terminal residue and via a linker made of three 
glycine residues. The corresponding peptide with the N-terminal linker but without the biotin label 
was also synthesised to investigate the effect of the linker by itself. It was chosen to attach the 
biotin to the N-terminus as it meant the labelling reaction could be carried out whilst the peptide 
was still attached to the solid phase resin and the side chain groups were protected, which should 
ensure that no competing side-reactions occur and the labelling efficiency is high. It also allows for 
the simple removal of reagents after the reaction.  
 
If having the biotin attached to the N-terminus rendered the peptide unsuitable for the SPR 
experiments, it was thought that the biotin could instead be attached to the C-terminus of the 
peptide (by using a resin which comprised a biotin that would be left attached to the C-terminus 
after cleavage) or that the biotin could be added to a residue side chain. However, this would 
involve a more complicated synthesis perhaps employing an orthogonal protecting group strategy. 
Therefore, the N-terminal biotin labelling was employed in the first instance. An overview of the 
biotin-labelled peptides and the corresponding unlabelled linker-peptide synthesised during this 
research can be seen in Table 13 and their structures can be seen in Figure 39. 
 
 
 
Table 13: Biotin-labelled peptides and linker-peptide synthesised 
Biotin-labelled peptides were synthesised to use for subsequent SPR experiments. Residues in bold show 
how the peptide sequence differs from that of the parent peptide. (NB: biotin- denotes biotinylated N-
terminus, H2N- denotes free N-terminus, –CONH2 denotes amidated C-terminus). 
 
  
Peptide name Peptide sequence 
b-Phe(3)-peptide biotin-Asp-Lys-Phe-Tyr-Ile-Val-Lys-Tyr-CONH2 
b-link-Phe(3)-peptide biotin-Gly-Gly-Gly-Asp-Lys-Phe-Tyr-Ile-Val-Lys-Tyr-CONH2 
link-Phe(3)-peptide H2N-Gly-Gly-Gly-Asp-Lys-Phe-Tyr-Ile-Val-Lys-Tyr-CONH2 
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Figure 39: Structures of biotin-labelled peptides and linker-peptide 
The biotin group is shown in blue and the linker made of 3 Gly residues in shown in green. 
 
The biotin-labelling reaction was achieved by allowing a solution of biotin-NHS ester (5 equivalents 
(eq)) and N,N-diisopropylethylamine (DIPEA) (1 eq) to react with the resin-bound Phe(3)-peptide, 
following which the reagents were removed by filtration and the resin washed with DMF. Cleavage 
from the resin and side-chain deprotection was then carried out as before. More details of the 
experimental procedures can be found in section 6.9.4 and an overview of the synthesis is seen in 
Scheme 15.  
 
 
b-Phe(3)-peptide 
 
 
 
 
 
 
 
 
 
 
b-link-Phe(3)-peptide 
 
 
 
 
 
 
 
 
 
 
link-Phe(3)-peptide 
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Scheme 15: Overview of biotinylation of the N-terminus of a resin-bound peptide 
The N-terminus of the resin-bound peptide was biotinylated using biotin-NHS ester and DIPEA. The 
biotinylated peptide was then cleaved from the resin using a mixture of 95% TFA, 2.5% TIS and 2.5% H2O 
which also removed any side chain protecting groups to leave the free peptide with an N-terminal biotin 
group and a C-terminal amide. 
 
The first biotin-labelling reaction was carried out, to synthesise b-Phe(3)-peptide, at rt for 1 hour, 
then the solution removed, the resin washed and the reaction repeated for a further 1 hour with 
fresh biotin-labelling solution. However, after cleavage from the resin and analysis by LC-MS, it 
was found that not all of the peptide had been biotinylated. The UV trace from the analytical LC-
MS of crude b-Phe(3)-peptide (Figure 40, A) showed a peak at retention time (Rt) = 8.99  min for 
the unlabelled peptide and a peak at Rt = 10.07 min for the biotinylated peptide. The reaction  
could not have gone to completion for a number of reasons; for example  if the biotin NHS ester 
reagent had decomposed, or if the resin was not ‘swollen’ enough in solvent before the reaction. 
However, it seemed most likely that the reaction time was too short. Even though not all the 
peptide b-Phe(3)-peptide was labelled, the peptides eluted one minute apart, so it was easy to 
separate and isolate the two peptides by preparative LC-MS and the UV trace for pure biotin-
labelled peptide (Figure 40, B) shows that all unlabelled peptide was removed and a single sharp 
peak for only the biotin-labelled peptide was observed.  
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Figure 40: Analytical LC-MS UV traces for crude and pure b-Phe(3)-peptide 
A = UV trace for crude biotinylated peptide showed that a mixture of unlabelled peptide (Rt = 8.99 min) and 
biotinylated peptide (Rt = 10.07 min) was obtained after cleavage from the resin and side-chain 
deprotection. B = UV trace for pure biotinylated peptide shows that the unlabelled peptide was successfully 
removed to leave only a peak for the pure biotinylated peptide (Rt = 10.16 min). 
 
In order to improve the yield of the biotin-labelled peptide, the next time the labelling reaction 
was carried out, to synthesise b-link-Phe(3)-peptide, the reaction time was increased to 16 hours. 
This time only biotin-labelled peptide was seen in the UV trace from the analytical LC-MS of crude 
b-link-Phe(3)-peptide (Figure 41, A) indicating that the increased reaction time was key to 
improving the yield. However, this peptide did contain the glycine linker which could also have 
been a factor in making the synthesis more successful. Since there was an N-terminal glycine, 
rather than an aspartic acid, there could have been less steric hindrance during the reaction. The 
b-link-Phe(3)-peptide was then successfully purified using preparative LC-MS and the UV trace for 
the pure peptide can be seen in Figure 41, B.  
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Figure 41: Analytical LC-MS UV traces for crude and pure b-link-Phe(3)-peptide 
A = UV trace for crude biotinylated peptide showed that only biotinylated peptide (Rt = 9.94 min) was 
obtained after cleavage from the resin and side-chain deprotection, which indicated that all peptide was 
labelled during the biotinylation reaction. B = UV trace for pure biotinylated peptide (Rt = 9.90 min). 
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4.2 Testing peptide inhibitors with the ELISA 
Two of the peptides synthesised during the PhD, the C-strand peptide and the Bip(3)-peptide, had 
not previously been tested with the ELISA. These peptides were therefore tested using the ELISA 
methodology described earlier and the IC50 values can be seen in Table 14. 
 
Peptide name Peptide sequence IC50 (μM) 
C-strand peptide H2N-Tyr-Lys-Val-Ile-Tyr-Tyr-Lys-Asp-CONH2 >1000 
Bip(3)-peptide H2N-Asp-Lys-Bip-Tyr-Ile-Val-Lys-Tyr-CONH2 173 ± 12 
 
Table 14: ELISA inhibition assay IC50 values for peptides 
 
It can be seen from Table 13, that the C-strand peptide, which consists of the sequence found in 
the C-strand hotspot region of FcεRI, did not inhibit the IgE:FcεRI interaction and this confirms the 
previous result (Dr Bingli Mo, IC).139 The Bip(3)-peptide did inhibit the interaction (IC50 = 173 μM) 
which is in the same range as the parent peptide and the Phe(3)-peptide tested previously.131 It is 
promising that this peptide shows inhibition of the PPI, as it indicates that the larger biaryl group is 
tolerated at this position, and it is advantageous as the biaryl group has been previously reported 
not only to confer increased activity and selectivity but also stability to proteolytic degradation.145  
 
4.3 Testing peptide inhibitors with the TR-FRET assay 
All peptides were then tested in the TR-FRET assay, using the methodology described earlier, to 
compare IC50 values to those obtained in the ELISA and to see if the TR-FRET assay was higher 
throughput than then ELISA and would be a more efficient assay for testing further libraries of 
peptide inhibitors. Examples of the TR-FRET inhibition curves for Phe(3)-peptide can be seen in 
Figure 42 and the TR-FRET assay IC50 values for all peptides can be seen in Table 15. 
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Figure 42: TR-FRET inhibition assay curves for Bip(3)-peptide 
A = Bip(3)-peptide preincubated with IgE-Fc-A647 (IC50 = 16 ± 1 μM). B = Bip(3)-peptide preincubated with 
αγ-Tb (IC50 = 11 ± 1 μM). 
 
Peptide name Peptide sequence 
IC50 (μM) 
Pre-inc. 
IgE-Fc 
IC50 (μM) 
Pre-inc.  
αγ 
C-strand-peptide H2N-Tyr-Lys-Val-Ile-Tyr-Tyr-Lys-Asp-CONH2 >1000 >1000 
parent- peptide  H2N-Asp-Lys-Tyr-Tyr-Ile-Val-Lys-Tyr-CONH2 
459 ± 42 
371 ± 58 
355 ± 38 
176 ± 13 
165 ± 22 
133 ± 7 
Phe(3)-peptide H2N-Asp-Lys-Phe-Tyr-Ile-Val-Lys-Tyr-CONH2 
12 ± 0.7 
155 ± 12 
11 ± 0.7 
58 ± 2 
Trp(3)-peptide H2N-Asp-Lys-Trp-Tyr-Ile-Val-Lys-Tyr-CONH2 51 ± 3 70 ± 11 
Bip(3)-peptide H2N-Asp-Lys-Bip-Tyr-Ile-Val-Lys-Tyr-CONH2 16 ± 1 11 ± 1 
His(3)-peptide H2N-Asp-Lys-His-Tyr-Ile-Val-Lys-Tyr-CONH2 >1000 >1000 
link-Phe(3)-peptide H2N-Gly-Gly-Gly-Asp-Lys-Phe-Tyr-Ile-Val-Lys-Tyr-CONH2 26 ± 4 7 ± 1 
Table 15: TR-FRET inhibition assay IC50 values for peptides 
NB: Multiple IC50 values indicate the assay has been repeated on a different occasion. 
 
It can be seen from Table 14 that overall the same trends are seen as when the peptides were 
tested with the ELISA (Tables 11 and 13). Lower IC50 values are generally obtained from the TR-
FRET assay, as the concentrations of proteins are lower than in the ELISA and closer to the Kd of 
the IgE:FcεRI interaction, suggesting the TR-FRET assay is more sensitive and that less inhibitor is 
required to inhibit the IgE:FcεRI interaction. The C-strand peptide does not inhibit the IgE:FcεRI 
interaction, which confirms the previous ELISA results and indicates that this peptide may not be a 
good mimic the key binding region of FcεRI and therefore cannot compete with FcεRI for binding 
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to IgE. The parent-peptide showed moderate inhibition of the IgE:FcεRI interaction (IC50 = 133 – 
176 μM when pre-incubated with αγ), however an improved inhibition is seen for Phe(3)-peptide 
and Trp(3)-peptide (IC50 = 11 – 58 μM and 70 μM respectively when pre-incubated with αγ), 
indicating that phenylalanine and tryptophan residues at position 3 make more favourable 
interactions with one of the proteins than tyrosine. Bip(3)-peptide also displayed good inhibition 
of the IgE:FcεRI interaction (IC50 = 11 μM when pre-incubated with αγ) which indicates that the 
larger biaryl group is also tolerated at position 3. His (3)-peptide did not inhibit the interaction, 
confirming the previous ELISA result and implying that histidine makes unfavourable interactions 
with one of the proteins, perhaps because of the charged nature of its side chain. The link-Phe(3)-
peptide was also tested and showed good inhibition (IC50 = 7 μM when preincubated with αγ), 
implying that the extra  glycine residues of the linker do not adversely affect the ability of the 
peptide to inhibit the IgE:FcεRI interaction, but actually give a slightly improved inhibition 
compared to the Phe(3)-peptide. Some variation between IC50 values for peptides tested on 
different occasions was seen. This could have been due to differences in the solubility of the 
peptides or between different synthesised batches of the same peptide or due to random error in 
the measurement.  
 
It can also be seen that, on the whole, lower IC50 values are obtained when the peptide is pre-
incubated for 1 hour with   αγ,   rather   than   with   IgE-Fc. As it is not known which protein the 
peptides bind to, these results could  imply  that  the  peptides  bind  to  αγ  rather  than  IgE-Fc. It was 
planned to further investigate this with subsequent biophysical and structural experiments. It 
would be important to deduce to which protein the peptides bind and try to obtain structural 
information about how they bind to that protein, to allow the rational design of peptides with 
improved affinity. There may be a slight disadvantage to an  inhibitor  binding  to  FcεRI,  rather  than  
to IgE-Fc, as binding to the receptor might cause a possible agonist effect and mast cell 
degranulation, so this is something that should be tested for in the future if it was confirmed that 
peptides  do  indeed  bind  to  FcεRI. 
 
4.4 Testing biotin-peptide inhibitors with the TR-FRET assay 
It was planned to immobilise b-Phe(3)-peptide and b-link-Phe(3)-peptide, the biotin-labelled 
versions of the most active peptide Phe(3)-peptide, to an SPR chip and inject solutions of IgE-Fc 
and  αγ  over the chip, in the hope that the peptide would bind to one protein preferentially over 
the other. However, it was important to first check that these biotin-labelled peptides could still 
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inhibit  the  IgE:FcεRI  interaction. These peptides were therefore tested in the TR-FRET assay using 
the same methodology as before and the results can be seen in Table 16. 
Peptide name Peptide sequence 
IC50 (μM) 
Pre-inc.  
IgE-Fc 
IC50 (μM) 
Pre-inc. 
αγ 
b-Phe(3)-peptide biotin-Asp-Lys-Phe-Tyr-Ile-Val-Lys-Tyr-CONH2 
7 ± 1 
60 ± 7 
1 ± 1 
15 ± 5 
b-link-Phe(3)-peptide biotin-Gly-Gly-Gly-Asp-Lys-Phe-Tyr-Ile-Val-Lys-Tyr-CONH2 13 ± 2 4 ± 0.4 
Table 16: TR-FRET inhibition assay IC50 values for biotin-peptides 
NB: Multiple IC50 values indicate the assay has been repeated on a different occasion. 
 
It was found that the activity of both b-Phe(3)-peptide and b-link-Phe(3)-peptide was actually 
improved by having biotin on the N-terminus (IC50 = 1 – 15 μM and 4 μM respectively when pre-
incubated with αγ), rather than with a free N-terminus. This could imply that biotin makes a more 
favourable interaction with one of the proteins, or that simply not having a charged free N-
terminus improves activity.  
 
4.5 Testing biotin-peptide inhibitors with streptavidin in the TR-FRET assay 
It was then planned to test these biotin-peptides with streptavidin in the TR-FRET assay, to check 
that the peptides could still inhibit the IgE:FcεRI interaction even when bound to streptavidin, as 
they would need to do this in the subsequent SPR experiments. In order to ensure that any 
inhibition was actually due to the streptavidin-bound peptide and not due to the free peptide, an 
excess of streptavidin was used to ensure that all biotin-peptide was bound to streptavidin. To 
ensure streptavidin was in excess, the concentration of biotin-peptide was decreased, from an 
upper concentration of 1 mM to an upper concentration of 125 μM, as it was predicated from 
their inhibition curves that they could still inhibit the IgE:FcεRI interaction even at the lower 
concentrations. The biotin-peptides were tested in the TR-FRET assay at these lower 
concentrations and the results can be seen in Table 17. 
Peptide name Peptide sequence IC50 (μM) Pre-inc. αγ 
b-Phe(3)-peptide 
(lower concentration)a biotin-Asp-Lys-Phe-Tyr-Ile-Val-Lys-Tyr-CONH2 2 ± 4 
b-link-Phe(3)-peptide 
(lower concentration) biotin-Gly-Gly-Gly-Asp-Lys-Phe-Tyr-Ile-Val-Lys-Tyr-CONH2 98 ± 104 
Table 17: TR-FRET inhibition assay IC50 values for biotin-peptides at lower concentrations 
aMaximum concentration of peptide was reduced from 1 mM to 125 μM. 
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It can be seen that the peptides still showed inhibition at these lower concentrations and that b-
Phe(3)-peptide showed particularly good inhibition (IC50 = 2 μM when preincubated with αγ). Both 
biotin-peptides were then tested at these lower concentrations with streptavidin (2 eq) in the TR-
FRET assay and the results can be seen in Table 18. 
 
Peptide name Peptide sequence IC50 (μM) Pre-inc. αγ 
b-Phe(3)-peptide 
(lower concentration)a 
+ streptavidin (2 eq) 
biotin-Asp-Lys-Phe-Tyr-Ile-Val-Lys-Tyr-CONH2 5 ± 1 
b-link-Phe(3)-peptide 
(lower concentration) 
+ streptavidin (2 eq) 
biotin-Gly-Gly-Gly-Asp-Lys-Phe-Tyr-Ile-Val-Lys-Tyr-CONH2 >1000 
 
Table 18: TR-FRET inhibition assay IC50 values for biotin-peptides with streptavidin 
aMaximum concentration of peptide was reduced from 1 mM to 125 μM. 
 
It can be seen that b-Phe(3)-peptide still showed good inhibition of the IgE:FcεRI interaction even 
when it was bound to streptavidin (IC50 = 5 μM when preincubated with αγ), however b-link-
Phe(3)-peptide did not show any inhibition. It was therefore decided to use b-Phe(3)-peptide for 
immobilisation to the SPR chip for subsequent SPR binding assays  (discussed in section 4.7). 
 
4.6 X-ray crystallography experiments 
At the same time as testing all the peptides in the TR-FRET assay, x-ray crystallography 
experiments were also being carried out for both Phe(3)-peptide and Trp(3)-peptide with IgE-Fc, 
as these were the two most active peptides when the crystallography experiments were carried 
out. The aim was to obtain a co-crystal of IgE-Fc with a peptide bound in a particular position, to 
confirm that peptides do bind to IgE-Fc and to give structural information about their mode of 
action and facilitate improvements in inhibition. It was planned to carry out both co-crystallisation 
and soak crystallisation experiments and these are discussed in this section. 
 
4.6.1 Co-crystallisations of peptides with IgE-Fc 
First co-crystallisation experiments with Phe(3)-peptide and Trp(3)-peptide 
Solutions of both Phe(3)-peptide and Trp(3)-peptide at concentrations of both 50 μM and 100 μM 
were incubated with IgE-Fc (27 μM) and IgE-Fc seeds (ground up apo crystals of IgE-Fc, provided by 
Dr Nyssa Drinkwater, KCL). More detailed experimental details can be found in section 6.6. After 
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approximately 5 days, oblong crystals measuring approximately 100 x 200 μm had formed for all 
four experiments. Single crystals from the co-crystallisations of both Phe(3)-peptide and Trp(3)-
peptide at 100 μM were frozen in liquid nitrogen and x-ray diffraction data was collected at the 
Diamond Light Source synchrotron. Figure 43 shows photos of the crystals grown in the 
experiments and the x-ray diffraction patterns obtained and Table 19 shows the data collection 
statistics for the experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 43: Crystal photos and x-ray diffractions - first co-crystallisations of peptides and IgE-Fc 
A1 = Crystal photos and B1 = x-ray diffraction data for co-crystallisation experiment of Phe(3)-peptide (100 
μM) with IgE-Fc (27 μM). A2 = Crystal photos and B2 = x-ray diffraction data for co-crystallisation 
experiment of Trp(3)-peptide (100 μM) with IgE-Fc (27 μM).  Crystals measured approximately 100 μm x 
200 μm. X-ray data collected at the Diamond Light Source synchrotron. 
A1        B1 
A2        B2  
200 μm 
200 μm 
112 
 
 Phe(3)-peptide Trp(3)-peptide 
Resolution (Å) 2.07 2.28 
Rmerge 0.099 0.069 
I/sigma 11.2 11.5 
Completeness (%) 99.7 98.7 
Multiplicity 4.7 3.9 
Rfactor 0.2490 0.2380 
Rfree 0.2846 0.2838 
Average unit cell a = 128.33, b = 74.78, c = 79.33 a = 128.06, b = 74.86, c = 79.23 
Space group P 21 21 2 P 21 21 2 
 
Table 19: Data collection statistics - first co-crystallisations of peptides and IgE-Fc 
Co-crystallisation experiments of Phe(3)-peptide (100 μM) with IgE-Fc (27 μM) and Trp(3)-peptide (100 μM) 
with IgE-Fc (27 μM). Data collected at Diamond Light Source synchrotron.   
 
As Table 18 shows, crystals from both experiments diffracted to a high resolution (2.07 Å for 
Phe(3)-peptide and 2.28 Å for Trp(3)-peptide) and refinement statistics were good. The crystal 
structures were solved by molecular displacement using a high resolution structure of IgE-Fc (PDB 
code 2WQR)22 and the CCP4 software Phenix Refine and Coot. Unfortunately, for both cases the 
structures were found to be of IgE-Fc only with no unaccounted electron density which would be 
indicative of a bound peptide. This could indicate that the peptides do not bind to IgE-Fc but 
instead bind to FcεRI, which would be consistent with the fact that in general lower IC50 values 
were obtained in the TR-FRET assay when peptides were pre-incubated with αγ rather than with 
IgE-Fc. Or it could indicate that peptides do bind to IgE-Fc but were not able to form a co-crystal 
structure due to their affinity being too low, or that too low a concentration of peptide was used.  
 
Second co-crystallisation experiments with Phe(3)-peptide and Trp(3)-peptide 
It was therefore decided to repeat the co-crystallisation experiments for both Phe(3)-peptide and 
Trp(3)-peptide with IgE-Fc using higher peptide concentrations of 200 μM and 300 μM in the hope 
that this would be more amenable to co-crystallisation. Crystals were grown successfully in all four 
experiments after approximately 5 days as before. Crystals from the co-crystallisations of both 
peptides were frozen in liquid nitrogen and x-ray diffraction data was collected at KCL using a 
single crystal diffractometer. Figure 44 shows photos of the crystals obtained and Table 20 shows 
the data collection statistics for the experiments. 
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Figure 44: Crystal photos - second co-crystallisations of peptides and IgE-Fc 
A1 = Co-crystallisation experiment of Phe(3)-peptide (200 μM) with IgE-Fc (27 μM). B1 = Co-crystallisation 
experiment of Phe(3)-peptide (300 μM) with IgE-Fc (27 μM). A2 = Co-crystallisation experiment of Trp(3)-
peptide (200 μM) with IgE-Fc (27 μM). B2 = Co-crystallisation experiment of Trp(3)-peptide (300 μM) with 
IgE-Fc (27 μM). Crystals measured approximately 100 μm x 200 μm. Data collected at KCL using a single 
crystal diffractometer. 
 
 
 Phe(3)-peptide Trp(3)-peptide 
Resolution (Å) 2.6 2.4 
Rfactor 0.2646 0.2625 
Rfree 0.3253 0.3223 
 
Table 20: Data collection statistics - second co-crystallisations of peptides and IgE-Fc 
Co-crystallisation experiments of Phe(3)-peptide (300 μM) with IgE-Fc (27 μM) and Trp(3)-peptide (300 μM) 
with IgE-Fc (27 μM). Data collected at KCL using a single crystal diffractometer.   
 
Crystals diffracted well, good refinement statistics were obtained and the structures were solved 
using molecular displacement as before. However, unfortunately the solved structures were of 
IgE-Fc only and no bound peptides were observed. It was therefore decided to try soak 
crystallisation experiments in case this was a more effective method of obtaining a co-crystal. 
 
A1    B1 
A2    B2 
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4.6.2 Soak crystallisations of peptides with IgE-Fc 
Soak crystallisation experiments were carried out for both Phe(3)-peptide and Trp(3)-peptide with 
IgE-Fc. Solutions of both peptides at a concentration of 500 μM were incubated with 4 – 6 apo 
crystals of IgE-Fc (provided by Dr Nyssa Drinkwater, KCL). The solutions were left for 5 – 10 days, 
after which crystals were frozen in liquid nitrogen and X-ray diffraction data was collected at 
Diamond light source. X-ray data collection for Phe(3)-peptide had low completeness and 
unfortunately data could not be obtained, however data was collected for Trp(3)-peptide and this 
can be seen in Table 21. 
 
Resolution (Å) 2.08 
Rmerge 0.123 
I/sigma 6.9 
Completeness (%) 99.9 
Multiplicity 4.4 
Rfactor 0.2461 
Rfree 0.2786 
Average unit cell a = 128.59, b = 75.05, c = 79.45 
Space group P 21 21 2 
 
Table 21: Data collection statistics - soak crystallisation of IgE-Fc and Trp(3)-peptide  
Soak crystallisation experiment of Trp(3)-peptide (500 μM) with IgE-Fc crystals. Data collected at Diamond 
light source.   
 
Trp(3)-peptide diffracted to a high resolution of 2.08 Å and good refinement statistics were 
obtained. The structure was solved using molecular displacement as described earlier, however 
unfortunately no peptide was found to be bound to IgE-Fc in the crystal structure. The fact that no 
co-crystal structure of IgE-Fc with a peptide bound in a particular position was obtained from 
either the co-crystallisation or soak crystallisation experiments with Phe(3)-peptide or Trp(3)-
peptide is disappointing. However, it is beneficial that the conditions to grow crystals of IgE-Fc are 
optimised and if it was determined by other methods that peptides do actually bind to IgE-Fc and 
their binding affinity could be improved, this would improve the chances of obtaining a co-crystal.  
Alternative crystallisation experiments with IgE-Fc could be used, as mentioned earlier, for 
instance using IgE-Fc3-4, or purifying IgE-Fc with the peptide bound and screening different 
crystallisation conditions, or even to form a covalent attachment between the peptide and IgE-Fc. 
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However, it was felt that efforts should first be focussed on obtaining conclusive information 
about which protein the peptides were binding to.  
 
4.7 SPR experiments  
SPR has proven a useful and varied technique for investigating peptide inhibitors of the IgE:FcεRI 
interaction as reported in the literature. It was decided to carry out SPR experiments with Phe(3)-
peptide as overviewed in Scheme 9.  
 
4.7.1 SPR with immobilised proteins 
Inhibition of IgE-Fc  binding  to  immobilised  αγ by Phe(3)-peptide 
Phe(3)-peptide was tested as an inhibitor of IgE-Fc binding to immobilised  αγ in an inhibition assay. 
A solution of IgE-Fc (10 nM) and Phe(3)-peptide (150  μM) was injected over the immobilised αγ. 
However, a large increase in resonance units was observed along with sharp injection peaks for 
the peptide. This indicated poor solubility of the peptide in the SPR running buffer, as the sharp 
peaks could show the  peptide  was  being  injected  in  ‘clumps’  if  precipitating  out  of  solution.    The  
large increase in resonance units was likely to indicate that the peptide was binding non-
specifically to the chip due to its hydrophobic nature, despite the detergent present in the buffer. 
In fact, when studying the raw data it was found that the largest increase in signal was for the 
control flow cell with no protein bound to the surface, meaning the peptides could have been 
binding non-specifically to the CM matrix on the chip. Glycine pH 2.5, NaCl (5 M) and MgCl2 (4 M) 
were all injected to try to remove the bound peptide but without success.  
 
4.7.2 SPR with immobilised biotin-peptide 
SPR experiments were then carried out with Phe(3)-peptide immobilised to the SPR chip instead 
of the proteins, as it was hoped this would overcome the problem of the peptide precipitating out 
of solution and binding non-specifically to the sensor chip. It would also mean that if a protein 
bound to the immobilised peptide, this would give a much larger increase in signal than if the 
peptide bound to an immobilised protein, due to the much larger molecular weight of the protein 
compared to the peptide. It was planned to use the biotin-labelled peptide b-Phe(3)-peptide, as 
described earlier, and immobilise this to a streptavidin coated SPR chip. A sensor chip pre-
immobilised with streptavidin was chosen for the experiments, to avoid the extra streptavidin 
immobilisation step and give a more uniform density of streptavidin across the active and control 
flow cells of the sensor chip. It was planned to immobilise the b-Phe(3)-peptide, via the high-
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affinity biotin-streptavidin interaction, then carry out direct binding assays where IgE-Fc   and  αγ  
are injected in turn over the peptide-chip (Scheme 16). 
 
Scheme 16: Overview of SPR experiments with immobilised b-Phe(3)-peptide 
1 = immobilisation of peptide to streptavidin coated SPR chip, 2 = direct binding assay with injection of IgE-
Fc, 3 = direct binding assay with injection of αγ. 
 
Immobilisation of b-Phe(3)-peptide 
The b-Phe(3)-peptide (100 nM) was injected over the streptavidin coated chip and the binding was 
allowed to reach saturation so the maximum density of immobilised peptide was achieved. An 
increase of ~350 resonance units was observed.  
 
Initial binding of IgE-Fc and αγ to b-Phe(3)-peptide 
IgE-Fc (13.3  μM)  was  then injected over the peptide-chip which gave an increase in signal of ~ 40 
resonance units. This experiment was repeated with an injection of αγ  (2.66  μM)  over the peptide-
chip which gave an increase in signal of ~70 resonance units. These initial results indicated that 
both proteins could have been binding to the peptide, but further assays with a dilution series of 
each protein and also a control protein were carried out to further confirm the results.  
 
Binding assay with IgE-Fc, αγ and IgG4 binding to immobilised b-Phe(3)-peptide 
IgE-Fc was prepared in 12 different  concentrations  starting  at  13.3  μM  with  2-fold dilutions to a 
final concentration of 0.03 μM. αγ was prepared in 9 different concentrations starting at 3.0 μM 
with 2-fold dilutions to a final concentration of 0.06 μM. IgG4 was used as a control protein as the 
peptide was not expected to bind to this. IgG4 was prepared in 12 different concentrations starting 
at 4.0 μM with 2-fold dilutions to a final concentration of 0.03 μM. Due to the relatively weak 
binding of the peptide to the proteins, after the end of the injection the baseline had returned to 
its previous value, therefore no proteins stayed bound to the peptide and a glycine injection to 
remove any protein was not required. Further experimental details can be found in section 6.5. 
gold surface of sensor chip 
streptavidin 
biotinylated peptide 
IgE-Fc 
αγ 
 
1 
 
2 
 
3 
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The sensorgrams and corresponding Langmuir curves for each binding assay can be seen in Figures 
45, 46 and 47. In each case the SPR binding assay was carried out twice to check the 
reproducibility and it was found that results were very consistent across the duplicate experiments. 
It can be seen that there was negligible binding of IgE-Fc to the immobilised b-Phe(3)-peptide, 
even at the highest concentration of 13.3 μM (Figure 45). Also, the control protein IgG4 did not 
show any binding to immobilised b-Phe(3)-peptide, which was to be expected (Figure 46).  
 
However, αγ appeared to bind to immobilised b-Phe(3)-peptide in a dose dependent manner and 
a series of sensorgrams were obtained (Figure 47, A1 and A2). These show that at the highest 
concentration of αγ (3.0 μM) there was an increase of nearly 60 resonance units. The Langmuir 
isotherm for αγ  (Figure  47,  B)  also  shows  a  dose  dependent  binding  of  αγ  to  immobilised  b-Phe(3)-
peptide. Even though this curve does not go to saturation, this was to be expected as the 
maximum  concentration  of  αγ  used in the assay was  3  μM,  which  is  in  the  same  range  as  the  IC50 
value for b-Phe(3)-peptide (IC50 = 1 – 15  μM  when  pre-incubated  with  αγ   in   the  TR-FRET assay, 
Table 16). The upper concentrations of IgE-Fc, IgG4 and αγ were chosen as they were the 
maximum concentrations available. If a higher concentration of αγ was able to be used, above the 
range of the IC50 value for the peptide, then the Langmuir isotherm could indeed reach saturation. 
 
These are interesting results and indicate that Phe(3)-peptide (and analogues) inhibit the IgE:FcεRI 
interaction by binding to FcεRI rather than by binding to IgE. This is consistent with the fact that a 
co-crystal structure of IgE-Fc and a peptide was not be obtained and also with the fact that 
peptides showed more potent inhibition in the TR-FRET assay when they were pre-incubated with 
αγ. It is pleasing that it can be said with reasonable confidence that the peptides bind to FcεRI as it 
means that future biophysical and structural experiments with FcεRI could be planned to find out 
the mode of action of the peptides and to facilitate improvements in affinity.   
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Figure 45: SPR sensorgrams and Langmuir isotherm - IgE-Fc binding to immobilised b-Phe(3)-peptide 
A1 and A2 = SPR sensorgrams (two repeats of the binding assay). B = Langmuir isotherm. 
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Figure 46: SPR sensorgrams and Langmuir isotherm - IgG4 binding to immobilised b-Phe(3)-peptide 
A1 and A2 = SPR sensorgrams (two repeats of the binding assay). B = Langmuir isotherm. 
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Figure 47: SPR sensorgrams and Langmuir isotherm - αγ binding to immobilised b-Phe(3)-peptide 
A1 and A2 = SPR sensorgrams (two repeats of the binding assay). B = Langmuir isotherm. 
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Chapter 5: Summary and future work 
5.1 Summary 
The main objectives of this PhD were to design and synthesise inhibitors of the PPI between IgE 
and FcεRI, which is a key component of the allergic reaction, and to develop and carry out assays 
and structural experiments to test these compounds. Two main series of compounds were studied 
as inhibitors of the IgE:FcεRI interaction; small molecules based on the natural product 
aspercyclide A and short, linear peptides derived from a sequence that was originally designed to 
mimic a key hotspot of the interaction.  
 
A TR-FRET assay was developed and optimised to test the small molecule and peptide inhibitors. 
This involved labelling of the two proteins IgE and αγ with appropriate acceptor and long lifetime 
donor fluorophores and carrying out initial binding and inhibition assays to determine optimal 
protein concentrations, incubation times and assay format. The TR-FRET assay was found to be a 
more attractive assay than the previously developed ELISA, as it was carried out in solution, with 
no secondary reagents or washing steps required and it used less material. The TR-FRET assay was 
found to have a good S/B of 12.6 and an excellent Z-factor of 0.79.  SPR experiments involving 
immobilisation of each of the two proteins were also investigated and individual domains of IgE 
were expressed and purified which could be used in subsequent experiments. The main results 
from the small molecule and peptide compound libraries are summarised in the following sections. 
 
5.1.1 Small molecules 
The natural product aspercyclide A was originally isolated from natural product extracts, tested in 
an ELISA and found to inhibit the IgE:FcεRI interaction with IC50 = 200 μM.86 As this compound 
offered an interesting starting point for the design of potentially more potent inhibitors, co-
workers in the Spivey research group at IC carried out the asymmetric synthesis of the natural 
product (+)-aspercyclide A and various analogues. (+)-Aspercyclide A and a benzoxathiazine-2,2-
dioxide derivative were found to inhibit the IgE:FcεRI interaction when tested with an ELISA (IC50 = 
424 – 538 μM and  162 – 463 μM respectively) and the synthesis and assay results for these 
compounds were published recently.92 The structures of these compounds can be seen in Figure 
48. The activity of the benzoxathiazine derivative was also confirmed by collaborators at Novartis, 
who also found that this compound showed inhibition of the IgE:FcεRI interaction when tested in 
an ELISA (EC50 = 124 – 156 μM).  
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Figure 48: Structures of (+)aspercyclide A and its benzoxathiazine-2,2-dioxide derivative 
These compounds were the most active small molecules at inhibiting the IgE:FcεRI interaction when tested 
with an ELISA (IC50 = 424 – 538 μM for (+)-aspercyclide A and  162 – 463 μM for the benzoxathiazine 
derivative). 
 
A dibenzofuran analogue, originally isolated as a byproduct during the final macrocyclisation 
reaction to form the aspercyclide A compounds, appeared to inhibit the IgE:FcεRI interaction when 
tested with the ELISA (IC50 = 3 – 5 μM). However, subsequent SPR inhibition assays found that this 
compound did not inhibit the IgE:FcεRI interaction and x-ray crystallography experiments with IgE-
Fc found that this compound did not show any binding to IgE-Fc. On re-synthesis and re-testing of 
this compound with the ELISA, no inhibition was seen, therefore it was thought the initial result 
was a false positive and that the dibenzofuran was inhibiting another component of the ELISA and 
not the interaction between IgE and FcεRI. 
 
5.1.2 Peptides 
A short, linear peptide known as parent-peptide (H2N-Asp-Lys-Tyr-Tyr-Ile-Val-Lys-Tyr-CONH2), was 
previously found to inhibit the IgE:FcεRI interaction when tested with an ELISA131 and it was also 
found that Tyr(3) was key for the activity139. A series of analogues with aromatic substitutions at 
position 3 were previously synthesised and tested in the ELISA an the analogous peptide Phe(3)-
peptide (H2N-Asp-Lys-Phe-Tyr-Ile-Val-Lys-Tyr-CONH2) displayed an improved inhibition.131 A 
further peptide Bip(3)-peptide (H2N-Asp-Lys-Bip-Tyr-Ile-Val-Lys-Tyr-CONH2) was synthesised, to 
determine the effect of the unnatural amino acid biphenylalanine at position 3. The whole peptide 
library was tested with the new TR-FRET assay, to confirm the ELISA results and the Phe(3)-
peptide and Bip(3)-peptide were found to show good inhibition of the interaction between IgE 
and FcεRI (IC50 = 11 – 58 μM and 11 μM respectively). The structures of these peptides can be seen 
in Figure 49. 
 
  
(+)-aspercyclide A   benzoxathiazine-2,2-dioxide 
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Figure 49: Structures of the most active peptides Phe(3)-peptide and Bip(3)-peptide 
These were the two most active peptides at inhibiting the IgE:FcεRI interaction when tested with the TR-
FRET assay (IC50 = 11 – 58 μM for Phe(3)-peptide and 11 μM for Bip(3)-peptide when preincubated with αγ-
Tb). 
 
X-ray crystallography experiments for Phe(3)-peptide, and an analogue Trp(3)-peptide, with IgE-Fc 
were carried out, but a co-crystal structure of a peptide bound to IgE-Fc was not obtained. Phe(3)-
peptide was then labelled with biotin on the N-terminus for subsequent SPR experiments; the 
peptide was immobilised to a streptavidin coated chip and solutions of both IgE and αγ were 
injected over the chip to try to determine to which protein the peptide was binding. It was found 
that the αγ  bound  to  the  immobilised  Phe(3)-peptide, but neither the IgE-Fc or the control protein 
IgG4 did, which indicated that  this  peptide  inhibits  the  IgE:FcεRI  by  binding  to  FcεRI. 
 
The fact that an 8-residue, linear peptide can inhibit this high affinity PPI with a low micromolar 
IC50 value, and that its protein partner has been identified, is an ideal starting point for future 
inhibitor investigations. Further structural and biophysical experiments focussing on the 
interaction between the peptide and FcεRI could now be carried out, with the aim of obtaining 
structural information about exactly how this peptide interacts with FcεRI which would facilitate 
the development of more potent peptide inhibitors. 
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5.2 Future work 
5.2.1 Small molecules 
Future work in the area of small molecule inhibitors of the IgE:FcεRI interaction should focus on 
the benzoxathiazine derivative of aspercyclide A; determining its protein binding partner, carrying 
out structural experiments and using this information to improve potency, whilst also improving 
other properties including solubility. As it is not known whether this compound binds to IgE or to 
FcεRI, or even to the protein complex, it would be important to determine this. It could be 
envisaged that this compound could be immobilised to an SPR chip and binding assays with both 
IgE-Fc and αγ could be carried with the aim of determining to which protein this compound binds. 
As this compound is small, it would be important to immobilise it via a number of different 
attachment points, to ensure an active orientation on the SPR chip. Attachment via the C19 methyl 
ether of the macrocycle could be a good first option for an immobilisation point, as the methyl 
ether group at this position does not seem to have any significant effect on the activity. 
 
If the benzoxathiazine derivative of (+)-aspercyclide A was found to bind to IgE, then x-ray 
crystallography experiments with IgE-Fc could be carried out, along with STD and 15N-HSQC NMR 
experiments with the Cε2 and Cε3 domains of IgE-Fc as described earlier. If the compound was 
found to bind to αγ, then x-ray crystallography experiments with sFcεRIα could be carried out. This 
would hopefully give important structural information about the key areas of the protein that 
make contact with the compound and allow the development of more potent inhibitors. If the 
potency could be improved to the nanomolar range, it would then be important to determine the 
cell-based activity of this compound, by carrying out subsequent cell-based assays, for example 
monitoring the ability of the compound to inhibit IgE-triggered release of β-hexosaminidase or 5-
hydroxytryptamine from RBL cells. Selectivity for the IgE:FcεRI interaction over any other 
immunoglobulin-receptor interactions would also need to be determined.  
 
5.2.2 Peptides  
As Phe(3)-peptide has been found to bind to αγ, the next important step should by x-ray 
crystallography with sFcεRIα to further confirm that this is the protein the peptide is binding to, 
and to identify contact residues on the protein. This information could then be used for the 
rational design of further peptide analogues with potentially improved activity. If a co-crystal 
structure was obtained of Phe(3)-peptide bound to sFcεRIα, it would be interesting to see how the 
residue in position 3 interacts with the protein. It has been found that peptides with either a 
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tyrosine, phenylalanine, tryptophan or biphenylalanine at position 3 all inhibit the interaction, but 
that a histidine is not tolerated at this position. If a biphenylalanine residue made a favourable 
interaction with the protein, for example a π-stacking or hydrophobic interaction, it would be 
interesting to carry out subsequent chemistry towards the synthesis of a library of peptides with 
various biaryl groups at position 3, to further probe  the SAR at this position. Such modifications 
may give improved activity and stability, as discussed earlier, which would be advantageous. For 
example, Suzuki coupling could potentially be carried out if an iodo-phenylalanine was 
incorporated into the peptide during SPPS and then the peptide was reacted with a range of aryl 
boronic acids following the synthesis, which would build up a library of biaryl-containing peptides 
that could be tested. If more potent peptide inhibitors were developed, it would also be important 
to determine their cell-based activity and selectivity, as mentioned in section 5.2.1. 
  
It could also be that a different series of peptides altogether would be a better starting point for 
the design of more potent peptide inhibitors of this interaction. As the TR-FRET assay has been 
found to be reasonably high throughput, if a larger library of peptide inhibitors was prepared, the 
library could be tested with the TR-FRET assay, perhaps even employing automation and robotic 
pipetting. Various methods could be used to synthesise a much larger library of peptides for 
screening, for instance SPOT technology to create a large library of peptides on a membrane146,147 
or a technique known as split-intein circular ligation of peptides and proteins (SICLOPPS)148 to 
make large libraries of small, cyclic peptides. Other assays to test inhibition, such as ITC, thermal 
melt experiments or a fluorescence polarisation assay could also be employed to measure the 
inhibition of peptide inhibitors, as an alternative to the TR-FRET assay. 
 
5.2.3 Other future directions for investigating inhibitors of the IgE:FcεRI interaction 
Various alternative methods could also be employed for the discovery and development of new 
inhibitors of the interaction between IgE and FcεRI and these are discussed in this section.  
 
Fragment based approaches 
Fragment-based screening is an alternative to HTS that uses low MW fragment molecules that 
generally conform  to  the  ‘Rule  of  3’  (MW < 300, < 3 H-bond donors, < 3 H-bond acceptors, cLogP < 
3), have good aqueous solubility and typically bind with a weak affinity to a protein target.149-151 
These fragment libraries are screened for binding to a protein by various biophysical assays, such 
as thermal shift or SPR. Active fragments are good starting points for chemical expansion and can 
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then be linked together or optimised in some way to generate a set of drug-sized molecules which 
can then be screened for improved activity. This has the advantage over HTS in that a larger 
proportion of chemical space can be tested and also that the smaller fragments tend to be very 
atom efficient binders.150 
 
Tethering approaches 
Another method of fragment discovery is to capture fragments that bind with a moderate affinity 
to  a  particular  site  on  a  protein  using  a  ‘tethering’  approach.34,35  A library of fragments containing 
a disulfide bond could be added to a protein which had a cysteine mutation at a particular position. 
At equilibrium, the fragments that bound to the protein and formed a disulfide bond would be 
strongly bound to the protein.34 Mass spectrometry of the protein/fragment library mixture could 
then be carried out to identify which fragments are conjugated to the protein. This approach could 
allow the screening of large libraries of fragments and also allow different regions of the protein to 
be studied by changing the position of the modified cysteine.35 
 
Virtual screening 
Computational approaches have also been useful in identifying small molecules that target PPI 
interfaces.152-154  Virtual screening of small molecule libraries against the IgE:FcεRI interaction 
would be a useful approach to identify potential  inhibitors and the results of such docking 
experiments, combined with advances in structural technique could be useful. 
 
This PhD work has been a good step forward to the long-term goal of achieving potent, small 
molecule inhibitors of the IgE:FcεRI PPI and it will be interesting to see how further inhibitors  of 
this important interaction develop in the coming years.  
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Chapter 6: Experimental 
6.1 Expression and purification of IgE-Fc  and  αγ 
The following two proteins (used in the ELISA and labelled with fluorophores and used in the TR-
FRET assay) were synthesised by the MRC/Asthma UK Centre in Allergic Mechanisms of Asthma 
Protein Production Facility at the Randall Division of Cell and Molecular Biophysics, KCL. For the 
experimental procedures see Dr Marie Pang, PhD thesis.155 
 
IgE-Fc: This  protein  consists  of  the  Cε2,  Cε3  and  Cε4  domains  of  IgE with a MW of 75,000. It was 
stored in aliquots of 1 mg/mL in PBS with 0.1% sodium azide at -80 °C (or at 4 °C if in use).  
 
αγ  (also  referred  to  as  FcεRIα:IgG4-Fc): This fusion protein consists of the extracellular domains of 
the  α-chain  of  FcεRI  fused  to  the  Cγ2  and Cγ3  domains  of  IgG4 with a MW of 93,860. It was stored 
in aliquots of 0.25 mg/mL in PBS with 0.1% sodium azide at -80 °C (or at 4 °C if in use). 
 
6.2 TR-FRET assay 
6.2.1 TR-FRET assay general directions 
Chemicals: NaHCO3 and NaCl from Sigma-Aldrich. LanthaScreen amine reactive Tb chelate 
isothiocyanate and TR-FRET dilution buffer from Invitrogen. PBS Dulbecco A tablets from Oxoid. 
Dialysis membrane: BioDesign Dialysis Tubing MW 8000 cut off, 6.4 mm diameter, 0.32 mL/cm 
volume from Fisher Scientific. Protein concentration: determined using UV absorption at 280 nm 
and 343 nm on a Nanodrop ND1000 spectrophotometer from Thermo Scientific. SEC: analysis of 
αγ-Tb carried out in PBS with 0.05% sodium azide using a dual wavelength of 280 nm and 343 nm, 
a flow rate of 0.3 mL/min and a run time of 15 min using a Superdex 200 5/150 mm GL column 
from GE Healthcare Life Sciences. Analysis of IgE-Fc-A647 carried out in PBS with 0.1% sodium 
azide using a wavelength of 280 nm, a flow rate of 0.75 mL/min and a run time of 40 min using a 
Superdex 200 10/300 GL column from GE Healthcare Life Sciences. Purification of IgE-Fc-A647 
carried out in PBS with 0.1% sodium azide using a wavelength of 280 nm, a flow rate of 0.75 
mL/min and a run time of 25 min using a Superdex 75 10/300 GL column from GE Healthcare Life 
Sciences. Microplates: assays carried out in white, polystyrene, flat bottom, small volume, 
medium-binding 384-well microplates from Greiner Bio-One. All assays were carried out at rt. 
Plate reader: plates excited at 340 nm and read at 620 nm and 665 nm using an HTRF-compatible 
microplate reader from Artemis. Delay time, integral  time  and  number  of  flashes  were  all  100  μs.  
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6.2.2 TR-FRET assay buffers 
Sodium bicarbonate buffer: 125 mM NaCl, 100 mM NaHCO3, pH adjusted to 8.3 with NaOH 
TR-FRET dilution buffer: used as supplied by the manufacturers without dilution (exact buffer 
composition undisclosed by Invitrogen)  
 
6.2.3 Labelling of IgE-Fc with Alexa Fluor 647 NHS ester 
The labelling of IgE-Fc with Alexa Fluor 647 NHS ester was carried out by Dr Marie Pang, KCL. For 
the experimental procedure see Dr Marie Pang, PhD thesis.155 A 2.5x molar excess of Alexa Fluor 
647 NHS ester was used for the labelling of IgE-Fc and the resulting labelled protein (referred to as 
IgE-Fc-A647) had a dye:protein ratio of 1.9:1. IgE-Fc-A647 was stored in PBS with 0.1% azide at 4 °C. 
 
6.2.4 Labelling of αγ with Tb chelate isothiocyanate 
αγ  conjugated  to   the  donor   fluorophore Tb chelate (the resulting labelled protein referred to as 
αγ-Tb)   was   prepared   according   to   the   following   procedure.   Lyophilised   LanthaScreen™   amine  
reactive Tb chelate isothiocyanate (10  μg)  was  reconstituted  in  DMSO  (2  μL)  to  obtain  a  4.76  mM  
solution.  To  a  solution  of  αγ  in  sodium  bicarbonate  buffer  (37.8  μM,  25  μL)  was  added  Tb  chelate 
isothiocyanate (4.76  mM,  2  μL)  to  achieve  at  10x  molar  excess  of  fluorophore  and  the  solution  was  
shaken at rt in the dark for 3 h. The solution was then centrifuged at 12,000 rpm at rt for 2 min 
followed  by   the  addition  of  PBS   (175  μL).  The  solution  was  dialysed   into  PBS   (2  L)  at  4   °C   in  the  
dark  for  48  h,  changing  the  buffer  after  2  h  and  after  24  h.  The  final  concentration  of  αγ-Tb was 
determined using a spectrophotometer  and  found  to  be  5.1  μM.  Labelling  efficiency  and  removal  
of unreacted Tb chelate was determined using SEC and a dye:protein ratio of 6.3:1 was obtained. 
αγ-Tb was stored in PBS with 0.1% azide at 4 °C. The dye:protein ration was calculated as follows: 
 
 
 
 
 
Abs280 = absorbance at 280 nm for   αγ (mV), CF = correction factor to account for Tb chelate 
absorption at 280 nm (CF = 1.1 for Tb chelate), Abs343 = absorbance at 343 nm for Tb chelate (mV), 
εαγ = extinction coefficient for αγ  at 280 nm (M-1 cm-1)  (εαγ = 237,000 M-1cm-1)  and  εTb = extinction 
coefficient for Tb chelate at 343 nm (M-1 cm-1)  (εTb = 12,570 M-1cm-1). 
  
Abs280 – (CF x Abs343) 
εαγ protein peak = 
Abs343 
εTb 
dye peak = 
dye peak 
protein peak dye:protein ratio = 
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6.2.5 Optimisation of TR-FRET assay 
Initial binding assays: Binding assays between IgE-Fc-A647 and αγ-Tb were carried out in triplicate 
with  20  µL  volume  per  well.  The  concentration  of  αγ-Tb was fixed at 0.5 nM, 1 nM, 2 nM and 5 nM 
and for each concentration, IgE-Fc-A647 was titrated up to a 10x molar excess, with 12 different 
IgE-Fc-A647 concentrations and a 2-fold dilution to obtain each concentration. The titration of IgE-
Fc-A647  was  carried  out  first,  followed  by  the  addition  of  a  fixed  concentration  of  αγ-Tb and the 
plate  was  then  read  immediately.  It  was  found  that  0.5  nM  αγ-Tb and 1.25 nM IgE-Fc-A647 were 
ideal concentrations for use in subsequent inhibition assays. All solutions were prepared in TR-
FRET dilution buffer. 
 
Initial inhibition assays: Inhibition assays were carried out with either unlabelled IgE-Fc or 
unlabelled  αγ  as  an  inhibitor  of  the  interaction  between  IgE-Fc-A647  and  αγ-Tb. The assays were 
carried out in  triplicate  with  18  μL  volume  per  well.  The  concentration  of  αγ-Tb was fixed at 0.5 
nM, the concentration of IgE-Fc-A647 was fixed at 1.25 nM and either unlabelled IgE-Fc or 
unlabelled αγ  was  titrated  to  a  10x molar excess. The titration of unlabelled protein was carried 
out  first,  then  either  1)  αγ-Tb was added, the plate was incubated at rt for 1 h, then IgE-Fc-A647 
was added or 2) IgE-Fc-A647 was added, the plate was incubated at rt for 1 h, then αγ-Tb was 
added (this allowed the order of addition of the two fluorescently-labelled proteins to be 
investigated). The plate was then read immediately. All solutions were prepared in TR-FRET 
dilution buffer. 
 
6.2.6 TR-FRET inhibition assay format 
Inhibition assays were  carried  out   in  triplicate  with  18  μL  volume  per  well.  The  concentration  of  
αγ-Tb was fixed at 0.5 nM and the concentration of IgE-Fc-A647 was fixed at 1.25 nM. Inhibitors 
were prepared at 12 different concentrations with a maximum concentration of 1 mM and 2-fold 
dilutions to a  final  concentration  of  0.49  μM.  The  positive  control  was  IgE-Fc-A647 (1.25 nM) and 
αγ-Tb (0.5 nM) as they would form a complex and give the maximum TR-FRET signal. The negative 
control was IgE-Fc-A647   (1.25   nM),   αγ-Tb (0.5 nM) and either unlabelled IgE-Fc (5 nM) or 
unlabelled   αγ   (12.5   nM)   as   an   excess   of   the   unlabelled   protein   would   inhibit   the   interaction  
between IgE-Fc-A647   and  αγ-Tb and give the minimum TR-FRET signal. The background control 
was TR-FRET buffer with 2% DMSO. The titration of the inhibitor was carried out first, then either 1) 
αγ-Tb was added, the plate was incubated at rt for 1 h, then IgE-Fc-A647 was added or 2) IgE-Fc-
A647 was added, the plate was incubated at rt for 1 h, then αγ-Tb was added (this allowed the 
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order of addition of the two fluorescently-labelled proteins to be investigated). The plate was then 
read immediately. All solutions were prepared in TR-FRET dilution buffer with 2% DMSO.  
 
6.2.7 TR-FRET inhibition assay data analysis  
The TR-FRET ratio was calculated as follows:  
 
 
The TR-FRET ratio was then normalised with the background and positive controls to give a % 
response using the following equation:  
 
 
av BG = average background control signal (TR-FRET dilution buffer with 2% DMSO) 
av POS = average positive control signal (IgE-Fc-A647 and αγ-Tb) 
 
This response was plotted against the concentration of inhibitor using GraFit version 7 
(Leatherbarrow, R. J., Erithacus Software Ltd, Horley, UK, 2010) using a template that fitted data to 
a 4-parameter logistic IC50 equation. IC50 value = concentration of inhibitor that gives 50% 
response. 
 
6.3 ELISA 
6.3.1 ELISA general directions 
Chemicals: PBS Dulbecco A tablets from Oxoid. Tween 20 for electrophoresis from Sigma-Aldrich. 
BSA lyophilised powder 96% (agarose gel electrophoresis) from Sigma-Aldrich. Biotinylated anti-
human IgE epsilon chain specific affinity purified made in goat from Vector laboratories. ELISA 
grade streptavidin conjugated to HRP with preservative 0.01% thimerosal from Biosource. Stable 
peroxide substrate buffer 10x from Thermo Scientific. OPD dihydrochloride 5 mg tablets from 
Sigma-Aldrich. Na2CO3, NaHCO3, DMSO and HCl from Sigma-Aldrich. All solvents and reagents used 
without further purification. Microplates: incubation carried out in Nunc microwell round bottom 
standard 96-well plates from Thermofisher Scientific and testing carried out in flat bottom F96 
MaxiSorp 96-well ImmunoPlates from Scientific Laboratory Supplies Ltd. Plate reader: plates 
scanned at 492 nm in a Multiskan EX Microplate Photometer from Thermoscientific.  
 
  
emission at 665 nm 
emission at 620 nm TR-FRET ratio = x 10,000 
TR-FRET ratio – av BG 
av POS – av BG % response = 100 x  
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6.3.2 ELISA buffers  
PBS: 140 mM NaCl, 8.10 mM Na2HPO4, 2.68 mM KCl, 1.47 mM KH2PO4, pH 7.3 
PBS-T: as above with 0.1% (v/v) Tween 20 
Carbonate buffer: 45.2 mM NaHCO3, 18.1 mM Na2CO3, pH adjusted to 9.6 with acetic acid, buffer 
filtered using a cellulose acetate filter, pore size 0.45 µm and a glass fibre prefilter from Sartorius 
Stedim Biotech 
 
6.3.3 ELISA inhibition assay format 
The  test  plate  was  coated  with  αγ  in  carbonate  buffer  (0.02  µM,  100  µL  per  well) and incubated at 
4 °C for 16 h then the solution was discarded and the test plate washed with PBS-T (300 µl per well) 
for 5 min x 3. The test plate was blocked with 2% BSA in PBS (300 µl per well) and incubated at 
37 °C for 1 h then the solution was discarded and the test plate washed with PBS-T (300 µl per well) 
for 5 min x 3. Peptides and controls were prepared in the incubation plate with 110 µL volume in 
each well. The positive control was IgE-Fc (0.033 nM in PBS with 2% DMSO), which would bind to 
the  immobilised  αγ  and  give  a  maximum  signal.  The negative  control  was  αγ  (0.2  µM  in  PBS  with  2%  
DMSO) and IgE-Fc (0.033 nM in PBS with 2% DMSO), which would form a complex and prevent IgE-
Fc  binding  to  immobilised  αγ  therefore  giving  a  minimum  signal.  The background control was PBS 
(with 2% DMSO). Inhibitors were prepared in 12 different concentrations starting at 1 mM with 2-
fold dilutions to a final concentration of 0.49 µM in PBS with 2% DMSO and each inhibitor solution 
contained 0.033 nM IgE-Fc. Inhibitors and controls were prepared in triplicate. The IgE-Fc was 
added last to all solutions and the plate was incubated at rt for 1 h.  
 
Solutions in the incubation plate were then added to the test plate (100 µL per well) and 
incubated at 37 °C for 1 h then the solutions discarded and the test plate washed with PBS-T (300 
µL per well) for 30 min and PBS-T (300 µL) for 5 min x 2. Biotinylated anti-human IgE was added to 
the  test  plate  (0.1  μg/mL  in  PBS  with  1%    BSA,  100  µL  per  well)  and  incubated  at  37  °C  for 1 h then 
the solution discarded and the test plate washed with PBS-T (300 µL per well) for 5 min x 3. 
Streptavidin  conjugated  to  HRP  was  added  to  the  test  plate  (0.2  μg/mL  in  PBS  with  1%  BSA,  100  µL  
per well) and incubated at 37 °C for 1 h then the solution discarded and the test plate washed with 
PBS only (300 µL per well) for 5 min x 3. A solution of OPD dihydrochloride was added to the test 
plate (0.5 mg/mL in stable peroxide substrate buffer, 50 µL per well) and incubated in the dark at 
rt for 4 min following which 3 M HCl was added to the test plate (50 µL per well). The absorbance 
of the test plate was then measured at 492 nm.  
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6.3.4 ELISA inhibition assay data analysis 
ELISA signal was normalised with the background and positive controls to give a % response using 
the following equation:  
 
 
av BG = average background control signal (PBS with 2% DMSO) 
av POS = average positive control signal (IgE-Fc and αγ) 
 
This response was plotted against the concentration of inhibitor using GraFit version 7 
(Leatherbarrow, R. J., Erithacus Software Ltd, Horley, UK, 2010) using a template that fitted data to 
a 4-parameter logistic IC50 equation. IC50 value = concentration of inhibitor that gives 50% 
response. 
 
6.4 Expression and purification of Cɛ2 and Cɛ3 
6.4.1 Expression and purification of Cɛ2 and Cɛ3 general directions 
Chemicals and reagents: Ampicillin and kanamycin from Melford Laboratories Ltd. LB Agar 
(Lennox L Agar) powder and LB Broth Base (Lennox L Broth Base) powder from Invitrogen. Super 
optimal broth with catabolite repression (SOC) medium from New England BioLabs. SDS for 
electrophoresis/molecular biology, 20% solution from Fisher BioReagents. Low MW calibration kit 
for SDS electrophoresis (14.4 kDa – 97.0 kDa) from GE Healthcare. Acrylamide ProtoFLOWGel (30% 
(w/v) acrylamide:0.8% (w/v) bis-acylamide) protein and sequencing electrophoresis grade from 
Flowgen Bioscience. Sample buffer 2x from Sigma. Instant Blue coomassie based staining solution 
for protein gels from Expedeon Protein Solutions. All other chemicals from Sigma-Aldrich, Fisher 
Scientific Fisher BioReagents, Merck Millipore Calbiochem or VWR. E. coli: One Shot TOP10 
chemically competent E. coli cells and BL21 Star (DE3) One Shot chemically competent E. coli cells 
from Invitrogen. Plasmids: the   Cε2   plasmid   (pET5a   vector,   ampicillin   resistant)   and  Cε3  plasmid  
(pET28a vector, kanomycin resistant) supplied by Dr Anthony Keeble, KCL. DNA purification: using 
a Wizard Plus Maxipreps DNA purification system from Promega. Agarose gel electrophoresis: gels 
were run in 1x running buffer at 100 V for ~ 15 min then at 150 V for ~ 15 min and visualised using 
ethidium bromide fluorescence under UV light with a molecular imager Gel Doc XR+ imaging 
system from Bio-Rad. Cɛ3 purification: carried out on an AKTA fast protein liquid chromatography 
(FPLC) instrument from Amersham Pharmacia Biotech. Protein concentration: determined on a 
Nanodrop ND1000 spectrophotometer from Thermo Scientific measuring UV absorption at 280 
TR-FRET ratio – av BG 
av POS – av BG % response = 100 x  
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nm. SDS-PAGE: 5  μg  – 20  μg  of  protein  in  1x sample buffer was heated to 100 °C for 10  min prior 
to loading into the gel. Gels were run in 1x running buffer at 160 V for ~ 25 min then at 180 V for ~ 
25 min and visualised using Instant Blue staining solution. Cɛ3 mass spectra: recorded on a Bruker 
Maxis  time  of  flight  (TOF)  instrument  with  a  Kd  Scientific  injector  using  ESI.  A  solution  of  Cε3  (10  
µg/mL,   200   μL)   in   1:1   acetonitrile:H2O with 0.1% formic acid was used to obtain the mass 
spectrum. Cɛ3 1H NMR spectra: recorded at 500 MHz on a Bruker500 Ultrashield DRX500 
instrument.  Chemical  shifts  (δH) are quoted in ppm. A solution of Cɛ3  (0.75  mg/mL,  580  μL)  in  PBS  
pH 7.3, 5% D2O was used to obtain the 1H NMR spectrum. 
 
6.4.2 Buffers and solutions for expression of Cɛ2 and Cɛ3  
LB agar (per L of H2O): 12 g agar, 10 g peptone, 5 g yeast extract, 5 g NaCl 
LB broth (per L of H2O): 10 g peptone, 5 g yeast extract, 5 g NaCl 
Minimal media (per L of H2O): 6 g Na2HPO4, 3 g KH2PO4, 0.7 g NH4Cl, 0.5 g NaCl, 2 mL 1M MgSO4, 
10 µL 1M CaCl2, 10 mL 20% glucose 
Tris/boric acid/EDTA (TBE) agarose gel electrophoresis running buffer (1x) (per L of H2O): 10.8 g 
Tris, 5.5 g boric acid, 4 mL of 0.5 M ethylenediaminetetraacetic acid (EDTA) 
Agarose gel (for 1 gel): 7 mL TBE buffer  (10x),  63  mL  agarose,  3.5  μL  ethidium  bromide 
 
6.4.3 Buffers for purification of Cɛ2 and Cɛ3 
Lysis buffer: 100 mM EDTA, 50 mM MgCl2, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM 
dithiothreitol (DTT), 1% Triton-X, pH 7.4  
Solubilisation buffer: 6 M guanidinium chloride, 0.5 M NaCl, 20 mM Na2HPO4, 1 mM DTT, pH 7.4 
Binding buffer: 6 M guanidinium chloride, 0.5 M NaCl, 20 mM Na2HPO4, pH 7.4  
Refolding buffer: 0.5 M NaCl, 20 mM Na2HPO4, pH 7.4 
Elution buffer: 0.5 M NaCl, 20 mM Na2HPO4, pH 1.5 
Gel filtration buffer: 0.5 M NaCl, 0.2 M arginine, 20 mM Na2HPO4, 0.02% sodium azide, pH 5.0 
 
6.4.4 Buffers and solutions for SDS-PAGE  
SDS-PAGE sample buffer (2x): 0.1 M tris-HCl, 24% glycerol, 4% 2-mercaptoethanol, 1% SDS, 0.02% 
brilliant blue G, pH 6.8 
Resolving gel (for 2 gels): 5.0 mL acrylamide (30%), 2.6 mL 1.5 mM tris (0.1% SDS, pH 8.5), 2.3 mL 
H2O,  50  μL  10%  ammonium  persulfate  (APS),  10  μL  tetramethylethylenediamine  (TMEDA) 
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Stacking gel (for 2 gels): 3.4  mL  0.5  M  tris  (0.1%  SDS,  pH  6.8),  0.54  mL  30%  acrylamide,  24  μL  10%  
APS,  10  μL  TMEDA, 1 drop bromophenol blue 
SDS-PAGE running buffer (1x) (per L of H2O): 3 g tris, 14.4 g glycine, 1 g SDS  
 
6.4.5 Expression  of  Cε2  and  Cε3 
Each   plasmid   (1   μL)   was   transformed   into   chemically   competent   TOP10   E. coli cells,   (20   μL)  
incubated on ice for 30 min then incubated at 42 °C for 30 s to heat shock cells. Pre-warmed LB 
agar   (250   μL)   containing   100   µg/mL   of   ampicillin   for   Cε2   or   30   μg/mL   kanamycin   for   Cε3   was  
added. E. coli cells  (100  μL)  were  spread  onto  an  LB  agar  plate  containing  100  µg/mL  of  ampicillin  
(Cε2)   or   30   μg/mL   kanamycin   (Cε3)   and   incubated   at   37   °C   overnight.   5   colonies   were   then  
removed and cultured in LB media (10 mL) containing 100 µg/mL ampicillin (Cɛ2)   or   30   μg/mL  
kanamycin (Cɛ3) at 37 °C overnight. Plasmids were purified using a DNA purification kit according 
to  the  manufacturer’s  instructions  and  a  brief  outline  is  described  here;  cell  resuspension  solution  
(200  μL),  followed  by  cell   lysis  solution  (200  μL)  was  added  and  cells  were  incubated  at  rt  for  10  
min.  Cell  neutralisation  solution   (400  μL)  was  added   to precipitate cell organelles and leave the 
DNA dissolved in the supernatant. Centrifugation (4000 rpm, 4 °C, 15 min) was used to pellet the 
cell organelles and the supernatant was removed and added to a mini-column containing DNA 
resin (1 mL). The resin was washed with was solution (2 mL) then H2O  (50  μL)  pre-warmed to 70 °C 
was added to dissolve the DNA. The DNA concentration was measured using absorbance at 260 
nm, the purity was measured using agarose gel electrophoresis and the DNA was sent for 
sequencing to confirm the correct sequence was obtained.  
 
Each plasmid (1 µL) was then transformed into chemically competent BL21 E. coli cells (100 µL), 
incubated on ice for 20 min then incubated at 42 °C for 45 s to heat shock cells. SOC medium (200 
μL)  was  then added and the cells were incubated at 37 °C with shaking for 45 min. E. coli cells (200 
μL)  were   then  spread  onto  LB  agar  plates  containing  100  µg/mL  of  ampicillin   (Cε2)  or  30  μg/mL  
kanamycin  (Cε3)  and  incubated  at  37  °C  overnight.  A  starter  culture  was set up by adding  1 colony 
to  LB  media   (20  mL)  containing  100  µg/mL  of  ampicillin   (Cε2)  or  30  μg/mL  kanamycin   (Cε3)  and  
incubating overnight at 37 °C in a shaker. The starter culture was then centrifuged (4000 
revolutions per minute (rpm), 20 °C, 5 min) to pellet cells, the supernatant was removed and cells 
were solubilised in minimal media (8 mL). This solution was then added to minimal media (2 L) 
containing  100  µg/mL  of  ampicillin  (Cε2)  or  30  μg/mL  kanamycin  (Cε3)  and  the  solution  shaken  at  
37 °C. OD was measured every hour and after ~ 8 hours when OD had reached at least 0.6, cells 
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were induced by the addition of 1 mM IPTG. Expression was allowed to continue for 20 h, then the 
solution was split into 2 x 1 L samples and centrifuged (4000 rpm, 4 °C, 20 min) to pellet cells. The 
supernatant media was removed and each cell sample was resuspended in PBS pH 7.3 (40 mL). 
The solutions were shaken, centrifuged (4000 rpm, 4°C, 20 min) and supernatant PBS was 
removed. Cell pellets were stored at -20 °C until purification. SDS-PAGE analysis of induced vs 
uninduced cells was used to confirm that expression had taken place following induction with IPTG.  
 
6.4.6 Purification  of  Cε3 
Pelleted cells were resuspended in lysis buffer (20 mL) using a homogeniser to break up cell pellets, 
sonicated for 8 x 30 sec and centrifuged (10,000 g, 4 °C, 12 min). Supernatant lysis buffer was 
discarded, fresh lysis buffer was added (20 mL) using a homogeniser to break up cell pellets, cells 
were spun slowly at 4 °C for 40 min then centrifuged (10,000 g, 4 °C, 12 min). This was repeated 
twice more, supernatant lysis buffer was discarded, solubilisation buffer (20 mL) was added to 
solubilise the protein inclusion bodies and proteins were spun slowly at 4 °C overnight. The 
solution was then centrifuged (10,000 g, 4 °C, 15 min) to remove cell organelles and filtered 
through a 0.22 µm membrane.  
 
Purification and refolding was carried out on an AKTA FPLC using a Ni2+ column. The Ni2+ column 
was   equilibrated   with   binding   buffer   then   Cε3  was   loaded on to the column and washed with 
binding   buffer.   Cε3  was   refolded   by   adding   refolding   buffer   from   a   gradient   of   0   – 100%, then 
eluted by adding elution buffer. One fraction (5 mL) containing pure protein was then run through 
a gel filtration column to remove any unfolded protein using gel filtration buffer and 8 pure 
fractions (each 10 mL) were obtained. These fractions were combined and concentrated by 
centrifugation (4000 rpm, 4 °C, 45 min) using a concentration tube with a 5,000 MW cut off until 1 
mL of pure protein was obtained. The protein was buffer exchanged by adding PBS pH 5.0 (20 mL) 
and centrifuging (4000 rpm, 4 °C, 1.5 hour) and this was repeated 4 times. The concentration of 
refolded, pure Cɛ3 was measured using absorption at 280 nm and found to be 7.53 mg/mL. SDS-
PAGE, MS and 1H NMR analysis were carried out to determine the purity of Cɛ3. Cɛ3 was stored in 
PBS pH 5.0 with 0.01% sodium azide at 4 °C.  
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6.5 SPR experiments 
6.5.1 SPR general directions 
Chemicals: EDC, NHS and ethanolamine hydrochloride pH 8.5 from GE Healthcare. Sodium acetate 
pH 4.5 from Sigma-Aldrich. Glycine pH 2.0 and pH 2.5 solutions from GE Healthcare. Streptavidin 
from Sigma-Aldrich. Biotin-IgE-Fc was synthesised by Dr Marie Pang, KCL.155 SPR chips: Series S 
sensor chip CM5 (carboxymethylated dextran matrix covalently attached to gold surface) and 
series S sensor chip SA (carboxymethylated dextran matrix pre-immobilised with streptavidin) 
both from GE Healthcare. New sensor chips stored under N2 at 4 °C, sensor chips with immobilised 
proteins stored in running buffer with 0.1% azide at 4 °C. SPR instrument: experiments carried out 
at 25 °C on a Biacore T200 biosensor from GE Healthcare.  
 
6.5.2 SPR buffers  
HBS running buffer: 150 mM NaCl, 10 mM HEPES, 3 mM EDTA, 0.005% Tween 20, pH 7.4.  
PBS running buffer: 140 mM NaCl, 8.10 mM Na2HPO4, 2.68 mM KCl, 1.47 mM KH2PO4, 2% DMSO, 
0.005% Tween 20, pH 7.3. 
 
6.5.3 Immobilisation  of  αγ  onto  CM5  sensor  chip 
The carboxymethylated matrix was activated by adding EDC (0.2 M) and NHS (0.05 M) for 420s at a 
flow  rate  of  10  μL/min.  Following  activation,  αγ  (100 nM) in sodium acetate buffer (10 mM, pH 4.5) 
was   added   for   between   500   and   2000s   at   a   flow   rate   of   10   μL/min.   To   cap   the   surface,  
ethanolamine  hydrochloride  pH  8.5  (1.0  M)  was  added  for  420s  at  a  flow  rate  of  10  μL/min.  The  αγ  
immobilisation was carried out on one flow cell only. Another flow cell was used as a control 
surface  that  had  been  activated  and  capped  only,  without  addition  of  αγ.  All  immobilisation  steps  
were carried out in HBS running buffer. 
 
6.5.4 Initial binding of IgE-Fc  to  immobilised  αγ 
To  determine  if  the  immobilised  αγ  was  an  active  surface,  IgE-Fc (10 nM) was added for 180s at a 
flow   rate   of   20   μL/min.   Glycine   (10  mM,   pH   2.5)   was   then   added   for   60s   at   a   flow   rate   of   20  
μL/min   to   remove   IgE-Fc   bound   to   the   immobilised   αγ.   This   was   repeated and if reproducible 
results were obtained then the chip was deemed ready to use for subsequent inhibition assays. 
Binding experiments were carried out in PBS running buffer with 2% DMSO. 
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6.5.5 Immobilisation of IgE-Fc onto CM5 sensor chip 
The carboxymethylated matrix was activated by adding EDC (0.2 M) and NHS (0.05 M) for 420s at a 
flow   rate  of   10  μL/min.   Following  activation   streptavidin (160 nM) in sodium acetate buffer (10 
mM,  pH  4.5)  was   added   for   300s   at   a   flow   rate  of   10  μL/min.   To   cap   the   surface ethanolamine 
hydrochloride  pH  8.5  (1.0  M)  was  added  for  420s  at  a   flow  rate  of  10  μL/min.  Biotin-IgE-Fc (125 
nM)  was   then   added   for   between   700   and  1000s   at   a   flow   rate   of   10  μL/min.   The   streptavidin  
immobilisation was carried out on two flow cells, the biotinylated IgE-Fc binding was carried out 
on one streptavidin flow cell only, with the other being used as a control surface. All 
immobilisation steps were carried out in HBS running buffer. 
 
6.5.6 Initial  binding  of  αγ  to  immobilised  IgE-Fc 
To determine if the immobilised IgE-Fc  was  an  active  surface,  αγ  (10  nM)  was  added  for  180s  at  a  
flow   rate   of   20   μL/min.   Glycine   (10  mM,   pH   2.5)   was   then   added   for   60s   at   a   flow   rate   of   20  
μL/min   to   remove   αγ   bound   to   the   immobilised   IgE-Fc. This was repeated and if reproducible 
results were obtained then the chip was deemed ready to use for subsequent inhibition assays. 
Binding experiments were carried out in PBS running buffer with 2% DMSO. 
 
6.5.7 Inhibition assay with dibenzofuran (±)-11, IgE-Fc and immobilised αγ  
Initial  inhibition  assays  were  carried  out  using  the  flow  cell  with  immobilised  αγ.  Dibenzofuran (±)-
11 (HJD-107) was  prepared  in  10  different  concentrations  starting  at  160  μM  with  2-fold dilutions 
to   a   final   concentration  of  0.313  μM.  Each   inhibitor   solution contained a fixed concentration of 
IgE-Fc (10 nM) and all inhibitor/IgE-Fc solutions were made in PBS 2% DMSO SPR running buffer. 
The inhibitor/IgE-Fc solutions were allowed to incubate for at least 1 h, then injected over the 
immobilised   αγ   for   180s   at   a   flow   rate   of   20   μL/min.   After   the   injection   of   each   different  
inhibitor/IgE-Fc  solution,  an  injection  of  glycine  (10  mM,  pH  2.5)  for  60s  at  a  flow  rate  of  20  μL/min  
removed any bound IgE-Fc. The inhibition assay was carried out in PBS 2% DMSO SPR running 
buffer. 
 
6.5.8 Immobilisation of b-Phe(3)-peptide onto SA sensor chip 
B-Phe(3)-peptide (LDS-002-1A) (100 nM, in HBS) was added to one flow cell for 120s at a flow rate 
of  20  μL/min  which  gave  an  increase  in  signal  of  ~ 100 resonance units. B-Phe(3)-peptide (100 nM, 
in  HBS)  was  then  added  to  the  same  flow  cell  for  a  further  1200s  at  a  flow  rate  of  5  μL/min  which  
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gave an increase in signal of ~ 350 resonance units and saturation of the chip surface. All 
immobilisation steps were carried out in HBS running buffer. 
 
6.5.9 Initial binding of IgE-Fc to immobilised b-Phe(3)-peptide 
IgE-Fc  (13.3  μM,  in  PBS)  was  added  for  120s  at  a  flow  rate  of  5  μL/min  in  HBS  running  buffer  which  
gave an increase in signal of ~ 40 resonance units. The IgE-Fc was injected over both the flow cell 
with immobilised b-Phe(3)-peptide (LDS-002-1A) and the flow cell with immobilised streptavidin 
only as a control. The data for the streptavidin flow cell was subtracted from the data for the 
peptide flow cell.  
 
6.5.10 Initial binding of αγ  to  immobilised  b-Phe(3)-peptide 
αγ  (2.66  μM,  in  PBS)  was  added  for  120s  at  a  flow  rate  of  5  μL/min  in  HBS  running  buffer  which 
gave an increase in signal of ~ 70 resonance units. The αγ was injected over both the flow cell with 
immobilised b-Phe(3)-peptide (LDS-002-1A) and the flow cell with immobilised streptavidin only as 
a control. The data for the streptavidin flow cell was subtracted from the data for the peptide flow 
cell.  
 
6.5.11 Binding assays of IgE-Fc,  αγ  and  IgG4 to immobilised b-Phe(3)-peptide 
IgE-Fc  was  prepared  in  12  different  concentrations  (13.3  μM,  12  μM,  10  μM,  8  μM,  6  μM,  4  μM,  2  
μM,  1  μM,  0.5  μM,  0.2  μM,  0.1  μM,  0.05  μM)  with  dilutions  made   in  HBS.  αγ  was  prepared   in  9 
different  concentrations  (3  μM,  2.5  μM,  2  μM,  1.5  μM,  1  μM,  0.5  μM,  0.25  μM,  0.125  μM,  0.06  μM)  
with dilutions made in HBS. IgG4 (provided by Dr Anna Davies, KCL) was used as a control protein 
as the peptide was not expected to bind to this. IgG4 was prepared in 12 different concentrations 
(4  μM,  3.5  μM,  3  μM,  2.5  μM,  2  μM,  1.5  μM,  1  μM,  0.5  μM,  0.25  μM,  0.125  μM,  0.06  μM,  0.03  μM)  
with dilutions made in HBS. Each different concentration of each protein was added in turn for 
120s  at  a   flow  rate  of  20  μL/min   in  HBS   running  buffer.  Each   injection  was  carried  out   twice   to  
obtain duplicate results. The proteins were injected over both the flow cell with immobilised b-
Phe(3)-peptide (LDS-002-1A) and the flow cell with immobilised streptavidin only as a control. The 
date for the streptavidin flow cell was subtracted from the data for the peptide flow cell to give 
the signal for this experiment. 
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6.6 Protein crystallography 
6.6.1 Protein crystallography general directions 
Chemicals: Li2SO4, tris, PEG, NaCl, sodium azide, ethylene glycol and hexylene glycol from Sigma-
Aldrich. Microplates: co-crystallisations carried out in a MRC 96-well 2-drop UV sitting drop 
crystallisation plate from Molecular Dimensions. Soak crystallisations carried out in a MRC MAXI 
48-well polystyrene crystallisation plate from Molecular Dimensions. Protein crystal seeds: 
generated using a PTFE Seed Bead from Hampton Research. Automated pipetting: carried out 
using a mosquito liquid handler from TTP Labtech. Sealing sheets: UV transparent ClearVue sheets 
from Molecular Dimensions. Apo IgE-Fc crystals: grown under the co-crystallisation conditions 
outlined below but with no inhibitor or ligand present, provided by Dr Nyssa Drinkwater, KCL. Data 
collection: carried out either at the Diamond Light Source synchrotron in Oxfordshire, UK using 
beamline I04 or at KCL using an Xcalibur PX Nova CCD single crystal diffractometer from Oxford 
Diffraction. Data analysis: crystal structures were solved by molecular displacement using a high 
resolution IgE-Fc structure with the PDB code 2WQR22 and with the CCP4 software Phenix Refine 
and Coot. IgE-Fc space group = P21212,  a  =  128.5,  b  =  75.0,  c  =  79.5,  α  =  β  =  γ  =  90  °. 
 
6.6.2 Protein crystallography buffers and solutions 
Co-crystallisation reservoir solution: 0.2 M Li2SO4, 0.1M tris (pH 7.5 – 9.0), PEG 8K (14 – 24%) 
IgE-Fc/inhibitor buffer: 25 mM tris pH 7.5, 20 mM NaCl, 0.05% azide 
Stabilising solution: 0.2 M Li2SO4, 0.1 M tris pH 7.5, 24% PEG 8K  
Cryoprotectant solution: 0.2 M Li2SO4, 0.1M tris pH 7.0, 24% PEG 8K, 16% ethylene glycol, 16% 
hexylene glycol 
 
6.6.3 Co-crystallisations 
Four experiments, each of 24 wells, were set up in one 96-well plate. Each well contained 70 µL 
reservoir solution and across the 24 wells the pH of the tris buffer was varied between 7.5 and 9.0 
(0.5 increments), the concentration of PEG 8K was varied between 14% and 24% (2% increments) 
and the concentration of Li2SO4 was kept constant. IgE-Fc/inhibitor solutions were prepared with 
IgE-Fc (26.7 µM) and inhibitor  (50  μM,  100  μM,  200  μM  or  300  μM  )  in  IgE-Fc/inhibitor buffer and 
incubated   for   1   h.   Next   to   each   well   were   two   ‘sitting   drops’   containing   1   µL   IgE-Fc/inhibitor 
solution, 400 nL reservoir solution and 100 nL seed solution (ground up apo crystals of IgE-Fc in 
stabilising solution). One drop contained seed solution diluted by a factor of 5 and one drop 
contained seed solution diluted by a factor of 10. The plate was covered and incubated at 18 °C for 
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~ 10 - 20 days, with plate-shaped, oblong crystals forming after ~ 5 days. Individual crystals were 
then  added  to  the  corresponding  inhibitor  (500  μM)  in  cryoprotectant  solution  and  frozen  in  liquid  
nitrogen.  
 
6.6.4 Soak crystallisations 
Two experiments, each of 1 well, were set up in one 24-well plate. Each well contained 100 µL 
cryoprotectant solution. Inhibitor solutions were prepared with inhibitor (500 µM or 2.5 mM) in 
cryoprotectant solution. Next to each well was one sitting drop containing 5 µL inhibitor solution 
and 4 – 6 apo crystals of IgE-Fc. The plate was covered and incubated at 18 °C for ~ 5 - 10 days, 
after which individual crystals were frozen in liquid nitrogen.   
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6.7 Synthesis of aspercyclide A and analogues 
All compounds in Table 22 were synthesised by Dr Jimmy Sejberg (IC).91,92 
 
(±)-1 
(JS-039) 
 
 (+)-3 (JS-287) 
 
(+)-1 
(JS-039-E1) 
 
 (+)-4 (JS-289) 
 
(+)-2a 
(JS-291) 
 
 (+)-5 (JS-312) 
 
(+)-2b 
(JS-256-P) 
 
   
 
Table 22: Aspercyclide A and analogues used in experiments 
NB: The references in parenthesis indicated the Spivey research group compound reference number. 
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6.8 Synthesis of dibenzofuran and analogues 
All compounds in Table 23 were synthesised by Dr Helena Dennison138, Dr Jimmy Sejberg or Dr 
Daniel Offerman (IC).  
 
 
(±)-11 
(HJD-107) 
 
  
  
 
(±)-23 
(JS-331) 
 
  
 
 
(±)-12 
(HJD-115) 
 
  
  
 
14 
(HJD-210) 
 
  
 
 
13  
(HJD-205) 
 
  
 
  15 
(HJD-211) 
 
 
 
 
(±)-16 
(HJD-186) 
 
 
 
  
18 
(HJD-214) 
 
 
 
 
17 
(HJD-213) 
 
 
 
 
 
19 
(HJD-212) 
 
 
 
(±)-20 
(JS-004/26) 
 
 
  
21 
(JS-322) 
 
 
 
8 
(DAO-268)  
  
 
 
Table 23: Dibenzofurans and analogues used in experiments 
NB: The references in parenthesis indicated the Spivey research group compound reference number. HJD, 
JS and DAO refer to compounds synthesised by Dr Helena Dennison, Dr Jimmy Sejberg and Dr Daniel 
Offerman respectively. 
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6.9 Peptide synthesis 
6.9.1 Peptide synthesis general directions 
Reagents and solvents: Fmoc-protected L-amino acids (side-chain protecting groups in parenthesis) 
Ala, Asp(OtBu), His, Ile, Lys(Boc), Phe, Trp(Boc), Tyr(tBu) and Val from AGTC Bioproducts. Fmoc-
protected unnatural amino acid L-biphenylalanine (Bip) from VWR International. (+)-Biotin-NHS 
ester from VWR International. HATU and HBTU from AGTC Bioproducts. TentaGel S Rink Amide 
Resin (0.23 mmol/g loading) from RAPP Polymere. NMM, NMP, DMF, DIPEA, piperidine, acetic 
anhydride, dichloromethane, methanol, diethyl ether, TFA, TIS and TBME from Sigma-Aldrich or 
VWR International. All solvents and reagents were used without further purification. Deionised 
water: obtained from Elix and MilliQ Millipore water purification systems. Peptide synthesis: 
carried out using an Intavis AG ResPep SL instrument. Centrifugation: carried out using a Jouan 
BR4 centrifuge. LC-MS: carried out using a Waters HPLC system equipped with a 2767 Sample 
Manager, a 515 HPLC Pump, a 3100 Mass Detector with ESI and a 2998 Photodiode Array Detector 
(detection at 200 - 600 nm). The system was fitted with Waters XBridge C18 columns (4.6 mm × 
100 mm for analytical LC-MS and 19.0 mm × 100 mm for preparative LC-MS). LC-MS solvent 
evaporation: carried out using a Genevac EZ-2 plus, HCI compatible personal evaporator. 
Lyophilisation: carried out using a Christ Alpha 1-4 instrument.  
 
6.9.2 Automated SPPS 
All   peptides  were   synthesised  on   a  20  μmol   scale   from   the   C-terminus to the N-terminus using 
standard,  automated  Fmoc  SPPS.  The  rink  amide  resin  (20  μmol  per  well  of  the  peptide synthesiser) 
was placed into the peptide synthesiser and swelled in DMF for 1 h, then the DMF removed by 
filtration. Fmoc deprotection (initially of the resin, then afterwards of each Fmoc-protected amino 
acid) was achieved with 20% piperidine in DMF (400 µL) for 10 min x 3, followed by washing the 
resin with DMF (400 µL) x 8. Coupling of the subsequent Fmoc-protected amino acid was carried 
out with HBTU in NMP (0.5 M, 170 µL), NMM in NMP (4 M, 52 µL), NMP (5 µL) and the Fmoc-
protected amino acid in NMP (0.5 M, 175 µL) for 35 min. This coupling reaction was then repeated 
for 45 min. A cap mixture consisting of 5% acetic anhydride in DMF (400 µL) was then added for 5 
min (this capped any unreacted N-terminal free amines on the growing peptide) followed by 
washing the resin with DMF (600 µL) x 2 and DMF (500 µL) x 5. This cycle of Fmoc-deprotection, 
washing, coupling, capping and washing was repeated until each peptide was the desired length. 
Deprotection of the N-terminal Fmoc protecting group on all peptides was then carried out with 
20% piperidine in DMF (400 µL) for 10 min x 3, followed by washing the resin with DMF (400 µL) x 
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8 and dichloromethane (600 µL) x 3. After the peptide synthesis was complete, the resin was 
removed from the synthesiser, placed in a syringe fitted with a polystyrene frit, washed with DMF 
(3 mL) x 3, dichloromethane (3 mL) x 3, methanol (3 mL) x 3 and diethyl ether (3 mL) x 3 and dried 
in a desiccator under vacuum for at least 16 h.  
 
Unnatural amino acid coupling: Synthesis was carried out as above, except the coupling of the 
unnatural amino acid Bip was carried out with the alternative coupling agent HATU in DMF (0.4 M, 
170  μL),  NMM  in  NMP  (4  M,  52  μL),  NMP  (5  μL)  and  the  Fmoc-protected Bip in DMF (0.6 M, 175 
μL).  The  reaction  time  was increased to 50 min and the reaction was then repeated for 50 min. 
 
6.9.3 Cleavage from resin and side-chain deprotection of peptides 
Cleavage of the peptide from the resin and simultaneous side chain deprotection was achieved 
using a deprotection mixture of 95% TFA, 2.5% H2O and 2.5% TIS (1.5 mL) and shaking at rt for 3 h. 
The mixture was removed by filtration and the resin washed with deprotection mixture (1 mL) and 
TFA (1 mL). The filtrate and washings were combined and the TFA removed under nitrogen to 
leave a volume of approximately 1 mL. Ice-cold TBME (10 mL) was added with vigorous shaking to 
precipitate the deprotected, cleaved peptide. The mixture was centrifuged (4000 rpm) at 5 °C for 
15 min and the supernatant TBME was removed. Fresh ice-cold TBME (10 mL) was added, the 
peptide pellet broken up, the mixture centrifuged (4000 rpm) at 5 °C for 15 min and the 
supernatant TBME removed. This process was repeated once more, then the peptide was dried in 
a desiccator under vacuum for at least 16 h.  
 
6.9.4 On-resin biotin labelling of peptides 
The biotin labelling reaction was carried out on the N-terminus of the resin-bound, side-chain 
protected peptide after SPPS.  
 
First biotin labelling reaction: The resin was shaken in DMF (2 mL) at rt for 1 h to swell the resin, 
then the DMF removed by flitration. Biotin-labelling solution (biotin-NHS ester 5 eq, 50 mM and 
DIPEA 1 eq, 10 mM, 2 mL) was added with shaking at rt for 1 h, then the solution removed by 
filtration and the resin washed with DMF (2 mL). This was repeated by adding fresh biotin-labelling 
solution (biotin-NHS ester 5 eq, 50 mM and DIPEA 1 eq, 10 mM, 2 mL) and shaking at rt for 1 h, 
then the solution removed by filtration. The resin was washed with DMF (3 mL) x 3, 
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dichloromethane (3 mL) x 3, methanol (3 mL) x 3 and diethyl ether (3 mL) x 3 and dried in a 
desiccator under vacuum for at least 16 h. 
  
Optimised biotin labelling reaction: The reaction was carried out as above, except after the initial 
labelling reaction for 1 h, fresh biotin-labelling solution was added and the resin shaken at rt for an 
increased reaction time of 16 h. 
 
Following the biotin labelling, the peptides were then cleaved from the resin with simultaneous 
side-chain deprotection as described in section 6.9.3. 
 
6.9.5 LC-MS analysis and purification of peptides 
LC-MS was used to analyse and purify all peptides. LC-MS grade methanol and deionised water, 
both degassed and containing 0.1% formic acid, were used as the mobile phases. 
 
Analytical LC-MS: a small amount of peptide (~ 0.1 mg) was dissolved in a solution of 5% methanol 
in H2O. A linear gradient of 5 – 98% methanol, a run time of 18 min and a flow rate of 1.2 mL/min 
was used.  
 
Preparative LC-MS: all of the crude peptide (~ 17 – 20 mg per well of the peptide synthesiser) was 
dissolved in a solution of 5% methanol in H2O,   then   filtered   through  a  0.45  μm  membrane   low  
protein binding syringe filter to give a clear solution. A linear gradient of 5 – 98% methanol, a run 
time of 18 min and a flow rate of 20 mL/min was used. 
 
Following preparative LC-MS, methanol was evaporated from pure fractions and the remaining 
aqueous solution was frozen in liquid nitrogen and lyophilised for at least 24 h to yield the pure 
peptide as a white amorphous powder. Pure peptides were further analysed using analytical LC-
MS (as described above) to check purity, then stored as solids at – 20 °C. 
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6.9.6 LC-MS characterisation data for all pure peptides 
LC-MS characterisation data for all pure peptides synthesised during the PhD can be seen in Table 
24. 
 
Name/Reference Sequence MW Mass (mg) 
Yield
a (%) 
Rt  
(min) 
m/z  
(ES-) 
Parent-peptide 
(LDS-001-1A) 
H2N-Asp-Lys-Tyr-Tyr-Ile-
Val-Lys-Tyr-CONH2 
1090.27 6.8 31 8.36 1088.73 
Phe(3)-peptide 
(LDS-001-2A) 
H2N-Asp-Lys-Phe-Tyr-Ile-
Val-Lys-Tyr-CONH2 
1074.27 6.2 29 8.87 1072.60 
Bip(3)-peptide 
(LDS-001-3A) 
H2N-Asp-Lys-Bip-Tyr-Ile-
Val-Lys-Tyr-CONH2 
1150.37 7.7 33 9.90 1148.68 
C-strand peptide 
(LDS-001-4A) 
H2N-Tyr-Lys-Val-Ile-Tyr-
Tyr-Lys-Asp-CONH2 
1090.27 8.4 39 6.94 1088.79 
link-Phe(3)-peptide 
(LDS-002-2B-free) 
H2N-Gly-Gly-Gly-Asp-
Lys-Phe-Tyr-Ile-Val-Lys-
Tyr-CONH2 
1245.45 2.9 23 8.35 1243.68 
b-Phe(3)-peptide 
(LDS-002-1A) 
biotin-Asp-Lys-Phe-Tyr-
Ile-Val-Lys-Tyr-CONH2 
1300.59 1.8 8 10.16 1298.84 
b-Phe(3)-peptide 
(LDS-002-1B) 
biotin-Asp-Lys-Phe-Tyr-
Ile-Val-Lys-Tyr-CONH2 
1300.59 3.3 15 9.96 1298.85 
b-link-Phe(3)-peptide 
(LDS-002-2A) 
biotin-Gly-Gly-Gly-Asp-
Lys-Phe-Tyr-Ile-Val-Lys-
Tyr-CONH2 
1471.74 0.9 4 9.97 1469.91 
b-link-Phe(3)-peptide 
(LDS-002-2B) 
biotin-Gly-Gly-Gly-Asp-
Lys-Phe-Tyr-Ile-Val-Lys-
Tyr-CONH2 
1471.74 0.8 3 9.90 1470.12 
 
Table 24: LC-MS characterisation data for all pure peptides synthesised during PhD 
ayield based on maximum theoretical yield of 20 μmol peptide per well of the peptide synthesiser.  
NB: H2N- denotes a free N-terminus and –CONH2 denotes an amidated C-terminus. The references in 
parenthesis indicated the Spivey research group compound reference number. 
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6.9.7 Other peptides used in experiments 
Some of the peptides used during the PhD were synthesised during the MRes research project131 
as outlined in Table 25 below. 
 
Name/Reference Sequence Synthesised by 
Phe(3)-peptide 
(LDS-001-3A-MRes) H2N-Asp-Lys-Phe-Tyr-Ile-Val-Lys-Tyr-CONH2 Lucy Smith – MRes (IC) 
Trp(3)-peptide 
(LDS-001-4A-MRes) H2N-Asp-Lys-Trp-Tyr-Ile-Val-Lys-Tyr-CONH2 Lucy Smith – MRes (IC) 
His(3)-peptide 
(LDS-005-5A-MRes) H2N-Asp-Lys-His-Tyr-Ile-Val-Lys-Tyr-CONH2 Lucy Smith – MRes (IC) 
 
Table 25: Other peptides used in experiments 
 
6.10 Novartis testing of small molecules and peptides 
The following compounds were tested in ELISA, FRET and SPR experiments by Dr Jeffrey 
Stonehouse (Investigator III, Global Discovery Chemistry, Novartis Institutes for Biomedical 
Research, Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex, RH12 5AB, UK) 
and his team: (±)-1 (JS-039), (+)-2b (JS-256), (+)-5 (JS-312), 13 (HJD-205), (±)-16 (HJD-186), 21 (JS-
322), (±)-23 (JS-331), parent peptide (LDS-001-1) and Phe(3)-peptide (LDS-001-2). 100 μL solutions 
of the above inhibitors at 50 mM in DMSO were shipped to Novartis on solid CO2. Compounds 
were screened by Novartis as full dose-response IC50 curves to a maximum concentration of 650 
μM  in  the  ELISA  and  FRET  assays  and  were  screened  at  200  μM  and  20  μM  in  the  SPR  experiments. 
ELISA buffer was: PBS, 3 mM EDTA, 0.1% Tween 30. FRET buffer was: 50 mM HEPES, 3 mM EDTA, 
0.02% Tween 20. Further assay procedures were not disclosed by Novartis. 
  
148 
 
7: References 
(1) Gupta, R.; Sheikh, A.; Strachan, D. P.; Anderson, H. R. Clin. Exp. Allergy 2004, 34, 520. 
(2) Eder, W.; Ege, M. J.; von Mutius, E. N. Engl. J. Med. 2006, 355, 2226. 
(3) Chang, T. W. Nat. Biotechnol. 2000, 18, 157. 
(4) Gould, H. J.; Sutton, B. J.; Beavil, A. J.; Beavil, R. L.; McCloskey, N.; Coker, H. A.; Fear, D.; 
Smurthwaite, L. Annu. Rev. Immunol. 2003, 21, 579. 
(5) Gould, H. J.; Sutton, B. J. Nat. Rev. Immunol. 2008, 8, 205. 
(6) Cookson, W.; Moffatt, M. F. Science 1997, 275, 41. 
(7) Mincarini, M.; Pasquali, M.; Cosentino, C.; Fumagalli, F.; Scordamaglia, A.; Quaglia, R.; 
Canonica, G. W.; Passalacqua, G. Pulm. Pharmacol. Ther. 2001, 14, 267. 
(8) Raphael, G. D.; Angello, J. T.; Wu, M. M.; Druce, H. A. Ann. Allerg. Asthma Im. 2006, 96, 606. 
(9) Kay, G. G.; Harris, A. G. Clin. Exp. Allergy 1999, 29, 147. 
(10) Cazzola, M.; Segreti, A.; Matera, M. G. Curr. Opin. Pulm. Med. 2010, 16, 6. 
(11) Stoloff, S. W.; Kelly, H. W. Curr. Opin. Allergy Clin. Immunol. 2011, 11, 337. 
(12) Holgate, S. T.; Chuchalin, A. G.; Hebert, J.; Lotvall, J.; Persson, G. B.; Chung, K. F.; Bousquet, 
J.; Kerstjens, H. A.; Fox, H.; Thirlwell, J.; Della Cioppa, G.; Omalizumab 011 Int Study, G. Clin. 
Exp. Allergy 2004, 34, 632. 
(13) Holgate, S.; Casale, T.; Wenzel, S.; Bousquet, J.; Deniz, Y.; Reisner, C. J. Allergy Clin. Immunol. 
2005, 115, 459. 
(14) Holgate, S.; Buhl, R.; Bousquet, J.; Smith, N.; Panahloo, Z.; Jimenez, P. Resp. Med. 2009, 103, 
1098. 
(15) Garman, S. C.; Wurzburg, B. A.; Tarchevskaya, S. S.; Kinet, J. P.; Jardetzky, T. S. Nature 2000, 
406, 259. 
(16) Wan, T.; Beavil, R. L.; Fabiane, S. M.; Beavil, A. J.; Sohi, M. K.; Keown, M.; Young, R. J.; Henry, 
A. J.; Owens, R. J.; Gould, H. J.; Sutton, B. J. Nat. Immunol. 2002, 3, 681. 
(17) Garman, S. C.; Sechi, S.; Kinet, J. P.; Jardetzky, T. S. J. Mol. Biol. 2001, 311, 1049. 
(18) Henry, A. J.; Cook, J. P. D.; McDonnell, J. M.; Mackay, G. A.; Shi, J. G.; Sutton, B. J.; Gould, H. 
J. Biochemistry 1997, 36, 15568. 
(19) Cook, J. P. D.; Henry, A. J.; McDonnell, J. M.; Owens, R. J.; Sutton, B. J.; Gould, H. J. 
Biochemistry 1997, 36, 15579. 
(20) Sayers, I.; Cain, S. A.; Swan, J. R. M.; Pickett, M. A.; Watt, P. J.; Holgate, S. T.; Padlan, E. A.; 
Schuck, P.; Helm, B. A. Biochemistry 1998, 37, 16152. 
(21) Sayers, I.; Helm, B. A. Clin. Exp. Allergy 1999, 29, 585. 
149 
 
(22) Holdom, M. D.; Davies, A. M.; Nettleship, J. E.; Bagby, S. C.; Dhaliwal, B.; Girardi, E.; Hunt, J.; 
Gould, H. J.; Beavil, A. J.; McDonnell, J. M.; Owens, R. J.; Sutton, B. J. Nat. Struct. Mol. Biol. 
2011, 18, 571. 
(23) Hunt, J.; Keeble, A. H.; Dale, R. E.; Corbett, M. K.; Beavil, R. L.; Levitt, J.; Swann, M. J.; 
Suhling, K.; Ameer-Beg, S.; Sutton, B. J.; Beavil, A. J. J. Biol. Chem. 2012, 287, 17459. 
(24) Hunt, J.; Beavil, R. L.; Calvert, R. A.; Gould, H. J.; Sutton, B. J.; Beavil, A. J. J. Biol. Chem. 2005, 
280, 16808. 
(25) Hunt, J.; Bracher, M. G.; Shi, J.; Fleury, S.; Dombrowicz, D.; Gould, H. J.; Sutton, B. J.; Beavil, 
A. J. J. Biol. Chem. 2008, 283, 29882. 
(26) Dhaliwal, B.; Yuan, D. P.; Pang, M. O. Y.; Henry, A. J.; Cain, K.; Oxbrow, A.; Fabiane, S. M.; 
Beavil, A. J.; McDonnell, J. M.; Gould, H. J.; Sutton, B. J. Proc. Natl. Acad. Sci. U.S.A. 2012, 
109, 12686. 
(27) Borthakur, S.; Hibbert, R. G.; Pang, M. O. Y.; Yahya, N.; Bax, H. J.; Kao, M. W.; Cooper, A. M.; 
Beavil, A. J.; Sutton, B. J.; Gould, H. J.; McDonnell, J. M. J. Biol. Chem. 2012, 287, 31457. 
(28) Wurzburg, B. A.; Jardetzky, T. S. J. Mol. Biol. 2009, 393, 176. 
(29) Wurzburg, B. A.; Kim, B.; Tarchevskaya, S. S.; Eggel, A.; Vogel, M.; Jardetzky, T. S. J. Biol. 
Chem. 2012, 287, 36251. 
(30) Yuan, D. P.; Keeble, A. H.; Hibbert, R. G.; Fabiane, S.; Gould, H. J.; McDonnell, J. M.; Beavil, 
A. J.; Sutton, B. J.; Dhaliwal, B. J. Biol. Chem. 2013, 288, 21667. 
(31) Dhaliwal, B.; Pang, M. O. Y.; Yuan, D. P.; Yahya, N.; Fabiane, S. M.; McDonnell, J. M.; Gould, 
H. J.; Beavil, A. J.; Sutton, B. J. Mol. Immunol. 2013, 56, 693. 
(32) Dhaliwal, B.; Pang, M. O. Y.; Yuan, D. P.; Beavil, A. J.; Sutton, B. J. Acta Crystallogr. F. 2014, 
70, 305. 
(33) Drinkwater, N.; Cossins, B. P.; Keeble, A. H.; Wright, M.; Cain, K.; Hailu, H.; Oxbrow, A.; 
Delgado, J.; Shuttleworth, L. K.; Kao, M. W. P.; McDonnell, J. M.; Beavil, A. J.; Henry, A. J.; 
Sutton, B. J. Nat. Struct. Mol. Biol. 2014, 21, 397. 
(34) Arkin, M. R.; Wells, J. A. Nat. Rev. Drug Discov. 2004, 3, 301. 
(35) Yin, H.; Hamilton, A. D. Angew. Chem. Int. Ed. 2005, 44, 4130. 
(36) Wells, J. A.; McClendon, C. L. Nature 2007, 450, 1001. 
(37) Zinzalla, G.; Thurston, D. E. Future Med. Chem. 2009, 1, 65. 
(38) Wilson, A. J. Chem. Soc. Rev. 2009, 38, 3289. 
(39) Buchwald, P. IUBMB Life 2010, 62, 724. 
(40) Moreira, I. S.; Fernandes, P. A.; Ramos, M. J. Proteins 2007, 68, 803. 
150 
 
(41) Hajduk, P. J.; Bures, M.; Praestgaard, J.; Fesik, S. W. J. Med. Chem. 2000, 43, 3443. 
(42) Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Adv. Drug Deliver. Rev. 1997, 23, 3. 
(43) Stigers, K. D.; Soth, M. J.; Nowick, J. S. Curr. Opin. Chem. Biol. 1999, 3, 714. 
(44) McDonnell, J. M.; Beavil, A. J.; Mackay, G. A.; Jameson, B. A.; Korngold, R.; Gould, H. J.; 
Sutton, B. J. Nat. Struct. Biol. 1996, 3, 419. 
(45) Hill, T. A.; Shepherd, N. E.; Diness, F.; Fairlie, D. P. Angew. Chem. Int. Ed. 2014, 53, 13020. 
(46) Kotha, S.; Lahiri, K. Bioorg. Med. Chem. Lett. 2001, 11, 2887. 
(47) Kotha, S.; Lahin, K. Biopolymers 2003, 69, 517. 
(48) Smith, L. D.; Leatherbarrow, R. J.; Spivey, A. C. Future Med. Chem. 2013, 5, 1423. 
(49) Hamburger, R. N. Science 1975, 189, 389. 
(50) Hamburger, R. N. Immunology 1979, 38, 781. 
(51) Stanworth, D. R.; Humphrey, J. H.; Bennich, H.; Johansson, S. G. O. Lancet 1968, 292, 17. 
(52) Burt, D. S.; Stanworth, D. R. Eur. J. Immunol. 1987, 17, 437. 
(53) Stanworth, D. R.; Jones, V. M.; Lewin, I. V.; Nayyar, S. Lancet 1990, 336, 1279. 
(54) Helm, B. A.; Spivey, A. C.; Padlan, E. A. Allergy 1997, 52, 1155. 
(55) Spivey, A. C.; McKendrick, J. E.; Srikaran, R.; Helm, B. A. J. Org. Chem. 2003, 68, 1843. 
(56) Offermann, D. A.; McKendrick, J. E.; Sejberg, J. J. P.; Mo, B. L.; Holdom, M. D.; Helm, B. A.; 
Leatherbarrow, R. J.; Beavil, A. J.; Sutton, B. J.; Spivey, A. C. J. Org. Chem. 2012, 77, 3197. 
(57) McDonnell, J. M.; Beavil, A. J.; Mackay, G. A.; Henry, A. J.; Cook, J. P. D.; Gould, H. J.; Sutton, 
B. J. Biochem. Soc. T. 1997, 25, 387. 
(58) McDonnell, J. M.; Fushman, D.; Cahill, S. M.; Sutton, B. J.; Cowburn, D. J. Am. Chem. Soc. 
1997, 119, 5321. 
(59) Danho, W.; Makofske, R.; Swistok, J.; Mallamaci, M.; Nettletton, M.; Madison, V.; Greeley, 
D.; Fry, D.; Kochan, J. Peptides Am. Symp. 1997, 15, 539. 
(60) Sandomenico, A.; Monti, S. M.; Marasco, D.; Dathan, N.; Palumbo, R.; Saviano, M.; Ruvo, M. 
Mol. Immunol. 2009, 46, 3300. 
(61) Sandomenico, A.; Monti, S. M.; Palumbo, R.; Ruvo, M. J. Pept. Res. 2011, 17, 604. 
(62) Zhou, J. S.; Sandomenico, A.; Severino, V.; Burton, O. T.; Darling, A.; Oettgen, H. C.; Ruvo, M. 
Mol. Biosyst. 2013, 9, 2853. 
(63) Nakamura, G. R.; Starovasnik, M. A.; Reynolds, M. E.; Lowman, H. B. Biochemistry 2001, 40, 
9828. 
(64) Nakamura, G. R.; Reynolds, M. E.; Chen, Y. M.; Starovasnik, M. A.; Lowman, H. B. Proc. Natl. 
Acad. Sci. U.S.A. 2002, 99, 1303. 
151 
 
(65) Stamos, J.; Eigenbrot, C.; Nakamura, G. R.; Reynolds, M. E.; Yin, J. P.; Lowman, H. B.; 
Fairbrother, W. J.; Starovasnik, M. A. Structure 2004, 12, 1289. 
(66) Fassina, G.; Verdoliva, A.; Odierna, M. R.; Ruvo, M.; Cassini, G. J. Mol. Recognit. 1996, 9, 
564. 
(67) Fassina, G.; Verdoliva, A.; Palombo, G.; Ruvo, M.; Cassani, G. J. Mol. Recognit. 1998, 11, 128. 
(68) Fassina, G.; Ruvo, M.; Palombo, G.; Verdoliva, A.; Marino, M. J. Biochem. Bioph. Meth. 2001, 
49, 481. 
(69) Palombo, G.; De Falco, S.; Tortora, M.; Cassani, G.; Fassina, G. J. Mol. Recognit. 1998, 11, 
243. 
(70) Palombo, G.; Rossi, M.; Cassani, G.; Fassina, G. J. Mol. Recognit. 1998, 11, 247. 
(71) Palombo, G.; Verdoliva, A.; Fassina, G. J. Chromatogr. B 1998, 715, 137. 
(72) Verdoliva, A.; Basile, G.; Fassina, G. J. Chromatogr. B 2000, 749, 233. 
(73) Verdoliva, A.; Pannone, F.; Rossi, M.; Catello, S.; Manfredi, V. J. Immunol. Methods 2002, 
271, 77. 
(74) Marino, M.; Ruvo, M.; De Falco, S.; Fassina, G. Nature Biotechnol. 2000, 18, 735. 
(75) Marino, M.; Rossi, M.; Ruvo, M.; Fassina, G. Curr. Drug Targets 2002, 3, 223. 
(76) Rossi, M.; Ruvo, M.; Marasco, D.; Colombo, M.; Cassani, G.; Verdoliva, A. Mol. Immunol. 
2008, 45, 226. 
(77) Ratcliffe, N. A.; Mello, C. B.; Garcia, E. S.; Butt, T. M.; Azambuja, P. Insect Biochem. Mol. Biol. 
2011, 41, 747. 
(78) Buku, A.; Maulik, G.; Hook, W. A. Peptides 1998, 19, 1. 
(79) Buku, A. Peptides 1999, 20, 415. 
(80) Buku, A.; Price, J. A. Peptides 2001, 22, 1987. 
(81) Buku, A.; Price, J. A.; Mendlowitz, M.; Masur, S. Peptides 2001, 22, 1993. 
(82) Buku, A.; Mendlowitz, M.; Condie, B. A.; Price, J. A. J. Med. Chem. 2003, 46, 3008. 
(83) Buku, A.; Mendlowitz, M.; Condie, B. A.; Price, J. A. J. Pept. Res. 2004, 10, 313. 
(84) Buku, A.; Condie, B. A.; Price, J. A.; Mezei, M. J. Pept. Res. 2005, 66, 132. 
(85) Buku, A.; Keselman, I.; Lupyan, D.; Mezei, M.; Price, J. A. Chem. Biol. Drug Des. 2008, 72, 
133. 
(86) Singh, S. B.; Jayasuriya, H.; Zink, D. L.; Polishook, J. D.; Dombrowski, A. W.; Zweerink, H. 
Tetrahedron Lett. 2004, 45, 7605. 
(87) Pospisil, J.; Muller, C.; Furstner, A. Chem. Eur. J. 2009, 15, 5956. 
(88) Yoshino, T.; Sato, I.; Hirama, M. Org. Lett. 2012, 14, 4290. 
152 
 
(89) Yoshino, T.; Yamashita, S.; Sato, I.; Hayashi, Y.; Hirama, M. Chem. Lett. 2014, 43, 349. 
(90) Carr, J. L.; Offermann, D. A.; Holdom, M. D.; Dusart, P.; White, A. J. P.; Beavil, A. J.; 
Leatherbarrow, R. J.; Lindell, S. D.; Sutton, B. J.; Spivey, A. C. Chem. Commun. 2010, 46, 
1824. 
(91) Carr, J. L.; Sejberg, J. J. P.; Saab, F.; Holdom, M. D.; Davies, A. M.; White, A. J. P.; 
Leatherbarrow, R. J.; Beavil, A. J.; Sutton, B. J.; Lindell, S. D.; Spivey, A. C. Org. Biomol. Chem. 
2011, 9, 6814. 
(92) Sejberg, J. J. P.; Smith, L. D.; Leatherbarrow, R. J.; Beavil, A. J.; Spivey, A. C. Tetrahedron Lett. 
2013, 54, 4970. 
(93) Charneira, C.; Godinho, A. L. A.; Oliveira, M. C.; Pereira, S. A.; Monteiro, E. C.; Marques, M. 
M.; Antunes, A. M. M. Chem. Res. Toxicol. 2011, 24, 2129. 
(94) Cheng, Y. S.-E. L., Y.; Chu, J.; Kinet, J.-P.; Jouvain, M.-H.; Sudo, Y.; Quian, X. WO 9740033 
1997. 
(95) Cheng, Y. S.-E. L., Y.; Chu, J.; Kinet, J.-P.; Jouvain, M.-H.; Sudo, Y.; Quian, X. US 5965605 
1999. 
(96) Wiegand, T.; Williams, P.; Dreskin, S.; Jouvin, M.; Kinet, J.; Tasset, D. J. Immunol. 1996, 157, 
221. 
(97) Eggel, A.; Baumann, M. J.; Amstutz, P.; Stadler, B. M.; Vogel, M. J. Mol. Biol. 2009, 393, 598. 
(98) Baumann, M. J.; Eggel, A.; Amstutz, P.; Stadler, B. M.; Vogel, M. Immunol. Lett. 2010, 133, 
78. 
(99) Eggel, A.; Buschor, P.; Baumann, M. J.; Amstutz, P.; Stadler, B. M.; Vogel, M. Allergy 2011, 
66, 961. 
(100) Kim, B.; Eggel, A.; Tarchevskaya, S. S.; Vogel, M.; Prinz, H.; Jardetzky, T. S. Nature 2012, 491, 
613. 
(101) Eggel, A.; Baravalle, G.; Hobi, G.; Kim, B.; Buschor, P.; Forrer, P.; Shin, J. S.; Vogel, M.; 
Stadler, B. M.; Dahinden, C. A.; Jardetzky, T. S. J. Allergy Clin. Immunol. 2014, 133, 1709. 
(102) Zhang, J. H.; Chung, T. D. Y.; Oldenburg, K. R. J. Biomol. Screen. 1999, 4, 67. 
(103) Sittampalam, G. S.; Kahl, S. D.; Janzen, W. P. Curr. Opin. Chem. Biol. 1997, 1, 384. 
(104) Engvall, E.; Perlmann, P. Immunochemistry 1971, 8, 871. 
(105) Vanweeme.Bk; Schuurs, A. H. W. FEBS Lett. 1971, 15, 232. 
(106) Lequin, R. M. Clin. Chem. 2005, 51, 2415. 
(107) Arkin, M. R.; Glicksman, M. A.; Fu, H.; Havel, J. J.; Du, Y. Assay Guidance Manual (Chapter 
14: Inhibition of Protein-Protein Interactions: Non-Cellular Assay Formats) 2012, 1. 
153 
 
(108) Selvin, P. R. Method Enzymol. 1995, 246, 300. 
(109) Selvin, P. R. Nat. Struct. Biol. 2000, 7, 730. 
(110) Förster, T. Annalen der Physik 1948, 437, 55. 
(111) Ormo, M.; Cubitt, A. B.; Kallio, K.; Gross, L. A.; Tsien, R. Y.; Remington, S. J. Science 1996, 
273, 1392. 
(112) Selvin, P. R.; Hearst, J. E. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 10024. 
(113) Li, M.; Selvin, P. R. J. Am. Chem. Soc. 1995, 117, 8132. 
(114) Selvin, P. R. IEEE J. Sel. Top. Quantum Electron. 1996, 2, 1077. 
(115) Li, M.; Selvin, P. R. Bioconjugate Chem. 1997, 8, 127. 
(116) Chen, J. Y.; Selvin, P. R. Bioconjugate Chem. 1999, 10, 311. 
(117) Xiao, M.; Selvin, P. R. J. Am. Chem. Soc. 2001, 123, 7067. 
(118) Selvin, P. R. Annu. Rev. Bioph. Biom. 2002, 31, 275. 
(119) Ge, P. H.; Selvin, P. R. Bioconjugate Chem. 2003, 14, 870. 
(120) Riddle, S. M.; Vedvik, K. L.; Hanson, G. T.; Vogel, K. W. Anal. Biochem. 2006, 356, 108. 
(121) Ge, P. H.; Selvin, P. R. Bioconjugate Chem. 2008, 19, 1105. 
(122) Ge, O. H.; Selvin, P. R. Bioconjugate Chem. 2004, 15, 1088. 
(123) Kim, B.; Tarchevskaya, S. S.; Eggel, A.; Vogel, M.; Jardetzky, T. S. Anal. Biochem. 2012, 431, 
84. 
(124) Pope, A. J.; Haupts, U. M.; Moore, K. J. Drug Discov. Today 1999, 4, 350. 
(125) Jameson, D. M.; Croney, J. C. Comb. Chem. High T. Scr. 2003, 6, 167. 
(126) Bingham, B. R.; Monk, P. N.; Helm, B. A. J. Biol. Chem. 1994, 269, 19300. 
(127) Giannetti, A. M.; Koch, B. D.; Browner, M. F. J. Med. Chem. 2008, 51, 574. 
(128) Rich, R. L.; Myszka, D. G. J. Mol. Recognit. 2011, 24, 892. 
(129) Meyer, B.; Peters, T. Angew. Chem. Int. Edit. 2003, 42, 864. 
(130) Mayer, M.; Meyer, B. J. Am. Chem. Soc. 2001, 123, 6108. 
(131) Smith, L. D. MRes Thesis 2011, Imperial College London. 
(132) Panchuk-Voloshina, N.; Haugland, R. P.; Bishop-Stewart, J.; Bhalgat, M. K.; Millard, P. J.; 
Mao, F.; Leung, W. Y. J. Histochem. Cytochem. 1999, 47, 1179. 
(133) Berlier, J. E.; Rothe, A.; Buller, G.; Bradford, J.; Gray, D. R.; Filanoski, B. J.; Telford, W. G.; 
Yue, S.; Liu, J. X.; Cheung, C. Y.; Chang, W.; Hirsch, J. D.; Beechem, J. M.; Haugland, R. P. J. 
Histochem. Cytochem. 2003, 51, 1699. 
(134) Johnson, I.; Spence, M. T. Z. The Molecular Probes Handbook - A Guide to Fluorescent 
Probes and Labelling Technologies; 11th ed.; Life Technologies, 2010. 
154 
 
(135) McDonnell, J. M.; Calvert, R.; Beavil, R. L.; Beavil, A. J.; Henry, A. J.; Sutton, B. J.; Gould, H. J.; 
Cowburn, D. Nat. Struct. Biol. 2001, 8, 437. 
(136) Price, N. E.; Price, N. C.; Kelly, S. M.; McDonnell, J. M. J. Biol. Chem. 2005, 280, 2324. 
(137) Harwood, N. E.; Price, N. C.; McDonnell, J. M. FEBS Lett. 2006, 580, 2129. 
(138) Dennison, H. J. PhD Thesis 2011, Imperial College London. 
(139) Mo, B. PhD Thesis 2011, Imperial College London. 
(140) Merrifield, R. J. Am. Chem. Soc. 1963, 85, 2149. 
(141) Carpino, L. A.; Han, G. Y. J. Am. Chem. Soc. 1970, 92, 5748. 
(142) Carpino, L. A.; Han, G. Y. J. Org. Chem. 1972, 37, 3404. 
(143) Jones, J. The Chemical Synthesis of Peptides; Oxford University Press, 1994. 
(144) Chan, W. C.; White, P. D. Fmoc Solid Phase Peptide Synthesis: A Practical Approach; Oxford 
University Press, 1999. 
(145) Afonso, A.; Roses, C.; Planas, M.; Feliu, L. Eur. J. Org. Chem. 2010, 1461. 
(146) Frank, R. J. Immunol. Methods 2002, 267, 13. 
(147) Hilpert, K.; Winkler, D. F. H.; Hancock, R. E. W. Nat. Protoc. 2007, 2, 1333. 
(148) Lennard, K. R.; Tavassoli, A. Chem. Eur. J. 2014, 20, 10608. 
(149) Coyne, A. G.; Scott, D. E.; Abell, C. Curr. Opin. Chem. Biol. 2010, 14, 299. 
(150) Scott, D. E.; Coyne, A. G.; Hudson, S. A.; Abell, C. Biochemistry 2012, 51, 4990. 
(151) Scott, D. E.; Ehebauer, M. T.; Pukala, T.; Marsh, M.; Blundell, T. L.; Venkitaraman, A. R.; 
Abell, C.; Hyvonen, M. ChemBioChem 2013, 14, 332. 
(152) Zhong, S. J.; Macias, A. T.; MacKerell, A. D. Curr. Top. Med. Chem. 2007, 7, 63. 
(153) Fletcher, S.; Hamilton, A. D. Curr. Top. Med. Chem. 2007, 7, 922. 
(154) Caputo, G. A.; Litvinov, R. I.; Li, W.; Bennett, J. S.; DeGrado, W. F.; Yin, H. Biochemistry 2008, 
47, 8600. 
(155) Pang, M. PhD Thesis 2013, King's College London. 
 
 
  
155 
 
8: Appendices 
8.1 Aspercyclide A and analogues – ELISA inhibition assay IC50 curves 
 
(±)-1 (JS-039)      (±)-1 (JS-039) (repeat) 
IC50 >  1000  μM (solubility issues)   IC50 >  1000  μM (solubility issues)  
[JS-039] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 19.5307 2.0955
IC 50 5.5361 6.4355
Slope factor -0.2731 0.0591
Background 79.5631 1.2078
IC50 Data
 
 
 
 
(±)-1 (JS-039) (repeat) 
IC50 >  1000  μM  
[JS-039] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 9.9643 2.9013
IC 50 2.0637 1.2106
Slope factor -1.1184 0.4730
Background 90.2083 2.7190
IC50 Data
  
[JS-039] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 29.8026 8.7337
IC 50 0.0624 0.7269
Slope factor -0.0630 0.0840
Background 77.1070 4.9824
IC50 Data
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(+)-2a (JS-291)      (+)-2a (JS-291) (repeat) 
IC50 = 424 ± 27 μM     IC50 = 538 ± 222 μM  
[JS-291] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 40.3960 2.4397
IC 50 424.4460 27.1284
Slope factor 5.4040 1.5864
Background 46.9803 2.2968
IC50 Data
 
 
 
 
(+)-2b (JS-256-P) 
IC50 >  1000  μM 
[JS-256-P] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 17.9189 9.6541
IC 50 30.0574 408.0740
Slope factor 0.1108 0.0867
Background 90.2885 4.9575
IC50 Data
 
  
[JS-291] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 79.3420 35.7175
IC 50 537.5600 222.2826
Slope factor 3.0682 3.3086
Background 15.2210 34.5955
IC50 Data
157 
 
(+)-3 (JS-287) 
IC50 >  1000  μM 
[JS-287] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 380.0372 2115.6735
IC 50 3138.1557 11313.0996
Slope factor 1.9122 0.6232
Background -279.4234 2115.5445
IC50 Data
 
 
 
 
(+)-4 (JS-289) 
IC50 >  1000  μM 
 
[JS-289] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 21.2087 4.3749
IC 50 10100.4242 43943.7944
Slope factor 0.1121 0.0788
Background 82.9515 2.8177
IC50 Data
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(+)-5 (JS-312)      (+)-5 (JS-312) (repeat) 
IC50 = 162 ± 5 μM     IC50 = 463 ± 19 μM  
[JS-312] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 98.0528 1.7953
IC 50 162.3684 4.6240
Slope factor 3.1802 0.2282
Background -0.2815 1.5947
IC50 Data
  
 
 
 
[JS-312] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 106.6603 4.4717
IC 50 462.7253 19.2118
Slope factor 3.1291 0.3088
Background -7.7408 4.2972
IC50 Data
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8.2 Aspercyclide A and analogues – TR-FRET inhibition assay IC50 curves 
 
(+)-1 (JS-039-E1) 
Pre-incubated with IgE-Fc-A647: 
IC50 > 1000  μM 
[JS-039-E1] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
120
Parameter Value Std. Error
Y Range 24.2903 8.1467
IC 50 2.6586 21.0212
Slope factor 0.0956 0.0978
Background 93.8851 3.8764
IC50 Data
 
 
 
 
Pre-incubated with αγ-Tb: 
IC50 >  1000  μM 
 
[JS-039-E1] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
120
Parameter Value Std. Error
Y Range 27.1934 39.8585
IC 50 62653550.7442 1.07628e+010
Slope factor -0.0235 0.1043
Background 88.1848 17.4825
IC50 Data
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(±)-1 (JS-039) 
Pre-incubated with IgE-Fc-A647: 
IC50 >  1000  μM 
[JS-039] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
120
140
160
180
200
220
Parameter Value Std. Error
Y Range 75.6852 72.9397
IC 50 2.3545 5.9691
Slope factor 0.5640 0.5326
Background 139.1852 14.0184
IC50 Data
 
 
 
 
Pre-incubated with αγ-Tb: 
IC50 >  1000  μM 
[JS-039] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
120
140
160
180
200
220
240
260
Parameter Value Std. Error
Y Range 68.5902 80.3172
IC 50 7.4169 169.2438
Slope factor 0.1592 0.2120
Background 176.8879 39.6322
IC50 Data
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(+)-2a (JS-291) 
Pre-incubated with IgE-Fc-A647: 
IC50 >  1000  μM 
[JS-291] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
120
140
160
Parameter Value Std. Error
Y Range 1423.1823 3293.8143
IC 50 2556.6931 2193.9780
Slope factor -2.8677 0.9290
Background 150.9864 2.8344
IC50 Data
 
 
 
 
Pre-incubated with αγ-Tb: 
IC50 >  1000  μM 
[JS-291] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
120
140
160
Parameter Value Std. Error
Y Range 573.6960 1103.9519
IC 50 1642.3440 1865.3926
Slope factor -2.3297 0.6696
Background 136.7255 3.8465
IC50 Data
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8.3 Dibenzofurans – ELISA inhibition assay IC50 curves 
 
(±)-11 (HJD-107)     (±)-11 (HJD-107) (repeat) 
IC50 = 4  ±  0.1  μM     IC50 = 5 ± 0.3 μM 
[HJD-107] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 78.5781 1.4538
IC 50 3.3668 0.1074
Slope factor 2.1389 0.1236
Background 4.1590 0.5049
IC50 Data
 
 
 
 
(±)-23 (JS-331)      (±)-23 (JS-331) (repeat) 
IC50 >  1000  μM     IC50 >  1000  μM
[JS-331] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 23.4509 3.0096
IC 50 116.7188 89.0590
Slope factor -0.3041 0.0580
Background 82.0045 1.3686
IC50 Data
 
 
 
[HJD-107] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 90.1722 2.6975
IC 50 5.0631 0.2943
Slope factor 1.8719 0.1741
Background 4.7443 1.0884
IC50 Data
[JS-331] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 19.5632 5.4841
IC 50 5.2603 29.3293
Slope factor -0.1562 0.1084
Background 79.8735 2.9287
IC50 Data
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14 (HJD-210)      14 (HJD-210) (repeat) 
IC50 >  1000  μM (solubility issues)   IC50 >  1000  μM 
[HJD-210-v4] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
120
Parameter Value Std. Error
Y Range 35.9082 10.7683
IC 50 10.8775 38.4092
Slope factor -0.2334 0.0907
Background 87.4992 5.7732
IC50 Data
  
 
 
 
13 (HJD-205)      13 (HJD-205) (repeat)  
IC50 = 529 ± 148 μM (solubility issues)  IC50 = 576 ± 122 μM  
[HJD-205-v6-9] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 38.5671 11.7728
IC 50 529.2105 147.5827
Slope factor 3.2321 2.1939
Background 64.6221 11.3966
IC50 Data
 
  
[HJD-210-v4] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 16.9769 3.4620
IC 50 265.1282 670.8035
Slope factor -0.1171 0.0599
Background 85.6419 1.6181
IC50 Data
[HJD-205-v6-9] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 114.8860 18.2971
IC 50 576.0253 121.7170
Slope factor 1.7698 0.2976
Background -18.2787 17.9798
IC50 Data
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(±)-16 (HJD-186)     (±)-16 (HJD-186) (repeat) 
IC50 > 1000  μM (solubility issues)   IC50 >  1000  μM  
[HJD-186-v11-12] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 22.8379 5.1843
IC 50 101.0696 152.2007
Slope factor -0.2270 0.0878
Background 84.4657 2.4699
IC50 Data
 
 
 
 
15 (HJD-211) 
IC50 >  1000  μM  
[HJD-211-v1] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 20.5808 6.4135
IC 50 35.1731 310.7567
Slope factor -0.0983 0.0975
Background 86.4149 3.1577
IC50 Data
   
[HJD-186-v11-12] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 14.1715 2.0054
IC 50 27.9316 81.9264
Slope factor -0.0884 0.0458
Background 85.9554 1.0048
IC50 Data
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18 (HJD-214) 
IC50 >  1000  μM  
[HJD-214-v8] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 17.4248 8.0068
IC 50 0.7300 0.8402
Slope factor -0.6552 0.5233
Background 83.6437 7.7484
IC50 Data
 
 
 
 
17 (HJD-213) 
IC50 >  1000  μM  
[HJD-213-v4] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 17.7228 3.2980
IC 50 2.4578 8.4589
Slope factor -0.1850 0.0813
Background 86.6092 1.8627
IC50 Data
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19 (HJD-212) 
IC50 >  1000  μM  
[HJD-212-v3-10] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 17.0673 3.8897
IC 50 81.8792 405.3635
Slope factor -0.1093 0.0691
Background 90.9172 1.8695
IC50 Data
 
 
 
 
(±)-12 (HJD-115) 
IC50 = 205 ± 51 μM 
[HJD-115-DBF] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 47.1163 8.1350
IC 50 204.5460 51.3388
Slope factor 3.2796 1.4730
Background 54.1939 7.3900
IC50 Data
   
167 
 
(±)-20 (JS-004/26) 
IC50 >  1000  μM  
[JS-004/26] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 33.8366 12.1187
IC 50 927.6961 989.0379
Slope factor -0.6667 0.2529
Background 88.2013 1.9983
IC50 Data
 
 
 
 
21 (JS-322) 
IC50 = 462 ± 89 μM 
[JS-322] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 81.7617 14.3337
IC 50 461.5029 89.2540
Slope factor 2.4648 1.0681
Background 10.7535 13.8172
IC50 Data
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Dibenzofuran-4-carboxylic acid 
IC50 >  1000  μM  
[DBF-COOH] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 29.1432 10.3910
IC 50 0.0074 0.1764
Slope factor -0.0810 0.1076
Background 69.4504 6.4988
IC50 Data
 
 
 
 
8 (DAO-268) 
IC50 >  1000  μM  
 
[DAO-268] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 52.6518 21.9857
IC 50 5.7809 34.5005
Slope factor -0.2108 0.1878
Background 60.2782 12.0854
IC50 Data
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8.4 Dibenzofurans – TR-FRET inhibition assay IC50 curves 
 
(±)-11 (HJD-107) 
Pre-incubated with IgE-Fc-A647: 
IC50 >  1000  μM 
[HJD-107] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
120
Parameter Value Std. Error
Y Range 33.7453 9.1271
IC 50 8.2552 5.0845
Slope factor 0.9267 0.5156
Background 81.6949 3.3924
IC50 Data
 
 
 
 
Pre-incubated with αγ-Tb: 
IC50 >  1000  μM 
[HJD-107] (µM)
1 101 102 103
TR
-F
R
E
T 
R
at
io
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 20.7127 25.4681
IC 50 316.9788 1019.5650
Slope factor 0.8030 0.9001
Background 78.5119 24.0296
IC50 Data
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(±)-12 (HJD-115) 
Pre-incubated with IgE-Fc-A647: 
IC50 >  1000  μM 
[HJD-115-DBF] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 21.8146 6.6620
IC 50 7.4471 41.4835
Slope factor 0.1200 0.0981
Background 73.8132 3.2512
IC50 Data
 
 
 
 
Pre-incubated with αγ-Tb: 
IC50 >  1000  μM 
[HJD-115-DBF] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 24.2672 5.4036
IC 50 367.7044 1229.5099
Slope factor 0.1964 0.1242
Background 56.8540 3.3906
IC50 Data
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8.5 LC-MS chromatograms and mass spectra of pure peptides 
C-strand peptide (H2N-Asp-Lys-Tyr-Tyr-Ile-Val-Lys-Tyr-CONH2) (LDS-001-1A) 
 
  
172 
 
Phe(3)-peptide (H2N-Asp-Lys-Phe-Tyr-Ile-Val-Lys-Tyr-CONH2) (LDS-001-2A) 
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Bip(3)-peptide (H2N-Asp-Lys-Bip-Tyr-Ile-Val-Lys-Tyr-CONH2) (LDS-001-3A_run 1) 
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Bip(3)-peptide (H2N-Asp-Lys-Bip-Tyr-Ile-Val-Lys-Tyr-CONH2) (LDS-001-3A_run 2) 
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C-strand peptide (H2N-Tyr-Lys-Val-Ile-Tyr-Tyr-Lys-Asp-CONH2) (LDS-001-4A) 
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link-Phe(3)-peptide (H2N-Gly-Gly-Gly-Asp-Lys-Phe-Tyr-Ile-Val-Lys-Tyr-CONH2) (LDS-002-2B-free) 
 
 
177 
 
b-Phe(3)-peptide (biotin-Asp-Lys-Phe-Tyr-Ile-Val-Lys-Tyr-CONH2) (LDS-002-1A) 
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b-Phe(3)-peptide (biotin-Asp-Lys-Phe-Tyr-Ile-Val-Lys-Tyr-CONH2) (LDS-002-1B) 
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b-link-Phe(3)-peptide (biotin-Gly-Gly-Gly-Asp-Lys-Phe-Tyr-Ile-Val-Lys-Tyr-CONH2) (LDS-002-2A) 
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b-link-Phe(3)-peptide (biotin-Gly-Gly-Gly-Asp-Lys-Phe-Tyr-Ile-Val-Lys-Tyr-CONH2) (LDS-002-2B) 
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8.6 Peptides - ELISA inhibition assay IC50 curves 
 
Bip(3)-peptide (H2N-Asp-Lys-Bip-Tyr-Ile-Val-Lys-Tyr-CONH2) (LDS-001-3A) 
IC50 = 173  ±  12  μM 
[LDS-001-3A] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 81.3212 3.6697
IC 50 172.5720 11.9625
Slope factor 3.2840 0.5444
Background 7.7108 3.2766
IC50 Data
 
 
 
 
C-strand peptide (H2N-Tyr-Lys-Val-Ile-Tyr-Tyr-Lys-Asp-CONH2) (LDS-001-4A) 
IC50 >  1000  μM 
[LDS-001-4A] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 25.2476 5.4783
IC 50 0.6042 3.1197
Slope factor -0.1537 0.0936
Background 84.9971 3.2611
IC50 Data
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8.7 Peptides - TR-FRET inhibition assay IC50 curves 
 
Phe(3)-peptide (H2N-Asp-Lys-Phe-Tyr-Ile-Val-Lys-Tyr-CONH2) (LDS-001-3A-MRes) 
 
Pre-incubated with IgE-Fc-A647:       
IC50 = 12  ±  0.7  μM      
[LDS-001-3A-MRes] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
120
140
Parameter Value Std. Error
Y Range 124.0105 3.3636
IC 50 12.3321 0.7114
Slope factor 2.0385 0.2105
Background 7.1114 1.9435
IC50 Data
 
 
 
Pre-incubated with αγ-Tb:     Pre-incubated with αγ-Tb (repeat): 
IC50 = 0.4  ±  0.2  μM      IC50 = 11  ±  0.7  μM     
[LDS-001-3A-MRes] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
120
140
Parameter Value Std. Error
Y Range 319.3328 105.5412
IC 50 0.4183 0.1549
Slope factor 2.5988 0.5854
Background 9.3717 2.7835
IC50 Data
     
[LDS-001-3A-MRes] (µM)
10-4 10-3 10-2 10-1 1 101 102 103
R
es
po
ns
e
-100
0
100
200
Parameter Value Std. Error
Y Range 294.4099 7.3191
IC 50 10.9801 0.7374
Slope factor 2.5797 0.3648
Background -106.2377 6.2337
IC50 Data
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Trp(3)-peptide (H2N-Asp-Lys-Trp-Tyr-Ile-Val-Lys-Tyr-CONH2) (LDS-001-4A-MRes) 
 
Pre-incubated with IgE-Fc-A647:     
IC50 = 51  ±  3  μM 
[LDS-001-4A-MRes] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
120
140
Parameter Value Std. Error
Y Range 123.2418 3.1987
IC 50 50.8515 2.6388
Slope factor 2.3376 0.2498
Background 7.6930 2.4660
IC50 Data
 
 
 
 
Pre-incubated with αγ-Tb:    Pre-incubated with αγ-Tb (repeat): 
IC50 = 2  ±  0.3  μM     IC50 = 70  ±  11  μM 
[LDS-001-4A-MRes] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
120
140
Parameter Value Std. Error
Y Range 138.5473 12.0254
IC 50 1.8367 0.3159
Slope factor 1.1689 0.1342
Background 8.6529 1.4961
IC50 Data
  
[LDS-001-4A-MRes] (µM)
10-4 10-3 10-2 10-1 1 101 102 103
R
es
po
ns
e
-100
0
100
200
Parameter Value Std. Error
Y Range 291.1433 20.3019
IC 50 69.9084 10.7972
Slope factor 2.0885 0.5853
Background -104.3774 18.8240
IC50 Data
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Bip(3)-peptide (H2N-Asp-Lys-Bip-Tyr-Ile-Val-Lys-Tyr-CONH2) (LDS-001-3A) 
 
Pre-incubated with IgE-Fc-A647: 
IC50 = 16 ± 1 μM 
[LDS-001-3A] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 90.6039 3.4248
IC 50 16.3649 1.4005
Slope factor 1.4845 0.1739
Background 12.7424 1.9983
IC50 Data
 
 
 
 
Pre-incubated with αγ-Tb: 
IC50 = 11 ± 1 μM 
[LDS-001-3A] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 88.9443 4.8121
IC 50 10.6751 1.2691
Slope factor 1.5752 0.2580
Background 15.1533 2.4636
IC50 Data
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C-strand peptide (H2N-Tyr-Lys-Val-Ile-Tyr-Tyr-Lys-Asp-CONH2) (LDS-001-4A) 
 
Pre-incubated with IgE-Fc-A647: 
IC50 >  1000  μM 
[LDS-001-4A] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
120
Parameter Value Std. Error
Y Range 18.3368 12.8257
IC 50 482.1486 20461.9832
Slope factor -0.0548 0.0731
Background 100.8534 6.1099
IC50 Data
 
 
 
 
Pre-incubated with αγ-Tb: 
IC50 >  1000  μM 
[LDS-001-4A] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 38.9160 13.4702
IC 50 1913.3454 4945.5284
Slope factor 0.2184 0.1996
Background 69.0267 9.0238
IC50 Data
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His(3)-peptide (H2N-Asp-Lys-His-Tyr-Ile-Val-Lys-Tyr-CONH2) (LDS-005-5A-MRes) 
 
Pre-incubated with IgE-Fc-A647: 
IC50 >  1000  μM 
[LDS-005-5A-MRes] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 40.6322 10.4612
IC 50 0.5645 5.2410
Slope factor -0.2234 0.1392
Background 66.7657 6.4364
IC50 Data
 
 
 
 
Pre-incubated with αγ-Tb: 
IC50 >  1000  μM 
[LDS-005-5A-MRes] µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 15.0273 2.7646
IC 50 30.9598 63.2773
Slope factor -0.1517 0.0663
Background 82.1861 1.3967
IC50 Data
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Parent peptide (H2N-Asp-Lys-Tyr-Tyr-Ile-Val-Lys-Tyr-CONH2) (LDS-001-1A) 
 
Pre-incubated with IgE-Fc-A647:   Pre-incubated with IgE-Fc-A647 (repeat): 
IC50 = 459 ± 42 μM     IC50 = 371 ± 58 μM 
[LDS-001-1A] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 76.9040 7.1167
IC 50 459.3115 42.3843
Slope factor 3.0799 0.6977
Background 17.3841 6.8334
IC50 Data
  
 
 
 
Pre-incubated with IgE-Fc-A647 (repeat): 
IC50 = 355 ± 38 μM 
[LDS-001-1A] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
120
140
Parameter Value Std. Error
Y Range 96.0282 8.4021
IC 50 354.6023 37.8480
Slope factor 3.7665 1.0718
Background 22.7332 7.9763
IC50 Data
   
[LDS-001-1A] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
120
140
160
Parameter Value Std. Error
Y Range 107.2458 13.4761
IC 50 370.5129 57.6934
Slope factor 2.6137 0.6679
Background 35.2346 12.9041
IC50 Data
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Parent peptide (H2N-Asp-Lys-Tyr-Tyr-Ile-Val-Lys-Tyr-CONH2) (LDS-001-1A) 
 
Pre-incubated with αγ-Tb:    Pre-incubated with αγ-Tb (repeat): 
IC50 = 176  ±  13  μM       IC50 = 176  ±  13  μM   
[LDS-001-1A] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 67.7002 3.1167
IC 50 175.7488 13.0240
Slope factor 2.4261 0.3629
Background 15.5218 2.7996
IC50 Data
 
 
 
 
Pre-incubated with αγ-Tb (repeat): 
IC50 = 133 ± 7 μM 
[LDS-001-1A] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
120
140
Parameter Value Std. Error
Y Range 101.0576 3.4410
IC 50 133.4278 7.2261
Slope factor 2.8611 0.4066
Background 19.9581 2.9756
IC50 Data
 
  
[LDS-001-1A] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
120
140
160
Parameter Value Std. Error
Y Range 123.5747 8.6457
IC 50 164.6288 22.3756
Slope factor 1.4355 0.1913
Background 22.5875 7.8521
IC50 Data
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Phe(3)-peptide (H2N-Asp-Lys-Phe-Tyr-Ile-Val-Lys-Tyr-CONH2) (LDS-001-2A) 
 
Pre-incubated with IgE-Fc-A647: 
IC50 = 155 ± 12 μM 
[LDS-001-2A] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
120
Parameter Value Std. Error
Y Range 94.2846 4.3234
IC 50 155.4465 11.8742
Slope factor 2.3926 0.3469
Background 23.4399 3.8417
IC50 Data
 
 
 
 
Pre-incubated with αγ-Tb: 
IC50 = 58 ± 2 μM 
[LDS-001-2A] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
120
Parameter Value Std. Error
Y Range 98.2161 1.6460
IC 50 58.2653 1.7468
Slope factor 2.9510 0.2372
Background 22.2817 1.2859
IC50 Data
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link-Phe(3)-peptide (H2N-Gly-Gly-Gly-Asp-Lys-Phe-Tyr-Ile-Val-Lys-Tyr-CONH2) (LDS-002-2B-free) 
 
Pre-incubated with IgE-Fc-A647: 
IC50 = 26 ± 4 μM 
[LDS-002-2B-free] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
120
Parameter Value Std. Error
Y Range 89.0711 5.3054
IC 50 26.1771 3.5038
Slope factor 1.7765 0.3481
Background 19.8993 3.5913
IC50 Data
 
 
 
 
Pre-incubated with αγ-Tb: 
IC50 = 7 ± 0.9 μM 
[LDS-002-2B-free] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
120
Parameter Value Std. Error
Y Range 103.8823 6.0949
IC 50 6.8557 0.9012
Slope factor 0.9962 0.1151
Background 16.7139 2.0576
IC50 Data
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8.8 Biotin-peptides – TR-FRET inhibition assay IC50 curves 
 
b-Phe(3)-peptide (biotin-Asp-Lys-Phe-Tyr-Ile-Val-Lys-Tyr-CONH2) (LDS-002-1A) 
 
Pre-incubated with IgE-Fc-A647:   Pre-incubated with IgE-Fc-A647 (repeat): 
IC50 = 7  ±  1  μM     IC50 = 60 ± 7 μM 
[LDS-002-1A] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
120
Parameter Value Std. Error
Y Range 90.1878 7.3429
IC 50 7.0599 1.2209
Slope factor 1.2635 0.2291
Background 21.9947 2.7647
IC50 Data
 
 
 
 
Pre-incubated with αγ-Tb:    Pre-incubated with αγ-Tb (repeat): 
IC50 = 0.9  ±  1  μM     IC50 = 15 ± 5 μM 
[LDS-002-1A] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
120
Parameter Value Std. Error
Y Range 139.4480 65.2422
IC 50 0.8657 1.1355
Slope factor 0.7836 0.2933
Background 19.1381 3.7068
IC50 Data
  
[LDS-002-1A] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
120
140
Parameter Value Std. Error
Y Range 73.3568 16.2747
IC 50 15.3492 5.4283
Slope factor 1.5860 0.3511
Background 49.1450 8.1412
IC50 Data
[LDS-002-1A] (µM)
1 101 102 103
R
es
po
ns
e
0
20
40
60
80
100
120
140
160
Parameter Value Std. Error
Y Range 108.7017 6.2333
IC 50 59.5128 7.3681
Slope factor 1.6622 0.2939
Background 42.7315 4.9287
IC50 Data
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b-link-Phe(3)-peptide (biotin-Gly-Gly-Gly-Asp-Lys-Phe-Tyr-Ile-Val-Lys-Tyr-CONH2) (LDS-002-2A) 
 
Pre-incubated with IgE-Fc-A647: 
IC50 = 13 ± 2 μM 
[LDS-002-2A] (µM)
1 101 102 103
R
es
po
ns
e
0
50
100
150
200
250
300
350
400
450
500
Parameter Value Std. Error
Y Range 394.3169 22.6089
IC 50 13.0591 1.6864
Slope factor 1.4784 0.2487
Background 94.3801 12.2034
IC50 Data
 
 
 
 
Pre-incubated with αγ-Tb: 
IC50 = 4 ± 0.4 μM 
[LDS-002-2A] (µM)
1 101 102 103
R
es
po
ns
e
0
50
100
150
200
250
300
350
400
450
500
Parameter Value Std. Error
Y Range 356.8550 21.9218
IC 50 3.6622 0.3980
Slope factor 2.1148 0.3987
Background 94.3160 7.8688
IC50 Data
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b-Phe(3)-peptide (biotin-Asp-Lys-Phe-Tyr-Ile-Val-Lys-Tyr-CONH2) (LDS-002-1A) 
(maximum concentration reduced from 1 mM to 125  μM) 
 
Pre-incubated with αγ-Tb: 
IC50 = 2 ± 0.4 μM  
[LDS-002-1A] (µM)
10-1 1 101 102
R
es
po
ns
e
0
20
40
60
80
100
120
Parameter Value Std. Error
Y Range 86.0704 6.4386
IC 50 2.4945 0.4160
Slope factor 1.0847 0.1956
Background 21.9748 3.7161
IC50 Data
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b-link-Phe(3)-peptide (biotin-Gly-Gly-Gly-Asp-Lys-Phe-Tyr-Ile-Val-Lys-Tyr-CONH2) (LDS-002-2A) 
(maximum  concentration  reduced  from  1  mM  to  125  μM) 
 
Pre-incubated with αγ-Tb: 
IC50 = 98 ± 104 μM  
[LDS-002-2A] (µM)
10-1 1 101 102
R
es
po
ns
e
0
20
40
60
80
100
120
Parameter Value Std. Error
Y Range 109.9581 53.5881
IC 50 97.6188 103.5828
Slope factor 0.9336 0.2473
Background -2.0997 52.7474
IC50 Data
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8.9 Biotin-peptides and streptavidin – TR-FRET inhibition assay IC50 curves 
 
b-Phe(3)-peptide (biotin-Asp-Lys-Phe-Tyr-Ile-Val-Lys-Tyr-CONH2) (LDS-002-1A) 
(maximum  concentration  reduced  from  1  mM  to  125  μM)  and 2 eq streptavidin 
 
Pre-incubated with αγ-Tb: 
IC50 = 5 ± 1 μM  
[LDS-002-1A] (µM)
10-1 1 101 102
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 93.8841 13.3578
IC 50 4.7919 1.3596
Slope factor 0.6291 0.1419
Background 7.4441 8.6986
IC50 Data
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b-link-Phe(3)-peptide (biotin-Gly-Gly-Gly-Asp-Lys-Phe-Tyr-Ile-Val-Lys-Tyr-CONH2) (LDS-002-2A) 
(maximum  concentration  reduced  from  1  mM  to  125  μM) and 2 eq streptavidin 
 
Pre-incubated with αγ-Tb: 
IC50 > 1000 μM  
[LDS-002-2A] (µM)
10-1 1 101 102
R
es
po
ns
e
0
20
40
60
80
100
Parameter Value Std. Error
Y Range 27.4592 1.5819
IC 50 8.7044 1.0056
Slope factor 2.0208 0.3977
Background 68.2386 1.2771
IC50 Data
  
